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The synuclein family came into the limelight with the discovery of two point
mutations in the human a-synuclein gene associated with autosomal dominant,
familial Parkinson's disease. This triggered numerous studies aimed at understanding
the mechanism of a-synuclein involvement in neurodegeneration. Fibrillated a-
synuclein has been identified as a major component of Lewy bodies in dopaminergic
neurones of the substantia nigra pars compacta (SNpc) in cases of idiopathic
Parkinson's disease as well as other diseases in which inclusions feature now known
as synucleinopathies. Moreover, it has been demonstrated that a-synuclein can
aggregate in vitro into filaments structurally similar to filaments found in
pathological inclusions and that mutated forms of human a-synuclein aggregate
substantially faster than wild-type protein. These results suggested a causative role of
a-synuclein aggregation in the development of synucleinopathies.
We studied the effects of a targeted inactivation of y-synuclein and later a-synuclein
and a/y-synuclein together on murine physiology and development. These animals
are viable and fertile with no gross physiological of morphological abnormalities.
A quantitative evaluation of the substantia nigra showed a reduction in the number of
dopaminergic neurones in the SNpc region but not in ventral tegmental area (VTA)
of adult y-synuclein null mutant mice. Similar reductions were revealed in a-
synuclein and double a/y-synuclein null mutant animals, this difference appearing
after birth and remaining constant throughout life. However, in none of these mutants
did this lead to significant changes in levels of striatal dopamine or dopamine
metabolite levels or motor function.
xvii
In all three studied types of null mutants, dopaminergic neurones of SNpc were
resistant to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) toxicity. We
propose that both synucleins are important for effective survival of some SNpc
neurones during a critical period of development and that, in the absence of these
proteins, permanent activation of compensatory mechanisms allow many neurones to
survive and become resistant to certain toxic insults.
We have shown that the absence of a-, y- or a- and y-synuclein does not precipitate
any obvious or serious developmental or functional abnormalities. If the synuclein
family are important for the correct development of the SNpc then compensatory
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Chapter Is INTRODUCTION
This thesis chronicles the work undertaken over the course of a postgraduate research
project funded by the Medical Research Council. The focus is a family of small
proteins, the synucleins, implicated in several neurodegenerative pathologies now
classified together as the synucleinopathies. This is an attempt to elucidate
potentially valuable information relating to their physiological function.
1.1 History of the synuclein family
1.1.1 Synucleins
Synucleins are small proteins (123-143 amino acids) characterised by imperfect
(KTKEGV) repeats distributed throughout the highly conserved amino-terminal half
of the polypeptide. Synucleins have a more diverse acidic carboxyl-terminal (C-
terminal) region possessing very little homology and are expressed exclusively in
vertebrates (Fig. 1.1).
The first synuclein was cloned from the electric ray Torpedo Californica by
screening an expression library with an antiserum raised against cholinergic vesicles
(Maroteaux, Campanelli and Scheller, 1988). This protein was named synuclein due
to its initial localisation within the presynaptic nerve terminal and neuronal nuclei.
There are three identified synuclein proteins now known as a-, (3- and y-synuclein.
These are a family of natively unfolded proteins, which have little or no ordered
tertiary structure under physiological conditions, characterised by a unique
combination of low overall hydrophobicity and large net charge (Weinreb, Zhen,
Poon, Conway, Lansbury, 1996; Uversky, Li and Fink, 2001).
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a-synuclein first began to attract attention in 1993 with the discovery that a 35 amino
acid fragment of the so-called non-Ap component precursor protein (NACP) was
present in the senile plaques found in Alzheimer's disease patients (Table 1.1) (Ueda,
Fukushima, Masliah, Xia, Iwai, Yoshimoto, Otero, Kondo, Ihara and Saitoh, 1993).
Subsequently, the avian ortholog of a-synuclein, synelfin, was described as being up-
regulated during the critical phase of song learning in the zebra finch, leading to the
hypothesis that this synuclein was involved in neuronal plasticity (George, Jin,
Woods and Clayton, 1995). Interest intensified with the discovery that a mutation at
the a-synuclein locus was present in families displaying inherited Parkinson's
disease. This mutation produces an alanine-53-threonine (A53T) amino acid
substitution in the encoded protein. This was found to be present in Italian kindred
and three unrelated Greek families suffering early onset familial Parkinson's disease
(PD) (Polymeropoulos, Lavedan, Leroy, Ide, Dehejia, Dutra, Pike, Root, Rubenstein,
Boyer, Stenroos, Chandrasekharappa, Athanassiadou, Papapetropoulos, Johnson,
Lazzarini, Duvoisin, Di Iorio, Golbe andNussbaum, 1997). A second mutation,
alanine-30-proline (A3 OP), was also reported to be associated with families
displaying this rare inherited form of the disease (Kruger, Kuhn, Muller, Woitalla,
Graeber, Kosel, Przuntek, Epplen, Schols and Riess, 1998). The pathological
significance of these mutations will be discussed in greater detail below, suffice to
say that synucleins have become of great interest due to their involvement in a wide
range of neurodegenerative disorders.
1.1.2 a-synuclein
The a-synuclein gene (SNCA) has been localised to chromosome 4ql2.3-q22 and
contains seven exons, five of which are highly conserved coding exons (Campion,
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Martin, Heilig, Charbonnier, Moreau, Flaman, Petit, Hannequin, Brice and Frebourg,
1995; Chen, de Silva, Pettenati, Rao, St George-Hyslop, Roses, Xia, Horsburgh,
Ueda and Saitoh, 1995; Shibasaki, Baillie, St Clair and Brookes, 1995). The 5'-
untranslated region of the a-synuclein gene contains an exon with two alternative
splice sites, which could be considered as two adjacent exons (exons 1 and 2).
All of the a-synuclein proteins described are identical between species for the first 42
amino acids. The human and rodent orthologs are 140 amino acids long in total and
the avian ortholog synelfin is three residues longer. Human and rodent proteins share
95.3% homology and rat and mouse only differ in one residue at Ser 121.
The unique motif, which is common to all the synucleins is a repeating KTKEGV
domain of which a-synuclein possesses six and was first described by Maroteaux
(Martoeaux et al., 1988). The most recently identified synuclein mutation with a
causative role in familial PD has also implicated these repeating domains in
regulating fibrilisation of the protein. The mutation within one of these N-terminal
repeats, E46K, has been shown to increase fibril formation in vivo (Greenbaum,
Graves, Mishizen-Eberz, Lupoli, Lynch, Englander, Axelsen and Giasson, 2005).
The fibrilisation of a-synuclein will be discussed in greater detail later (section
1.5.2).
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Figure 1.1 Amino acid sequence alignment of the human synuclein
proteins
The imperfect repeats of the type KTKEGV are identified. The black
background highlights amino acid residues conserved between all three
proteins. The sequences of a- and p-synucleins were obtained from Jakes,
Spillantini and Goedert (1994) and y-synuclein from Ji, Liu, Jia, Wang, Liu,





















Repeat5t6 NVGGWVTGVTAVAQKTVEGAGS >HLGg|fSGA Nj vlAVSkHvssvntvatktveeae|
\A7»F»<KDQL100 VYTW_1<REEF89 r\/TSHVW?KE--98
a-synucleinGK--NEEGAPMGILEDM—PVD-PDNEAYEM- SEE YQDYEPEA ^-synucleinPTDLKPEEVaHaaEEPLIEPLMEPEGESYEDPPQEE-YQ E A y-synuclein—DLRPSAPqHgEASKEKEEVAEEAQSGGD
140 134 127
1.1.3 p-synuclein
The protein which was to become P-synuclein was purified and described as an
acidic neurospecific protein present in bovine brain lysate (Nakajo, Tsukada, Omata,
Nakamura and Nakaya, 1993). This 14kDa protein termed phosphoneuroprotein
(PNP-14) (Table 1.1) was initially thought to be neurospecific, but this is now known
not to be the case (section 1.2.2) (Tobe, Nakajo, Tanaka, Mitoya, Omata, Nakaya,
Tomita and Nakamura, 1992; Nakajo et al., 1993). Further studies localised PNP to
synaptic membranes and observed that PNP made up 0.1% of total brain protein
(Shibayama-Imazu, Okahashi, Omata, Nakajo, Ochiai, Nakai, Hama, Nakamura and
Nakaya, 1993).
The P-synuclein gene (SNCB) has been localised to chromosome 5q35 and is made
up of six exons, five ofwhich are coding (Spillantini, Divane and Goedert, 1995;
Lavedan, Leroy, Torres, Dehejia, Dutra, Buchholtz, Nussbaum and Polymeropoulos,
1998b). The 61% homology between bovine PNP 14 and human a-synuclein was
noted by Jakes and colleagues who classified the two as members of the synuclein
family, referring to them as a and p (Jakes et al., 1994).
P-synuclein is a 134 amino acid protein and exhibits the highest degree of
interspecies homology of all the synucleins possessing five of the characteristic
KTKEGV repeat motifs. Mouse and rat orthologs are identical and share 97.8%
homology with human P-synuclein which in turn shares 78% identity with human a-
synuclein (Jakes et al., 1994).
2"h
p-synuclein has been shown to be phosphorylated in vivo by Ca /calmodulin
activated protein kinase II (CAMK-II) at residue Ser 118 which is conserved in all
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species. The conservation of this residue is not seen in either a- or y-synuclein
(Nakajo et ah, 1993).
1.1.4 y-synuclein
The third member of the synuclein family was initially described in a high
throughput screen as a protein abnormally expressed in cancerous breast tissue (Ji et
al., 1997). Breast cancer specific gene-1 (BCSG-1) was shown to be largely absent in
normal tissue but strongly expressed in malignant breast cancer tissue and was
advocated as a potential marker gene (Ji et ah, 1997). Homology with the NACP
peptide found in Alzheimer's disease brains was subsequently observed (Ji et ah,
1997). In 1998, human y-synuclein was identified, characterised and localised to
chromosome 10q23 (Lavedan et ah, 1998b). This was confirmed with the
independent characterisation and localisation of persyn, identical to y-synuclein, to
the long arm of chromosome 10 in the q23.2-23.3 region (Ninkina, Alimova-Kost,
Paterson, Delaney, Cohen, Imreh, Gnuchev, Davies and Buchman, 1998). Synoretin
was described as a member of the synuclein family expressed in retinal cells
(Surguchov, Surgucheva, Solessio and Baehr, 1999). However this protein is
identical to y-synuclein and this is now the accepted nomenclature for these proteins
(Table 1.1). The y-synuclein gene (SNCG) is comprised of five exons, all of which
include coding regions. This 127 amino acid protein shows the least amount of
homology of all the synuclein proteins. The human protein shares 87.7 and 83.8%
with the mouse and rat orthologs respectively and only 60% homology with human
a-synuclein at the amino acid level (George, 2002). The Torpedo ortholog is a longer
protein of 143 amino acids with an altered repeating motif TKQGVQDAAE, and the
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last 35 amino acids bear very little homology to either the human or rodent molecule
(George, 2002).
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Table 1.1 Orthologs of the synuclein proteins
Table identifies the previous names of the synuclein orthologs and the





Species Previous Name First Description




a Canary Synelfin George et al., 1995
P Human #
P Bovine PNP-14 Nakajo et al., 1993




y Human BCSG-1, Persyn Ji et al., 1997; Ninkina
et al., 1998
y Rat #
y Mouse Persyn Alimova-Kost et al.,
1999
y Chicken Persyn Tiunova et al., 2000
Y Bovine Synoretin Surguchov et al., 1999
y Electric ray Synoretin Surguchov et al., 1999
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1.2 Localisation of synucleins
1.2.1 Distribution and intracellular localisation of a-synuclein
As previously mentioned, the initial description of a-synuclein localised it to the
presynaptic compartment of the nerve terminals of the electric organ of Torpedo
Californica (Maroteaux et al., 1988). In rodents, a-synuclein mRNA has been shown
to be present in brain structures such as the cortex, substantia nigra (SN), the
amygdala and hippocampus (Abeliovich, Schmitz, Farinas, Choi-Lundberg, Ho,
Castillo, Shinsky, Verdugo, Armanini, Ryan, Hynes, Phillips, Sulzer and Rosenthal,
2000; Kholodilov, Neystat, Oo, Lo, Larsen, Sulzer and Burke, 1999; Lavedan, Leroy,
Dehejia, Buchholtz, Dutra, Nussbaum and Polymeropoulos, 1998a).
As early as 1995, a study in rat brain reported co-localisation of a-synuclein with
synaptophysin in the synaptic termini of the neocortex, hippocampus, olfactory bulb,
striatum, thalamus and cerebellum (Iwai, Masliah, Yoshimoto, Ge, Flanagan, de
Silva, Kittel and Saitoh, 1995). More recently, a study ofmurine brain showed the
presence of a-synuclein protein in the SN, ventral tegmental area (VTA), striatum,
globus pallidus, cortex with the most heterogeneous staining observed in the
hippocampus, dentate gyrus and amygdala (Totterdell, Hanger and Meredith, 2004).
Electron microscopy revealed that the majority of a-synuclein protein could be found
at synaptic boutons in association with vesicle membranes (Totterdell et al., 2004).
In humans, the highest level of a-synuclein mRNA expression is found in the
dopaminergic neurones of the SN (Solano, Miller, Augood, Young and Penney,
2000). It is also seen in the striatum, dentate granual cells, hippocampus, deep layers
of the cortex and the globus pallidus (Abeliovich et al., 2000). An expression study
of all three synucleins during the development of the SN revealed that expression
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began at 15, 17 and 18 weeks gestation for a-, (3- and y-synuclein respectively,
coinciding with proteins such as synaptotagmin and synaptobrevin (Galvin, Schuck,
Lee and Trojanowski, 2001b). A sequential re-distribution from the perikarya of SN
neurones to the nerve terminals was observed (Galvin et al., 2001b). Synaptotagmin
and a-synuclein are redistributed after 18 weeks gestation, synaptobrevin and P-
synuclein between 20-28 weeks and synaptophysin and y-synuclein between 33
weeks gestation and 9 months post partum (Galvin et al., 2001b). This evidence
supports the hypothesis that the synucleins have a role in the development and
maturation of neurones. A study of a-synuclein expression in the mouse brain
confirmed this shift in compartmentalisation (Hsu, Mallory, Xia, Veinbergs,
Hashimoto, Yoshimoto, Thai, Saitoh and Masliah, 1998). The same study also
confirmed that protein expression began during embryonic development and rose
sharply from El2 (Hsu et al., 1998).
1.2.2 Distribution and intracellular localisation of p-synuclein
The first expression study of P-synuclein carried out in the rat concluded that protein
expression began post partum and increased to a maximum level 21-28 days after
birth (Shibayama-Imazu et al., 1993). P-synuclein was localised to the termini of
cerebellar neurones and could also be observed in cultured midbrain neurones
(Shibayama-Imazu et al., 1993). In 1994, a study of mRNA expression in adult rat
brain identified P-synuclein transcripts in the granular, molecular and Purkinje layers
of the cerebellar cortex, in hippocampus, striatum and cerebral cortex particularly the
terminals of layer V (Nakajo, Shioda, Nakai and Nakaya, 1994). P-synuclein was
reported in non-neuronal tissue in 1998 with the finding that it was associated with
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fibrillar structures in Sertoli cells of the rat testes (Shibayama-Imazu, Ogane,
Hasegawa, Nakajo, Shioda, Ochiai, Nakai and Nakaya, 1998).
A study of p-synuclein protein expression in the central nervous system of adult rats
confirmed the pattern of mRNA expression, with positive immunostaining
throughout the brain (Li, Henning Jensen and Dahlstrom, 2002). Expression was
noted particularly at synaptic terminals in numerous structures including the
olfactory bulb, cortex, structures of the basal ganglia, basal forebrain and amygdala
(Li et al., 2002). The hippocampus, in particular the dentate gyrus, and many
midbrain structures including motor nuclei such as the trocular and occularmotor
nucleus also showed expression. As mentioned above, P-synuclein is expressed in
the SN during gestation in humans and undergoes redistribution between 20-28
weeks from perikarya to terminals (Galvin et ah, 2001b). A broad description of P-
synuclein expression would be that it is widely distributed throughout the brain
particularly in the cortex and in the synaptic terminals of cholinergic neurones (Li et
ah, 2002).
1.2.3 Distribution and intracellular localisation of y-synuclein
y-synuclein mRNA is expressed in the brain and spinal cord of vertebrate species,
but it is most abundant in the peripheral nervous system (PNS) including neurones of
the dorsal root ganglia and trigeminal ganglia beginning at El 1 in the mouse embryo
(Buchman, Hunter, Pinon, Thompson, Privalova, Ninkina and Davies, 1998;
Tiunova, Anokhin, Saha, Schmidt, Hanger, Anderton, Davies, Ninkina and
Buchman, 2000). In addition, y-synuclein is highly expressed in the stratum
granulosum of the epidermis from P5 in the mouse (Ninkina, Privalova, Pinon,
13
Davies and Buchman, 1999). Interestingly, y-synuclein expression is up-regulated in
advanced infiltrating breast carcinoma and over-expression in breast cancer cells
augments cell motility, invasiveness and metastasis, which will be described in
greater detail below (section 1.7) (Ji et al., 1997; Bruening, Giasson, Klein-Szanto,
Lee, Trojanowski and Godwin, 2000).
y-synuclein was reported as being highly expressed in the SN and in human embryos
expression begins at 18 weeks gestation (Galvin, Lee and Trojanowski, 2001a). As
mentioned, a translocation occurs at 33 weeks from the perikarya into the
dopaminergic terminals in parallel with synaptophysin (Lavedan et al., 1998a; Galvin
et al., 2001a).
A study of protein localisation in adult rat brain made the observation that y-
synuclein was expressed in fewer structures than either a- or P-synuclein and
significantly that expression was seen in the perikarya of cells in many structures (Li
et al., 2002). In contrast to a- and P-synuclein expression, y-synuclein was sparsely
expressed in the olfactory bulb and absent in the cortex, caudate, putamen,
hippocampus and thalamus (Li et al., 2002). High levels of immunostaining were
observed in the perikarya and processes of hypothalamic structures and the SN (Li et
al., 2002). In addition, cells of the mammillary, red, raphe, trochlear, oculormotor,
trigeminal motor and hypoglossal nuclei were seen to express y-synuclein (Li et al.,
2002). Moving caudally, the pons, the nerve terminals of the locus coreleus displayed
intense y-synuclein staining as did Lamina I and II of the spinal cord (Li et al., 2002).
In summary, expression of y-synuclein appeared very weak or was virtually absent
from the forebrain. However, it was abundant in somatic cholinergic nuclei and in
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autonomic components in the basal forebrain, the brainstem and the spinal cord (Li et
al., 2002).
The significance of the differential distribution of a-, p- and y-synucleins is not clear.
However, these differences could imply functional differences between these
proteins.
1.3 Physiological function of the synucleins
1.3.1 Functional characteristics of synucleins
The hypothesis that the synucleins have a role in synaptic plasticity was supported by
increased expression of the a-synuclein avian ortholog synelfin during a critical
patterning phase of neuronal plasticity in the development of the zebra finch (George
et al., 1995). Subsequent studies support the idea that synucleins are important in the
maturation of a developing synapse once synaptic connections have formed. For
example, in cultured rat hippocampal neurones a-synuclein is not detected until five
days after connections formed in culture (Withers, George, Banker and Clayton,
1997).
There is no doubt that the synucleins are present at the presynaptic terminal. What is
in doubt is their precise role. Synucleins may be exclusively associated with synaptic
vesicles or they may interact with other parts of synaptic infrastructure binding only
transiently to lipids. Interestingly, a-synuclein is not enriched in purified synaptic
vesicle preparations (George et al., 1995; Irizarry, Kim, McNamara, Tanzi, George,
Clayton and Hyman, 1996), which suggests that synucleins does not bind directly to
vesicles. However, other mutations demonstrated that a-synuclein could interact
directly with lipid vesicles (Davidson, Jonas, Clayton and George, 1998).
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The protein structure of a-synuclein suggests the presence of amphipathic alpha-
helical domains, similar to the exchangeable apolipoproteins (Davidson et al., 1998).
It was hypothesised by Davidson and colleagues that a-synuclein should associate
with phospholipid bilayers and that this lipid association should stabilise the a-
helical secondary structure in the protein (Davidson et al., 1998). a-synuclein binds
small unilamellar vesicles containing acidic phospholipids, but not to vesicles with a
net neutral charge (Davidson et al., 1998). Lipid binding was accompanied by an
increase in a-helicity from 3% to approximately 80% (Davidson et al., 1998).
Subsequently, the exact nature of this interaction has been characterised in greater
detail and a-synuclein has been shown to interact with acidic vesicles via the N-
terminal (Ramakrishnan, Jensen and Marsh, 2003). A conformational change occurs
as the hydrophobic N-terminal interacts with the vesicle changing from a flattened
conformation into two a-helical domains separated by a two amino acid break
(Chandra, Chen, Rizo, Jahn and Sudhof, 2003). From these results it was
hypothesised that a-synuclein forms a surface-active coat for phospholipid
membranes at the presynaptic membrane. The N-terminal homology shared between
the three synucleins suggests that all the proteins would form the same structures
(Chandra et al., 2003). However, a-synuclein differs from the other two synucleins as
it has a longer second a-helix than p-synuclein, and has a more hydrophobic surface
than y-synuclein (Chandra et al., 2003). This difference may explain the selective
propensity of a-synuclein to aggregate and thus explain its involvement in
neurodegenerative diseases.
A loss of a-synuclein expression has been shown to precipitate a reduction in the
number of reserve pool vesicles in hippocampal neurones both in vitro (Murphy,
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Rueter, Trojanowski and Lee, 2000) and in vivo (Cabin, Shimazu, Murphy, Cole,
Gottschalk, Mcllwain, Orrison, Chen, Ellis, Paylor, Lu and Nussbaum, 2002).
However, there is little effect on vesicles docked at the presynaptic membrane,
implying a role in vesicle formation possibly through an interaction with synphillin-
1, a protein shown to interact with a-synuclein in yeast two-hybrid screens (Ribeiro,
Carneiro, Ross, Menezes and Engelender, 2002).
1.3.2 Synucleins and the dopamine transporter
Controversy has arisen recently regarding the association of a-synuclein with the
dopamine transporter (DAT). The DAT is a member of a large gene family of Na+
and Cf dependent transporters. They share a common topology of 12 putative
transmembrane (TM) domains, intracellular amino and carboxyl termini, a large
extracellular loop between TM 3 and 4 which contain numerous consensus sequences
for TV-linked glycosylation (Loland, Norgaard-Nielsen and Gether, 2003). There are
putative sites for phosphorylation by protein kinase A (PKA), protein kinase C
(PKC) and CAMK-II within intracellular domains including the N- and C- termini
(Reith and Chen, 1997). The DAT is expressed in presynaptic terminals of SN
neurones (Reith and Chen, 1997).
Initial results indicated that a-synuclein complexed directly with DAT via the C-
terminal tail of the transporter in human neurones and co-transfected cells (Lee, Liu,
Pristupa and Niznik, 2001). This complex promotes clustering of the DAT in the
membrane thereby accelerating the re-uptake of dopamine from the synaptic cleft
possibly promoting excitotoxicity, which will be discussed later (section 1.5.3)
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(Reith and Chen, 1997; Lee et al., 2001). These results would implicate a-synuclein
directly in a possible cytotoxic mechanism.
However, other studies have noted the formation of a stable complex between a-
synuclein and DAT, with directly contradictory results. Wersinger et al. (2003)
reported an inhibitory effect on dopamine re-uptake in co-transfected cells, with a
reduced rate of flow as a function of a-synuclein concentration (Wersinger, Prou,
Vernier, Niznik and Sidhu, 2003). In vivo studies carried out to compare a-synuclein
null mutant mice to wild-types have revealed that the absence of a-synuclein has no
effect on the kinetics of DAT (Dauer, Kholodilov, Vila, Trillat, Goodchild, Larsen,
Staal, Tieu, Schmitz, Yuan, Rocha, Jackson-Lewis, Hersch, Sulzer, Przedborski,
Burke and Hen, 2002).
There is considerable evidence to suggest that a-synuclein does indeed form a
complex with DAT. However, the purpose and effect of this association is unclear.
Nonetheless the ability of a-synuclein to bind and modulate dopamine re-uptake may
have the potential to impact upon neuronal survival, and thus had direct relevance to
the pathological processes observed in synucleinopathies.
1.3.3 Chaperone activity of the synucleins
Many interaction partners have been reported for a-synuclein, including the
extracellular signal-regulated kinases (ERK1/2; Ostrerova, Petrucelli, Farrer, Mehta,
Choi, Hardy and Wolozin, 1999), 14-3-3 (Ostrerova et al., 1999), Tat binding protein
1 (Ghee, Fournier and Mallet, 2000), parkin (Shimura, Schlossmacher, Hattori,
Frosch, Trockenbacher, Schneider, Mizuno, Kosik and Selkoe D, 2001), tau and
microtubule associated protein IB (Jensen, Hager, Nielsen, Hojrup, Gliemann and
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Jakes, 1999), (3-synuclein (Hashimoto, Rockenstein, Mante, Mallory and Masliah,
2001) Ap and the P-amyloid peptide (NACP) (Yoshimoto, Iwai, Kang, Otero, Xia
and Saitoh, 1995). a-synuclein has also been shown to modulate the activity of
several crucial proteins via its interaction with them. These include tyrosine
hydroxylase (TH) (Perez and Zigmond, 2000), PKC (Ostrerova et al., 1999), ERK2
(Iwata, Miura, Kanazawa, Sawada and Nukina, 2001) and phospholipase D2 (PLD2)
(Jenco, Rawlingson, Daniels and Morris, 1998). The evidence showing the ability of
a-synuclein to bind and in some cases modulate the activity of a wide range of
different proteins has led to the hypothesis that a-synuclein is a chaperone protein
(Perez and Hastings, 2004).
Biochemical evidence shows that recombinant a-synuclein has a chaperone-like
function against thermal and chemical stress in vitro, protecting glutathione S-
transferase (GST) and aldolase from heat-induced precipitation, and alpha-
lactalbumin and bovine serum albumin from dithiothreitol-induced precipitation like
other molecular chaperones (Kim, Paik, Yang and Kim, 2000). In addition, a-
synuclein can be rapidly and significantly precipitated by heat in the presence of Zn2+
ions in vitro, whereas it was not affected by the presence of Ca2+ or Mg2+ ions (Kim
et ah, 2000). Circular dichroism spectra confirmed that a-synuclein undergoes a
2"bconformational change in the presence of Zn (Kim et ah, 2000), possibly to regulate
its chaperone activity.
14-3-3 proteins are a family of chaperone proteins which are also widely expressed
in the brain (Layfield, Fergusson, Aitken, Lowe, Landon and Mayer, 1996). a-
synuclein shares up to 40% sequence homology with 14-3-3 proteins and can bind to
14-3-3 proteins providing yet more evidence of a role for a-synuclein as a chaperone
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(Ostrerova et al., 1999). Another significant finding linking a-synuclein with 14-3-3
proteins is their shared ability to bind TH, the critical rate-limiting enzyme involved
in the dopamine synthesis pathway (Ichimura, Isobe, Okuyama, Takahashi, Araki,
Kuwano and Takahashi, 1988; Perez and Zigmond, 2000). a-synuclein is a negative
regulator of TH in vitro, thereby inhibiting normal function, precipitated as a
reduction in dopamine synthesis in transfected dopaminergic cells (Perez, Waymire,
Lin, Liu, Guo and Zigmond, 2002).
The interactions of a-synuclein with TH and DAT, combined with its ability to affect
synaptic vesicles, may thus have specific implications for nigral dopaminergic
neurones during the pathogenesis of Parkinson's disease. Chaperone activity is not
restricted to a-synuclein; P- and y-synuclein have also displayed this activity (Souza,
Giasson, Lee and Ischiropoulos, 2000). All three synucleins have been shown to
suppress the aggregation of thermally denatured alcohol dehydrogenase and
chemically denatured insulin (Souza et al., 2000). This same study also revealed that
residues 98-140 within the C-terminal are critical to the chaperone activity of a-
synuclein as this activity is lost upon removal of this stretch of amino acids. The C-
terminal is a highly acidic region which displays the least amount of homology
between the synuclein proteins, suggesting this region may be the source of the
specificity and activity of individual synucleins.
Subsequent studies of a-synuclein revealed that the N-terminal domain (residues 1-
95) bind to substrate proteins to form high molecular weight complexes. The C-
terminal acidic tail (residues 96-140) appears to be primarily involved in solubilising
the high molecular weight complexes. This suggests that it is the C-terminal domain
which is responsible for the specificity of the chaperone activity (Park, Jung, Kim,
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Park, Yang and Kim, 2002; Lee, Paik and Choi, 2004). p-synuclein has recently been
shown to be a more effective chaperone than a-synuclein when suppressing the heat
activated aggregation of adolase, alcohol dehydrogenase and citrate synthase (Lee et
al., 2004). Moreover, P-synuclein inhibits the amyloid formation of both Ap and a-
synuclein, suggesting a protective role in vivo (Lee et al., 2004).
1.3.4 Regulatory effects of synucleins
An animal model with an a-synuclein null mutation showed enhanced striatal
dopamine (DA) release when compared with wild-type mice in a paired pulse
paradigm of hippocampal plasticity (Abeliovich et al., 2000). This suggested that TH
may be more active in the absence of any inhibitory effects a-synuclein may have.
The absence of a-synuclein would be expected to increase TH activity therefore
producing more DA for release at the second pulse. Curiously, the a-synuclein null
mutant had a slight but significant reduction in striatal DA levels (Abeliovich et al.,
2000). This could be the result of a reduction in the efficiency of DAT in the absence
of a-synuclein, but this hypothesis has not yet been tested. It is noteworthy that a
different strain of a-synuclein null mutant mice generated by Thomas Sudhof and
colleagues had no reduction in striatal DA (Schluter, Fornai, Alessandri, Takamori,
Geppert, Jahn and Sudhof, 2003).
A second factor influenced by a-synuclein which may also have bearing on
neurotransmitter levels could be a change in the number of synaptic vesicles.
However, Sudhof and colleagues saw no change in vesicle proteins, implying that
normal vesicle numbers were maintained throughout the brain in these a-synuclein
null mice (Schluter et al., 2003). Reduced numbers of vesicles were seen in
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hippocampal neurones in a third of a-synuclein null mice (Cabin et al., 2002),
supporting findings of Murphy and colleagues who saw a similar reduction in vesicle
number in hippocampal neurones when treated with antisense-a-synuclein
oligonucleotides (Murphy et al., 2000).
The mice produced and described by Schulter et al. (2003) displayed a small but
significant increase in P-synuclein expression in the striatum suggesting a
compensatory mechanism in the absence of a-synuclein. This hypothesis is
supported by the finding that both a- and (3-synuclein can efficiently inhibit the
activity of PLD2 (Jenco et al., 1998), suggesting some redundancy of function
between these synuclein family members.
1.3.5 Proteosomal inhibition
Recent studies indicate that aggregated a-synuclein binds to S6', a component of the
19S in the 26S proteasome, and inhibits 26S proteasomal degradation in both a
ubiquitin-independent and ubiquitin-dependent manner (Snyder, Mensah, Hsu,
Hashimoto, Surgucheva, Festoff, Surguchov, Masliah, Matouschek and Wolozin,
2005). Monomeric a- and P-synuclein were shown to inhibit 20S and 26S
proteosome activity weakly, while y-synuclein strongly inhibited ubiquitin-
independent proteolysis (Snyder et al., 2005). Aggregated a-synuclein molecules
were shown to have an inhibitory effect on ubiquitin-independent proteosomal
degradation (Snyder et al., 2005). Co-incubating these proteins in various
combinations revealed that while P-synuclein has no direct effect on proteosomal
degradation it does act as a negative regulator of a-synuclein (Snyder et al., 2005).
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1.4 The pathological significance of the synucleins
1.4.1 Synucleinopathies
Synucleinopathies, or a-synucleinopathies as they are sometimes termed, are a
collection of neurodegenerative disorders that share one common feature;
cytoplasmic inclusions of which a-synuclein is a constituent part, as described below
(Galvin, IJryu, T ee and Trojanowski, 1999). However, this definition is not precisely
accurate as the other synucleins have been detected in lesions of certain
neurodegenerative diseases (Galvin, Giasson, Hurtig, Lee and Trojanowski, 2000).
The following is a summary of these "synucleinopathies" and the role the synucleins
play in their pathology.
1.4.2 Alzheimer's disease
The link between neurodegenerative disease and a-synuclein was first reported for
Alzheimer's disease (AD) when the small peptide termed "NAC" was purified from
an AD brain, leading to the cloning of the non-AP component precursor protein
(NACP) (Ueda et al., 1993) now known to be a fragment of a-synuclein. It was
thought that NACP, a 35 amino acid fragment of a-synuclein, was a constituent of
the AD senile plaques, the extracellular lesions abundant in AD brain (Ueda et al.,
1993). However, recent evidence revealed that a-synuclein was not an integral
component of senile plaques in either human AD (Culvenor, McLean, Cutt,
Campbell, Maher, Jakala, Hartmann, Beyreuther, Masters and Li, 1999) or in
transgenic mouse models of AD, but was sometimes present in neurites at the plaque
periphery (Yang, Ueda, Chen, Ashe and Cole, 2000).
23
1.4.3 Parkinson's disease
Parkinson's disease (PD) is a progressive neurodegenerative disorder that is
becoming more prevalent with a decreasing age of onset, currently afflicting around
1.6% of Europe's over sixty five population, four million globally (World Health
Organisation, 1998). The condition was first described in the 1817 monograph,
"Essay on the shaking palsy" by James Parkinson. It is characterised by severe motor
symptoms including uncontrollable tremor, postural imbalance, slowness of
movement and rigidity. The pathological hallmarks of this disorder are the presence
of eosinophilic inclusions named Lewy bodies (LB) (section 1.5.1) and a pronounced
loss of dopaminergic neurones in the substantia nigra pars compacta (SNpc). This
neuronal depletion results in a reduction in the levels of striatal dopamine, thus
disrupting the feedback regulation in the basal ganglia and hence motor function.
LBs, which contain a-synuclein are thought to be neurotoxic and hence play a role in
neurodegeneration.
1.4.4 Etiological factors of Parkinson's disease
The disease can arise sporadically, as a result of environmental factors or can be due
to genetic factors, discussed below. Environmental toxins, including transition metals
such as iron and copper, have been identified as potential risk factors (Gorell,
Johnson, Rybicki, Peterson, Kortsha, Brown and Richardson, 1997). Accumulation
of these metal ions within neurones is thought to be toxic as the metals participate in
oxidation reactions leading to neurotoxic products (Dexter, Wells, Lees, Agid, Agid,
Jenner and Marsden, 1989). Metals have also been shown to interact with a-
synuclein to promote fibrilisation (Uversky et al., 2001). Pesticides are another class
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of agent with an apparent neurotoxic effect relevant to PD. Agricultural workers
exposed to pesticides have been shown to have increased risks of developing PD in a
dose-dependant manner (Semchuk, Love and Lee, 1992; Gorell, Johnson, Rybicki,
Peterson and Richardson, 1998). Chemicals such as bipyridyl (paraquat),
organochlorine and carbamate are all widely used and have been implicated in PD
(Semchuk et al., 1992).
1.4.5 The genetic link to Parkinson's disease
Sporadic forms of the disease account for 95% of cases. Nevertheless, studying rare
genetic forms of the disease may uncover phenotypic similarities between genetic
and sporadic forms. This would indicate a common pathogenic mechanism such that
genetic analysis might reveal a common key biochemical pathway to target for
therapeutic development. This is particularly significant here as PD is the only
synucleinopathy in which a genetic mutation of the a-synuclein gene has been
directly linked with pathogenesis.
Five PD genes have been identified and studied in some detail; a-synuclein, parkin,
ubiquitin C-terminal hydrolase LI (UCHL-1), DJ-1 and PINK1. All have been
shown to participate in the ubiquitin-proteasome pathway, a particularly compelling
finding considering the Lewy body (LB) protein aggregates that characterise PD
neuropathology.
1.4.6 a-synuclein and Parkinson's disease
Interest in synucleins accelerated in the late 90's with the discovery of two point
mutations, A53T and A30P at the a-synuclein locus, present in families suffering
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early onset PD (Polymeropoulos et al., 1997; Kruger et al., 1998). The A53T
translocation in a-synuclein was identified in a number of Italian kindred and three
unrelated Greek families found on the long arm of human chromosome 4
(Polymeropoulos et al., 1997). The phenotypic appearance of the symptoms due to
this mutation were typical for PD, including the presence of Lewy bodies (section
1.5.1), the only exception being the relatively early age of onset, 46 ± 13 years
(Polymeropoulos et al., 1997). Within the large Italian family, the penetrance of the
mutated gene was approximately 85% suggesting that this single genetic defect was
sufficient to determine the PD phenotype (Polymeropoulos et al., 1997). The A30P
mutation has only been identified in one German family with autosomal dominantly-
inherited parkinsonism (Kruger et al., 1998).
The fact that fibrillated a-synuclein is abundant in LBs suggests that its propensity to
misfold and form amyloid fibrils may be responsible for its neurotoxicity in
pathological conditions such as PD and that pathogenic mutations precipitate a toxic
function (Wakabayashi, Engelender, Yoshimoto, Tsuji, Ross, Takahashi, 2000).
Misfolding of a-synuclein may interfere with its normal functions, but it is unlikely
that loss of function plays a major role in a-synuclein-related neurodegeneration
(Abeliovich et al., 2000; Dauer et al., 2002). Both wild-type and mutant a-synuclein
form amyloid fibrils resembling those seen in LBs (Conway, Harper and Lansbury,
1998; Giasson, Uryu, Trojanowski and Lee, 1999) and nonfibrillary oligomers
termed "protofibrils" (Conway et al., 1998). The two known pathogenic a-synuclein
mutations (A53T + A30P) promote the formation of protofibrils, suggesting they
may be the toxic species of a-synuclein (Conway, Lee, Rochet, Ding, Harper,
Williamson and Lansbury, 2000). Consistent with this view and the association of a-
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synuclein with synaptic vesicles, protofibrils may cause toxicity by permeabilising
synaptic vesicles (Voiles, Lee, Rochet, Shtilerman, Ding, Kessler and Lansbury,
2001; Lashuel, Petre, Wall, Simon, Nowak, Walz and Lansbury, 2002), allowing DA
to leak into the cytoplasm and participate in reactions that generate oxidative stress
as discussed below (section 1.5.3). To date protofibrils have only been observed and
studied in vitro, so further work will need to explore whether they form in neurones
and if their formation correlates with neurotoxicity.
In addition to the original two a-synuclein point mutations which linked synucleins
with familial PD, a third mutation has been shown to cause PD within a group known
as the Iowa kindred (Singleton, Farrer, Johnson, Singleton, Hague, Kachergus,
Hulihan, Peuralinna, Dutra, Nussbaum, Lincoln, Crawley, Hanson, Maraganore,
Adler, Cookson, Muenter, Baptista, Miller, Blancato, Hardy and Gwinn-Hardy,
2003). This mutation is a triplication of the a-synuclein gene at the correct locus on
one chromosome resulting in overproduction and accumulation of a-synuclein.
Excess cytosolic a-synuclein has shown to increase the likelihood of fibril formation
and hence increased neurotoxicity (section 1.5.2).
The most recent a-synuclein mutation linked to neurodegenerative conditions is the
E46K point mutation within one of the characteristic KTKEGV N-terminal repeat
regions. This was identified within a Spanish family exhibiting Parkinson's disease
and Lewy body dementia (Zarranz, Alegre, Gomez-Esteban, Lezcano, Ros,
Ampuero, Vidal, Hoenicka, Rodriguez, Atares, Llorens, Gomez Tortosa, del Ser,
Munoz and de Yebenes, 2004). This fostered the hypothesis that these repeats,
specifically glutamate residues, may regulate a-synuclein fibrilisation. This was
found to be the case by Greenbaum et al, who also reported that point mutations
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replacing other glutamate residues within other repeats had the same effect
(Greenbaum et al., 2005).
1.4.7 Parkin
Parkin is a second gene identified as a cause of familial PD. Although this form was
originally termed autosomal recessive juvenile parkinsonism, the clinical phenotype
is now known to include older-onset patients (Kitada, Asakawa, Hattori, Matsumine,
Yamamura, Minoshima, Yokochi, Mizuno and Shimizu, 1998; Lincoln, Wiley,
Lynch, Langston, Chen, Lang, Rogaeva, Sa, Munhoz, Harris, Marder, Klein,
Bisceglio, Hussey, West, Hulihan, Hardy and Farrer, 2003). In general, however,
parkin mutations are found in PD patients with onset before age 30, particularly
those with a family history consistent with recessive inheritance (Mizuno, Hattori,
Kitada, Matsumine, Mori, Shimura, Kubo, Kobayashi, Asakawa, Minoshima and
Shimizu, 2001). Unlike the PD arising from mutations in a-synuclein, Lewy Bodies
are not seen in the parkinsonism triggered by Parkin mutations (Mizuno, Hattori and
Matsumine, 1998). However the fundamental pathology remains the same in either
case, i.e. the irreversible loss of dopaminergic neurones in the SNpc. It is uncertain
how loss of parkin function leads to dopaminergic neurone degeneration, but clues
are emerging from the identification of its physiological function. Parkin is an E3
ubiquitin ligase (Zhang, Gao, Chung, Huang, Dawson and Dawson, 2000; Shimura et
al., 2001), a component of the ubiquitin-proteasome system that identifies and targets
misfolded proteins to the proteasome for degradation (Sherman and Goldberg, 2001).
The upstream ubiquitin ligases (El and E2) co-operate non-specifically to tag
misfolded proteins with a single ubiquitin protein, while E3 ligases confer target
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specificity by binding to specific molecules or classes ofmolecules facilitating the
polyubiquitination necessary for targeting to the proteasome. Many parkin mutations
abolish this E3 ligase activity, suggesting that the accumulation of misfolded parkin
substrates could be responsible for the demise of SNpc dopaminergic neurones in PD
(Petrucelli, O'Farrell, Lockhart, Baptista, Kehoe, Vink, Choi, Wolozin, Farrer, Hardy
and Cookson, 2002).
Three reports suggest a relationship between parkin and synuclein function or
aggregation (Shimura et al., 2001; Petrucelli et al., 2002; Chung, Zhang, Lim,
Tanaka, Huang, Gao, Ross, Dawson and Dawson, 2001). Notably, the E3 ligase
activity of parkin modulates the sensitivity of cells to both proteasome inhibitor- and
mutant synuclein-dependent cell death (Petrucelli et ah, 2002). A number of
observations suggest that the functional interaction between a-synuclein and parkin
may involve the proteasome. Synuclein interacts with and is possibly degraded by
the proteasome (Ghee et ah, 2000; Snyder, Mensah, Theisler, Lee, Matouschek and
Wolozin, 2003), synuclein over-expression can inhibit the proteasome (Stefanis,
Kholodilov, Rideout, Burke and Greene, 2001) and mutant synuclein increases the
sensitivity of cells to proteasome inhibition (Tanaka, Engelender, Igarashi, Rao,
Wanner, Tanzi, Sawa, Dawson, Dawson and Ross, 2001; Petrucelli et ah, 2002).
1.4.8 Other genetic triggers of Parkinson's disease
Three other genetic triggers for Parkinson's disease have been identified but are not
currently known to involve a-synuclein directly. A dominant mutation (I93M) in
UCH-L1 was identified in one family with inherited PD but no pathological data
were included in this report (Leroy, Boyer, Auburger, Leube, Ulm, Mezey, Harta,
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Brownstein, Jonnalagada, Chernova, Dehejia, Lavedan, Gasser, Steinbach,
Wilkinson and Polymeropoulos, 1998). The UCH-L1 enzyme catalyses the
hydrolysis of C-terminal ubiquityl esters and is thought to play a role in recycling
ubiquitin ligated to misfolded proteins after their degradation by the proteasome
(Wilkinson, 2002). Although the I93M mutation decreases the activity of this
uquitinating enzyme, UCH-L1 null mice do not display dopaminergic
neurodegeneration (Saigoh, Wang, Suh, Yamanishi, Sakai, Kiyosawa, Harada,
Ichihara, Wakana, Kikuchi and Wada, 1999). Rather, they develop an axonopathy
that affects sensory axons in the gracile nucleus of the medulla (Saigoh et al., 1999).
A second mutation S18Y has been shown to have the converse effect by promoting
ligase activity, thus acting in a neuroprotective manner (Liu, Fallon, Lashuel, Liu and
Lansbury, 2002).
DJ-1 is a homodimeric multifunctional protein ubiquitously expressed throughout
human tissues (Bonifati, Dekker, Vanacore, Fabbrini, Squitieri, Marconi, Antonini,
Brustenghi, Dalla Libera, De Mari, Stocchi, Montagna, Gallai, Rizzu, van Swieten,
Oostra, van Duijn, Meco and Heutink, 2002). Eleven different DJ-1 mutations,
missense, truncation, splice site and large deletions have been linked to autosomal
recessive forms of PD (Bonifati et ah, 2002; Hague, Rogaeva, Hernandez, Gulick,
Singleton, Hanson, Johnson, Weiser, Gallardo, Ravina, Gwinn-Hardy, Crawley, St
George-Hyslop, Lang, Heutink, Bonifati, Hardy and Singleton, 2003). One family
carried a deletion predicted to abolish protein function, while the other harboured a
missense mutation that results in the insertion of a proline into an a-helical region
(Hague et ah, 2003). Expression of this proline mutant form of DJ-1 appears to lead
to its accumulation in mitochondria (Bonifati et ah, 2002), and DJ-1 has been
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implicated as a cellular monitor of oxidative stress (Mitsumoto and Nakagawa, 2001;
Mitsumoto, Nakagawa, Takeuchi, Okawa, Iwamatsu and Takanezawa, 2001). The
cytotoxic implications of oxidative stress are discussed in greater detail below
(section 1.5.3). As this discovery is recent, no pathological studies have been
performed hence it is not known if typical parkinsonian hallmarks are present.
A Sicilian family has been identified which carries a mutation at the PARK 6 locus,
lp35-36, associated with an autosomal recessive form of early onset PD (Valente,
Bentivoglio, Dixon, Ferraris, Ialongo, Frontali, Albanese and Wood, 2001).
Subsequently, a further eight families have been identified as carrying mutations in
this region, sequencing revealed two homozygous mutations in the gene encoding
PTEN-induced putative kinase-1 (PINK1) (Valente, Salvi, Ialongo, Marongiu, Elia,
Caputo, Romito, Albanese, Dallapiccola and Bentivoglio, 2004). PINK1 is a 581
amino acid protein expressed ubiquitously in mouse and at higher levels in the brain
(Valente et al., 2004). A single serine/threonine kinase domain appears to be the only
functional domain, however a mitochondrial trafficking signal may be present as the
protein was found to localise there in transfected cell lines (Valente et ah, 2004).
Although critical substrates have not yet been identified, loss of correct function
appears to be sufficient to trigger PD.
1.4.9 Multiple system atrophy
Multiple system atrophy (MSA) is a sporadic neurodegenerative disease of unknown
etiology with adult onset. The characteristic symptoms of MSA include
parkinsonism, ataxia and autonomic failure in any combination. The term MSA was
first coined in 1969 by Graham and Oppenheimer to describe a group of patients
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displaying symptoms of an unknown disorder which affected the pyramidal,
extrapyramidal, cerebellar and autonomic pathways (Graham and Oppenheimer,
1969). This term encompassed disorders previously named striatonigral degeneration
(SND), sporadic olivopontocerebellar atrophy (OPAC) and the Shy-Drager
Syndrome (SDS). Subsequently, further distinctions have been made. Patients with
predominantly parkinsonian symptoms were designated MSA-P rather than
striatonigral degeneration and those with predominantly cerebellar symptoms, MSA-
C as opposed to olivopontcerebellar atrophy (Kato, Nakamura, Hirano, Ito, Llena and
Yen, 1991; Papp and Lantos, 1992). The defining evidence that MSA was a clinico-
pathological entity was the discovery of argyrophillic glial cytoplasmic inclusions
(GCI's) in the oligodendrocytes of patients with phenotypically varied MSA (Papp
and Lantos, 1992). Similar inclusions were identified in glial nuclei (GNI's),
neuronal nuclei (NNI's), neuronal cytoplasm (NCI's) and also in neuronal axons
(NAI's) (Papp and Lantos, 1992). The mechanism behind the formation of these
inclusion bodies is still unclear, as is the nature of their cytotoxicity. However, the
discovery of a-synuclein as part of these inclusions begins to shed light on some of
the symptomatic and pathological similarities with PD and Lewy bodies, leading to
the inclusion of MSA as a synucleinopathy. a-synuclein is now known to be a major
component of GCI's, NCI's and NNI's but not of GNI's (Goedert and Spillantini,
1998; Gai, Power, Blumbergs and Blessing, 1998; Tu, Galvin, Baba, Giasson,
Tomita, Leight, Nakajo, Iwatsubo, Trojanowski and Lee, 1998).
In fixed MSA brain sections, GCIs were composed of amorphous material-coated
filaments up to 30 nm in size (Gai, Pountney, Power, Li, Culvenor, McLean, Jensen
and Blumbergs, 2003). The filaments were often organised in parallel bundles
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extending into oligodendroglial processes. In freshly isolated GCIs, progressive
buffer washes removed amorphous material and revealed that GCI filaments
consisted of 1 Onm sized central core fibrils that were strongly a-synuclein
immunoreactive (Gai et al., 2003). Analysis revealed that each of these core fibrils
was made of two subfibrils, and each of which was made of a string of 3 to 6nm
sized particles probably a-synuclein oligomers (Gai et al., 2003). Immunogold
labelling demonstrated that epitopes encompassing entire a-synuclein molecules
were represented in the core fibrils, with the N-terminal 11-26 and C-terminal 108-
131 amino acid residues most accessible to antibodies, probably exposed on the
surface of the fibril (Gai et al., 2003). This study indicated that GCI filaments are
multilayered in structure, with a-synuclein oligomers forming the central core fibrils
of the filaments.
1.4.10 Dementia with Lewy bodies
Dementia with Lewy bodies (DLB) is now considered the second most common
cause of dementia accounting for 20% of recorded cases, behind Alzheimer's which
accounts for 60% (McKeith, 2004). DLB tends to affect more males than females
with the age of onset falling between 50 and 80 (Cercy and Bylsma, 1997). The three
core diagnostic features that must be present in order for a diagnosis of DLB to be
given are fluctuating alertness/cognition, fully formed visual hallucinations and
spontaneous Parkinson's disease (Ballard, McKeith, Harrison, O'Brien, Thompson,
Lowery, Perry and Ince, 1997; McKeith, 2004). REM sleep behaviour disorder
(RBD) often accompanies DLB and is a useful marker when distinguishing DLB
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from AD (Boeve, Silber, Ferman, Kokmen, Smith, Ivnik, Parisi, Olson and Petersen,
1998).
The dementia in DLB takes the form of a progressive cognitive deterioration
accompanied by a general loss of functional ability. Initial complaints include a
short/variable attention span and visual perceptual difficulties, not always a primary
memory complaint. The first case was described in 1961 (Okazaki, Lipkin and
Aronson, 1961). In PD, Lewy body formation occurs predominantly in the SN. In
DLB, formation occurs predominantly in the SN and locus coerulus but also cerebral
cortex, particularly in cingular gyrus, the parahippocampal gyrus, the amygdala, the
temporal neocortex and in the nuclei of the brain stem (McKeith, 2004).
An extensive depletion of cholinergic neurotransmission occurs in neocortical areas
as a direct result of neurodegeneration in areas of the brainstem and basal forebrain.
Neurodendritic degeneration also occurs within certain populations as a direct result
of the formation of Lewy neurites that stain positive for a-synuclein and ubiquitin
(Fig. 1.2a) (Arai, Ueda, Ikeda, Akiyama, Haga, Kondo, Kuroki, Niizato, Iritani and
Tsuchiya, 1998; Irizarry, Growdon, Gomez-Isla, Newell, George, Clayton and
Hyman, 1998; Kruger and Schulz, 2002). Such degeneration is seen in the SN,
hippocampal regions, dorsal vagal nuclei, basal nucleus of Meynert and the
transentorhinal cortex (Gomez-Tortosa, Newell, Irizarry, Albert, Growdon and
Hyman, 1999). Like most other neurodegenerative conditions there is no absolute
cure, however acetylcholine-esterase inhibitors can ease neuropsychotic symptoms
by attenuating cholinergic depletion (Simard and van Reekum, 2004).
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1.4.11 Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz
syndrome)
Hallervorden-Spatz syndrome (HSS) involves neurodegeneration with brain iron
accumulation type-1 (NBIA-1) and is a rare inherited autosomal recessive
neurological movement disorder characterised by progressive degeneration of the
nervous system, first described in 1922 (Hallervorden and Spatz, 1922). Recently,
the pantothenate kinase gene (PANK2) has been identified as the causative gene for
HSS (Zhou, Westaway, Levinson, Johnson, Gitschier and Hayflick, 2001). The
detection of several mutations in almost all exons of PANK2 has led to the renaming
of HSS to pantothenate kinase-associated neurodegeneration (PKAN). Symptoms,
which vary greatly among patients and usually develop during childhood, are unique
among the synucleinopathies and may include slow writhing, distorting muscle
contractions of the limbs, face or trunk, choreoathetosis (involuntary, purposeless
jerky muscle movements), muscle rigidity (uncontrolled tightness of the muscles),
spasticity (sudden, involuntary muscle spasms), ataxia (inability to coordinate
movements), confusion, disorientation, seizures, stupor and dementia (Vasconcelos,
Harter, Duffy, McDonough, Seidman and Seidman, 2003). Other less common
symptoms may include painful muscle spasms, dysphasia (difficulty speaking),
mental retardation, facial grimacing, dysarthria (poorly articulated speech) and visual
impairment (Vasconcelos et al., 2003).
Pathological investigations of PKAN brains have revealed mild fronto-temporal
atrophy and discoloration of the globus pallidus and the SNpr (Neumann, Adler,
Schluter, Kremmer, Benecke and Kretzschmar, 2000). Typical histological features
include widespread axonal spheroids and large deposits of iron pigment in the
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discoloured regions and excessive numbers of Lewy bodies (LBs) throughout the
brain stem and cortical regions (Neumann et al., 2000). LBs as well as Lewy neurites
in cases of PKAN, were strongly labelled by antibodies against a-synuclein
(Neumann et al., 2000; Galvin et al., 2000). Other spheroidal inclusions which do not
resemble LBs have been identified and significantly the presence of |3- and y-
synuclein has been detected implicating all three synuclein proteins in the pathology
of the disease (Galvin et al., 2000).
It is clear that the aberrant expression and/or changes in intracellular
compartmentalisation of synucleins has dire consequences in the nervous system. To
make progress in understanding the pathology of these conditions, the physiological
function of the synucleins must be elucidated.
1.5 Pathogenic a-synuclein
1.5.1 Lewy bodies
Lewy bodies (LBs) are eosinophilic inclusions found in the cell bodies and neurites
of certain neuronal populations, most notably the SNpc. LBs are present in normal
aging brains, but are also the pathological hallmark of Parkinson's disease as well as
being present in other synucleinopathies such as dementia with Lewy bodies (DLB)
(Forster and Lewy, 1912; Goedert, Spillantini, Serpell, Berriman, Smith, Jakes and
Crowther, 2001).
Significantly, LBs (Fig. 1.2b) contain a-synuclein filaments, 20-600nm in length and
5-10nm in diameter and the a-synuclein binding protein synphilin-1 (Goedert et al.,
2001; Wakabayashi et al., 2000). LBs contain components of the ubiquitin-
proteasome system, the major pathway for the degradation and clearance of
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redundant proteins such as mutant, misfolded, denatured, damaged and short-lived
regulatory proteins (Lennox, Lowe, Morrell, Landon and Mayer, 1998). These
components include ubiquitination and deubiquitination enzymes, proteasomal
subunits and proteasome activators (McNaught, Shashidharan, Perl, Jenner and
Olanow, 2002; Li, Nijhawan, Budihardjo, Srinivasula, Ahmad, Alnemri and Wang,
1997; Lowe, McDermott, Landon, Mayer and Wilkinson, 1990).
LBs also contain heat shock proteins, such as HSP70 and HSP90 that have a key role
in protein transport, degradation and folding (McNaught et al., 2002; Auluck, Chan,
Trojanowski, Lee and Bonini, 2002).
The proteins which constitute LBs may be nitrated (Good, Hsu, Werner, Perl and
Olanow, 1998), oxidised (Castellani, Perry and Siedlak, 2002), ubiquitinated or
phosphorylated (Fujiwara, Hasegawa and Dohmae, 2002). The granular material in
the centre of the Lewy body is considered to be comprised of ubiquitinated protein
aggregates (McNaught et al., 2002) and the radiating filaments of the periphery are
formed at least in part from fibrillar a-synuclein and neurofilaments (Spillantini,
Crowther, Jakes, Cairns, Lantos and Goedert, 1997).
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Figure 1.2 The Lewy neurite and Lewy body
(a) Image shows a Lewy neurite from a human parkinsonian brain stained
with anti-a-synuclein antibody (arrow).
(b) A Lewy body again from a human parkinsonian brain, stained with
anti-a-synuclein antibody, highlighting the extent of a-synuclein
throughout the structure (arrow).




1.5.2 Fibril formation and cytotoxicity
Fibrillated a-synuclein has subsequently been identified as a major component of
Lewy bodies found in dopaminergic neurones of the SNpc (Spillantini, Schmidt, Lee,
Trojanowski, Jakes and Goedert, 1997). Moreover, it has been demonstrated that a-
synuclein can aggregate in vitro into filaments structurally similar to those found in
pathological inclusions and mutated forms of human a-synuclein aggregate
substantially faster than wild-type protein (Conway et al., 1998, 2000; Narhi, Wood,
Steavenson, Jiang, Wu, Anafi, Kaufman, Martin, Sitney, Denis, Louis, Wypych,
Biere and Citron, 1999; Serpell, Berriman, Jakes, Goedert and Crowther, 2000).
These results suggest a causative role for a-synuclein aggregation in the development
of certain neuropathologies. At the same time it was shown that a-synuclein could
cause cell death or render cells more sensitive to toxic insults independently of
protein fibrillation (Lee et al., 2001; Ostrerova et al., 1999; Petrucelli et al., 2002).
For example, over-expression of a- but not y-synuclein in cultured nodose neurones
has shown that both wild-type and the A53T and A30P mutant forms can be
neurotoxic without fibril formation (Saha, Ninkina, Hanger, Anderton, Davies and
Buchman, 2000).
In certain cases, more prominent effects of mutant a-synuclein on cell survival have
been demonstrated. Cultured dopaminergic neuroblastoma SH-SY5Y cells
expressing either wild-type, A53T or A30P a-synuclein all displayed elevated levels
of reactive oxygen species (ROS) levels, the mutated forms more so (Junn and
Mouradian, 2002). In addition upon exposure of these cells to dopamine, the cells
expressing mutated a-synuclein showed a much greater reduction in viability (Junn
and Mouradian, 2002). Furthermore, similar studies using truncated forms of a-
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synuclein revealed that proteins with a truncated C-terminal showed the greatest
susceptibility to neurotoxic insult (Kanda, Bishop, Eglitis, Yang and Mouradian,
2000). The aberrant over-expression of human a-synuclein has also been shown to
produce toxic effects in primary culture of human dopaminergic neurones, the A53T
mutated form being particularly neurotoxic (Zhou, Hurlbert, Schaack, Prasad and
Freed, 2000).
Significantly, it has been demonstrated that both (f- and y-synuclein have the ability
to inhibit a-synuclein protofibril formation in vivo and despite having similar
biophysical properties neither p- or y-synuclein display any fibril formation activity
(Uversky, Li, Bower and Fink, 2002). It has been shown that in transgenic models
expressing human a-synuclein, mice develop a parkinsonian movement disorder,
concurrent with nonfibrillar a-synuclein inclusions and the loss of dopaminergic
nerve terminals. Mice expressing both human a- and P-synuclein show significant
amelioration of all neurotoxic effects, with p-synuclein preventing the formation of
toxic protofibrils (Hashimoto et al., 2001).
P-synuclein has subsequently been shown to act as a negative regulator of a-
synuclein preventing its inhibition of ubiquitin-independent proteosomal degradation
as discussed above (section 1.3.5) (Snyder et al., 2005).
The presence of elevated levels or a mutated form of a-synuclein is sufficient to
cause the accumulation of cytoplasmic dopamine which can trigger oxidative stress,
a-synuclein is appearing as the key molecule in this downward cycle, as presence of
its mutated forms in familial cases or accumulation of the wild-type protein within
the cell appears to be cytotoxic, possibly as a consequence of dopamine induced
oxidative stress (Martin, Williamson, Paleologou, Allsop and El-Agnaf, 2004).
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These findings have fostered the hypothesis that the balance of synucleins is critical
in vivo, where p- and y-synuclein act synergistically with the toxic a-synuclein.
1.5.3 Oxidative stress mechanism of neurotoxicity
Oxidative stress is a damaging condition resulting from insufficient scavenging of
reactive oxygen species (ROS), which are restrained under normal physiological
conditions. The efficient anti-oxidant systems that scavenge these damaging
molecules may become impaired as part of the normal aging process or under
pathological conditions which can cause irreversible damage. Nigral dopaminergic
neurones are particularly sensitive to oxidative stress as the metabolism of dopamine
produces a number of molecules that can act as endogenous toxins. For example,
dopamine can auto-oxidise at physiological pH into toxic dopamine-quinone species,
superoxide radicals and hydrogen peroxide (Graham, 1978).
Reactive oxygen species cause functional alterations to proteins, lipids and DNA.
Damage to protein and DNA are obviously undesirable and damage to lipids results
in loss of lipid integrity and increased permeability to ions such as calcium, which
can promote excitotoxicity (Halliwell, 1998). As dopamine is a neurotransmitter,
under normal circumstances it would be sequestered into vesicles and thus cells are
protected from the deleterious effects of dopamine. In PD, nigral cells show a
heightened state of oxidative stress, highlighted by increased levels of lipid by¬
products, protein and DNA oxidation and compensatory increases in antioxidant
systems (Jenner, 1998; Floor and Wetzel, 1998). Conversely, glutathione, a co-
substrate in the detoxification of hydrogen peroxide by glutathione peroxidase, is
markedly decreased in the SN of PD patients (Alam, Jenner, Daniel, Lees, Cairns,
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Marsden, Jenner and Halliwell, 1997). The predisposition of this region to oxidative
stress is evident in rats where a dietary deficiency of the antioxidant vitamin E leads
to a 33% reduction in the number of TH positive cells in the substantia nigra,
leaving other brain area un-effected (Dexter, Nanayakkara, Goss-Sampson, Muller,
Harding, Marsden and Jenner, 1994).
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1.6 The role of synucleins in the development and function of the
Substantia Nigra (SN)
A considerable weight of evidence implicates the synuclein family in
neurodegeneration, particularly within the SN, making this population a critical
target for further study. The shift in intracellular compartmentalisation of y-synuclein
seen in the substantia nigra during development highlights the necessity for further
study.
1.6.1 The substantia nigra
The midbrain (mesencephalon) is the smallest and most rostral part of the brainstem,
the centre ofwhich is the tegmentum, containing nuclei involved in the modulation
of movement. These nuclei include the SN and the red nucleus, in addition the
oculomotor nucleus and its accessory nucleus, the Edinger-Westphal nucleus
(Carpenter, 1976). The entity described as the SN is in fact composed of two distinct
structures, the pars reticulata (SNpr) and the pars compacta (SNpc). The SNpr is the
ventral aspect of the SN, a subnucleus that contains large amounts of the enzyme
glutamate decarboxylase required for the synthesis of gamma-am ino butyric acid
(GABA) by its complement of neurones (Korotkova, Ponomarenko, Brown and
Haas, 2004). The neurones in the SNpr project principally to the thalamus (ventral
anterior, ventral lateral, and dorsomedial nuclei) but also to brain stem nuclei
(superior colliculus, pedunculopontine nucleus) and use GABA as their
neurotransmitter (Beckstead, Domesick and Nauta, 1976; Korotkova et al., 2004).
The SNpc is the dorsal aspect of the SN, with neurones projecting primarily to the
neostriatum which use dopamine (DA) as a neurotransmitter. They also contain the
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black pigment neuromelanin, a product similar to dopamine that is produced from
tyrosine (Obeso JA, Rodriguez-Oroz, Rodriguez, Macias, Alvarez, Guridi, Vitek and
DeLong, 2000).
The ventral tegmental area (VTA) lies directly adjacent to the SN, the cells of which
also use DA as its primary neurotransmitter. Axons arising from the dopaminergic
neurones of the VTA form the mesolimbic pathway, which innervate the nucleus
accumbens and the olfactory tubercle. Recently, it has been suggested that changes in
the limbic system can contribute to schizophrenia and other psychological disorders
(Meyer-Lindenberg, Miletich, Kohn, Esposito, Carson, Quarantelli, Weinberger and
Berman, 2002). Together the SN and VTA comprise the largest concentration of the
excitatory transmitter dopamine (DA) in the mammalian CNS (Nelson, Liang, Sinton
and German, 1996). However, the SN and the VTA are not the only structures which
utilise dopamine as their neurotransmitter; there are in fact eight groups of
dopaminergic cells in the mammalian CNS identified by the nomenclature A8-17
(Table 1.2).
The SNpc neurones which innervate the striatum are implicated in Parkinson's
disease (PD), as described above (section 1.4.3). A slow progressive loss of the
dopaminergic neurones within the SNpc leads to a diminished release of dopamine in
the striatum. When this reaches a critical threshold level comprising a loss of 70-80%
of striatal DA, the clinical symptoms of PD appear. To reach this threshold level
approximately 40% of tyrosine hydroxylase (TH, the rate limiting enzyme in
dopamine production) positive neurones of the SNpc will have become dysfunctional
(Bezard, Dovero, Prunier, Ravenscroft, Chalon, Guilloteau, Crossman, Bioulac,
Brotchie and Gross, 2001).
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The fully developed dopaminergic neurones of the substantia nigra play their
physiological role as a part of the basal ganglia (BG) (Fig. 1.3). The basal ganglia
include the caudate nucleus, lentiform nucleus, putamen, pallidum, sub-thalamic
nucleus and the substantia nigra. A feedback network of neuronal connections exists
between the constituents of the BG, with the dopaminergic, GABAergic and
glutamatergic neurons exerting excitatory and inhibitory control on the system. The
caudate nucleus and the putamen make up the corpus striatum, the largest structure in
the basal ganglia and as a unit constituting a major centre in the extrapyramidal
motor system. It is the putamen which receives the majority of inputs from the SNpc
hence the depletion seen in nigrostriatal dopamine. The current understanding is that
the two pathways exist to modulate the tonic stimulation of the motor areas of the
cerebral cortex by the thalamus and are therefore involved in the control of normal
voluntary movements (Fig 1.4) (Middleton and Strick, 2000). Disorders relating to
the BG tend to manifest as an inability to initiate voluntary movement and inability
to suppress involuntary movement, abnormal velocity and amount of movement as
well as disturbances in muscle tone. The archetypal example of this is Parkinson's
disease (Murray, Sepic, Gardner and Downs, 1978).
To gain a more complete understanding ofhow the synucleins may affect cell
survival and or physiology in normal and neuropathological conditions it is important
to consider how these structures and their constituent parts are formed.
46
Table 1.2 Mammalian dopaminergic cell groups
Table outlines the known dopaminergic cell groups, their reference and
location.
Mammalian dopaminergic cell groups
Group Location Region
A8 Retro-rubral nucleus Mesencephalic
A9 Substantia nigra pars compacta Mesencephalic
A10 Ventral tegmental area Mesencephalic
A11 Caudal hypothalamus Diencephalic
A12 Arcuate infundibular nucleus Diencephalic
A13 Zona incerta Diencephalic
A14 Medial rostral hypothalamus Diencephalic
A15 Olfactory tubercle Telencephalic
A16 Olfactory bulb Telencephalic
A17 Retina Telencephalic
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Figure 1.3 Anatomy of the basal ganglia
A diagramatic illustration of the structures which make up the basal ganglia.















Figure 1.4 Pathways of the basal ganglia
The projections from the medium spiny neurons of the caudate and putamen
to the internal segment of the globus pallidus and substantia nigra are part of
the "direct pathway" and serve to release the upper motor neurons from tonic
inhibition. A second pathway serves to increase the level of tonic inhibition
and is called the "indirect pathway". This pathway provides a second route
linking the corpus striatum with the internal globus pallidus and substantia
nigra. In the indirect pathway, another population of medium spiny neurons
projects to the lateral or external segment of the globus pallidus. This
external division sends projections to both the internal segment of the globus
pallidus and the subthalamic nucleus of the ventral thalamus. But, instead of
projecting to structures outside of the basal ganglia, the subthalamic nucleus
projects back to the internal segment of the globus pallidus and to the
substantia nigra. These latter two nuclei project out of the basal ganglia,
which thus allows the indirect pathway to influence the activity of the upper
motor neurons.
Abbreviations: D1/2 - dopamine receptors; Hypo - Hypothalamus ; STN - Sub











1.6.2 Embryogenesis and development of the CNS and dopaminergic neurones
The CNS arises from the neuroectoderm, which is generated shortly after
gastrulation in the developing embryo. After a period of thickening, the
neuroectoderm begins to roll up along its long axis to form the neural tube, which,
upon closure, subdivides to form the fore-, mid- and hind-brain. These processes are
mediated by diffusible growth factors emitted from structures such as the floor plate,
notochord, non-epidermal ectoderm and later, by roof plate cells (Lee and Jessell,
1999) It is from this primitive midbrain, more accurately the anterior neuroectoderm
that the dopaminergic neurones will eventually differentiate. The majority of mouse
dopaminergic neurones are thought to become post-mitotic at around embryonic day
12 (El2) and only 24 hours later TH begins to be synthesised and results in
dopamine production (Foster, Schultzberg, Kokfelt, Goldstein, Hemmings, Ouimet,
Walaas and Greengard, 1988).
Differentiation advances with the outgrowth of the first processes towards their target
fields and the formation of axonal terminals by El8. To date, three independent
pathways have been identified which play a role in the differentiation of DA
neurones. The key transcription factors controlling these pathways are Nurrl, Lmxlb
and the engrailed genes Enl and En2.
Nurrl is expressed by 95% of all TH-positive, thus dopamine-producing, midbrain
neurones and is thought to influence the use of dopamine as their neurotransmitter
(Backman, Perlmann, Wallen, Hoffer and Morales, 1999). In the absence of Nurrl,
several proteins concerned with the synthesis, axonal transport, storage, uptake and
reuptake of dopamine are also absent. These key proteins include TE1, aromatic
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amino acid decarboxylase, vesicle membrane associated transporter and dopamine
transporter (DAT). Mice lacking Nurrl appear to develop normally but are unable to
feed and die shortly after birth confirming its importance (Castillo, Baffi, Palkovits,
Goldstein, Kopin, Witta, Magnuson and Nikodem, 1998). Significantly, TH and
DAT have been shown to interact with a-synuclein, as discussed previously (section
1.3.2).
Lmxlb is a member of the homeodomain family of proteins and is widely expressed
throughout the body, including in skeletal, ocular and renal as well as neuronal
tissues. Expression begins at E7.5 in several locations including the region of the
ventral midbrain that will give rise to dopaminergic neurones. If this factor is absent,
very few TH-positive cells are present during development and are completely absent
by El6 (Smidt, Asbreuk, Cox, Chen, Johnson and Burbach, 2000). Lmxlb is thought
to have a crucial role in the production and maintenance of Wntl, a proto-oncogene
critical to patterning during midbrain development, the loss of which, results in the
complete absence of the midbrain (Adams, Maida, Golden and Riddle, 2000).
The engrailed genes Enl and En2 are also homeodomain transcription factors that
are expressed from E8 in patches in the anterior ectoderm and from El2 are
expressed constantly within dopaminergic neurones (Simon, Saueressig, Wurst,
Goulding and O'Leary, 2001). These patches fuse and form a line of cells which will
later become the border between mid- and hindbrain regions. Only double mutant
animals lacking both Enl and En2 show any developmental deficit with respect to
midbrain dopaminergic neurones (Liu and Joyner, 2001). Cells generated in the
ventral midbrain of double mutant mice begin to generate TH but fail to progress any
further through development and by El 4 are lost. These mice show a deletion of the
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midbrain and anterior hindbrain and die shortly after birth (Joyner, Herrup,
Auerbach, Davis and Rossant, 1991). Interestingly, a-synuclein expression is thought
to be regulated in part by the engrailed genes, as a-synuclein expression is reduced at
El2 in Enl mutants and is absent altogether in the remaining midbrain dopaminergic
cells of double Enl/2 mutants (Simon et al., 2001).
1.6.3 Natural cell death
Dopaminergic cell numbers continue to increase during a period of mitosis lasting
from El 1 to El 5 in the SN and migration of these cells is complete at El 8. This
period of growth and differentiation is followed by a period of natural cell death
(NCD). In mice, this event begins around the time of birth and is completed by
postnatal day 30 (P30). The wave of apoptotic cell death peaks at P2, trailing off
until P14 when a second smaller peak occurs (Jackson-Lewis, Vila, Djaldetti,
Guegan, Liberatore, Liu, O'Malley, Burke and Przedborski, 2000).
The NCD of SN neurones is exclusively apoptotic and is thought to be mediated via
the intrinsic pathway which initially involves the release of the electron transfer
protein cytochrome c from its mitochondrial inter-membrane location into the
cytoplasm (Liu, Kim, Yang, Jemmerson and Wang, 1996). Mounting evidence
suggests that this release is mediated by members of the Bcl-2 family of proteins
(Adams and Cory, 1998). Fifteen member proteins exist in mammals, which include
pro-apoptotic proteins such as Bak, Bim, Bad, and Bax; and members with anti-
apoptotic activity like Bcl-2 and Bcl-Xi. Bax, Bak, and Bid have been reported to
directly cause the release of cytochrome c from mitochondria (Jurgensmeier, Xie,
Deveraux, Ellerby, Bredesen an Reed, 1998; Kuwana, Smith, Muzio, Dixit,
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Newmeyer and Kornbluth, 1998; Li, Zhu, Xu and Yuan, 1998). Once released into
the cytoplasm, cytochrome c forms a multimeric complex with Apaf-1 (Li et al.,
1997, Zou, Henzel, Liu, Lutschg and Wang, 1997), a 130 kDa protein with a caspase
recruitment domain (Zou et al., 1997). This complex activates procaspase-9 which in
turn activates caspases 3, 6, and 9. Caspases are proteins which carry out the
proteolytic cleavage which brings about the death of a cell. The term caspase is an
amalgamation of cysteinyl aspartate-specific proteinases, highlighting the enzymes'
characteristic feature of cleaving their substrates after aspartic acid residues. The
morphological hallmarks of apoptosis, chromatin condensation, DNA fragmentation,
and breakdown of the nuclear membrane are the direct consequence of caspase
activity (Nicholson and Thornberry, 1997; Thornberry and Lazebnik, 1998).
In transgenic mice, over-expressing the anti-apoptotic protein Bcl-2 under the control
of the TH promoter, causes a reduction in NCD in the SN, with increased numbers of
TH-positive cells in adult animals (Jackson-Lewis et al., 2000). These findings
support the theory that the intrinsic pathway ofNCD operates within the SN. In
addition, Bax null mutant animals show a trend for diminished levels ofNCD in the
SN lending more support to this hypothesis (Vila, Vukosavic, Jackson-Lewis,
Neystat, Jakowec and Przedborski, 2000). Activated caspase-3 and caspase cleavage
products have been observed in apoptotic profiles ofNCD in SN nuclei (Jeon,
Kholodilov, Oo, Kim, Tomaselli, Srinivasan, Stefanis and Burke, 1999; Vila,
Jackson-Lewis, Vukosavic, Djaldetti, Liberatore, Offen, Korsmeyer and Przedborski,
2001). However, caspase-3 may not be the essential mediator of NCD in the
dopaminergic neurones as caspase-3 null mutant mice do not display any reduction
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the level ofNCD seen in SN neurones (Oppenheim, Flavell, Vinsant, Prevette, Kuan
and Rakic, 2001).
The cell death discussed above occurs normally during development in response to a
lack of neurotrophic support, enabling neuronal populations to regulate their size.
There is a great weight of evidence suggesting that glial cell-line derived
neurotrophic factor (GDNF) is responsible for regulating the survival of the nigro-
striatal dopaminergic neurones. GDNF was identified as a protein capable of
supporting the development of embryonic mesencephalic dopamine neurones in
tissue culture (Lin, Doherty, Lile, Bektesh and Collins, 1993). GDNF mRNA is
present in the striatum and is expressed at its highest levels during early postnatal
development, with protein expression being highest post partum (Schaar, Sieber,
Dreyfus and Black, 1993; Lopez-Martin, Caruncho, Rodriguez-Pallares, Guerra and
Labandeira-Garcia, 1999). GDNF can also be transported retrogradely from the
striatum to the SNpc and the GDNF receptor, GFRal as well as the tyrosine kinase
Ret are both expressed in the SNpc (Tomac, Widenfalk, Lin, Kohno, Ebendal, Hoffer
and Olson, 1995; Glazner, Mu and Springer, 1998).
However, mice lacking GDNF itself and GFRal null mutant mice show no deficit in
the number of dopaminergic neurones in the SN at birth (Enomoto, Araki, Jackman,
Heuckeroth, Snider, Johnson and Milbrandt, 1998; Rosenthal, 1999). These animals
die very early on during the period of natural cell death, likely due to other adverse
effects such as enteric nervous and renal system abnormalities, hence any
mesencephalic effects may not be identifiable (Pichel, Shen, Sheng, Granholm,
Drago, Grinberg, Lee, Huang, Saarma, Hoffer, Sariola and Westphal, 1996). More
recently, it has been shown that only GDNF was capable of supporting postnatal
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dopaminergic neurones in vitro by suppressing apoptosis (Burke, Antonelli and
Sulzer, 1998).
1.7 Synucleins and cancer
The synuclein family have been implicated in pathologies outside the nervous
system, were the focus of attention shifts from a- to y-synuclein. High throughput
cDNA screening revealed that y-synuclein (BCSG-1) (Table 1.1) was expressed at a
dramatically increased level in breast cancer tissue (Ji et al., 1997). In normal tissue,
y-synuclein expression is at a very low level and this is also the case in benign breast
carcinomas. Expression increases slightly in ductal carcinomas but a dramatic rise is
seen in highly malignant, infiltrating tumours (Bruening et al., 2000). This increase
in expression led to the hypothesis that y-synuclein may be linked to tumour
progression from benign to the highly malignant stage (Ji et al., 1997). Further
investigations using western blotting revealed that 82% of all ductal carcinomas
studied expressed either p- or y-synuclein or both, but no expression was detected in
normal tissue, and no detection of a-synuclein was reported under either condition
(Bruening et al., 2000). Immunohistochemical analysis of ovarian epithelial cells has
shown no expression of any synuclein in normal ovarian tissue (Bruening et al.,
2000). Expression of at least one member of the synuclein family was detected in
87% of ovarian carcinoma samples studied with 42% showing the presence of all
three (Bruening et al., 2000). Interestingly however, y-synuclein expression was also
observed in 20% of preneoplastic lesions of the ovary, including epithelial inclusion
cysts, hyperplastic epithelium and papillary structures (Bruening et al., 2000).
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There is considerable evidence to suggest that y- synuclein has an important role in
tumour progression in both breast and ovarian tumours. Evidence supporting this has
recently been reported, whereby y-synuclein strongly stimulated the ligand-
dependent transcriptional activity of oestrogen receptor-a (ER-a) in breast cancer
cells (Jiang, Liu, Goldberg and Shi, 2004). The stimulatory effect of y-synuclein on
ER-a-regulated gene expression and cell growth could be effectively inhibited by
anti-estrogens (Jiang et al., 2004). These data indicate that y-synuclein is required for
efficient ER-a signalling and thus, stimulated hormone-responsive mammary
tumours.
1.8 The generation of y-synuclein null mutant mice
The previous body of synuclein research has been disproportionably swayed toward
a-synuclein. However, P- and y-synuclein have also been implicated in pathological
conditions. Given the homology displayed between these proteins, any information
relating to their physiological functions could have critical importance to the
development of any therapeutic strategies for the diseases with which they are
associated.
To this end, a line ofy-synuclein null mutant mice (yv~) were produced in our
laboratory by Dr N. Ninkina and Dr V. Buchman (Ninkina, Papachroni, Robertson,
Schmidt, Delaney, O'Neill, Court, Rosenthal, Fleetwood-Walker, Davies and
Buchman, 2003) to gain a greater understanding of any effect ofy-synuclein on
murine physiology and development. These animals were used during the course of
this project and their generation is described below. Subsequently these animals were
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used to generate a-/y-synuclein double null mutant mice but this will be discussed
later (Chapter 3, section 3.5.7).
1.8.1 Generating chimeras
To achieve the null mutation, first three coding exons from the y-synuclein locus
were replaced with a Neomycin resistance cassette in mouse ES cells (Fig. 1.5). This
was achieved via homologous recombination between the targeting vector and ES
cells from 12901a mice. During the selection of clones with correct homologous
recombination, southern blotting was performed (Fig. 1.6) using DNA taken from
clones transformed with the targeting cassette. Those found to carry a mutant allele
were selected for further use. The chosen clones were then injected into blastocysts
harvested from C57B16 mice before being transferred into pseudo-pregnant females
to develop.
Several chimeric mice were generated from three independent ES cell clones. These
chimeras were interbred with C57B16 mice to prove their ability to transfer the ES
cells genotype to the next generation and produce heterozygous animals, from which
the first true y-synuclein null mutants were generated, by interbreeding the
heterozygous progeny. The resulting animals were then screened to ensure that
possession of two copies of the mutated allele precipitated a loss of functional y-
synuclein protein (Chapter 3, section 3.3).
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Figure 1.5 Deletion of exons I, II, III and promoter region of the mouse
y-synuclein gene by homologous recombination
The organisation of the wild-type genomic locus (top), targeting vector
(middle) and the resulting knock-out locus (bottom) are shown. The
restriction endonuclease sites are designated as: E, EcoR1; B, BamH1; Xb,
Xbal; K, Kpn1; Bg, Bgllll. Hybridisation probes a, b and c, which were used










Figure 1.6 Southern hybridisation showing an example of the
analysis of ES cell clones
DNA from four neomycin-resistant embryonic stem (ES) cell lines were
digested with EcoR1 and hybridised with either probe a or b. Only a 20 kb
wild-type (+/+) band was detected in two clones with random insertion of
PGK-neo cassette and the homologous recombination in two other clones
resulted in the detection of a 17 kb band.
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1.9 Hypotheses & Aims
1.9.1 Hypotheses
• A targeted disruption of the y-synuclein gene in mus musculus which results
in loss of protein may precipitate phenotypic abnormalities as the gene is
expressed during development.
• Phenotypic abnormalities arising from the y-synuclein mutation may be
exacerbated in the absence of both a- and y-synuclein.
• The balance of the synuclein proteins is thought to have importance in
neuronal survival. Thus any alteration of this balance may cause increased
sensitivity of neurones to neurotoxic insult.
1.9.2 Aims
• To produce a highly specific mouse-y-synuclein antibody in order to
investigate protein localisation and verify mRNA expression data.
• To investigate the effects of synuclein null mutations on selected neuronal
populations shown to express y-synuclein.
• To test the sensitivity of synuclein null mutant neurones to various forms of
neurotoxic insult.
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Chapter 2: Materials & Methods

















Fisher Scientific UK Ltd.,
Leicestershire, LEI 1 5RE.
Gibco Life Technologies Ltd.,
Inchinnan Park, Paisley, PA4 9RP
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Taq Polymerase
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lOg Bovine Serum Albumin
ddH20 to 500ml










lOmM EDTA pH 8.0
7gl/ml P-mercaptoethanol
Laemmli Lysis Buffer
0.652M Tris-Cl, pH 6.8; 2% (w/v) SDS
0.1% (w/v) bromophenol blue
50% (v/v) glycerol
MOPS buffer
0.05 M Sodium Acetate
0.01 M EDTA
0.2 M MOPS, pH 7.0

































Western blot Running buffer 10X Western blot Transfer buffer
Tris 30.25g 2.5mM Tris
Glycine 144g 15mM Glycine
SDS (10%) 10ml 20% Methanol
ddH20 to 1L
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2.3 Generation and maintenance of experimental synuclein null
mutant mice
2.3.1 y-synuclein null mutant mice
A male chimera was successfully generated as described above (Chapter 1, section
1.8). This animal was crossed with wild-type female C57B16/J mice to check for
germline transfer of ES cells genotype. The progeny had a mottled coat colour
indicating that germline transfer had occurred. Following genotyping, heterozygous
animals were considered as the F1 generation. Before true null mutant animals could
be produced for experimental purposes, the genetic background of the animals was
purified by a series of consecutive backcrosses. The male heterozygous animals from
each backcross were mated with C57B16 wild-type females obtained from Charles
River (Chapter 3, section 3.5.3). This backcrossing was repeated for six generations
before heterozygous male and female animals were intercrossed to produce a
heterogeneous litter containing null mutant, heterozygotes and wild-type animals
(Chapter 3, section 3.5.3; Fig. 3.14). One male heterozygote animal was placed in a
cage with two wild-type females, which were checked for the presence of a
mucopolysaccharide plug daily to indicate mating had occurred. Once plugged,
females were separated for the duration of the pregnancy and nursing.
2.3.2 a-synuclein null mutant mice
a-synuclein null mutant mice (a"/_) were gifted to our laboratory and have been
described previously (Abeliovich et al., 2000). These mice were backcrossed with
C57B16/J mice for at least six generations before setting up intercrosses.
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2.3.3 a-/y-synuclein double null mutant mice
In order to generate double null mutant animals from those described above, a
planned program of genotyping and breeding was undertaken. F6 a- and y-synuclein
null mutants were intercrossed, thus producing a litter of animals which were
heterozygous for both genes (a+/7y+/"). Interbreeding these male and female
littermates created the possibility of a one in sixteen chance of being homozygous for
both the null mutant alleles (a~'7y~/~) (Fig. 2.1).
2.3.4 Animal care and regulations
All procedures relating to animals were carried out under and according to the UK
Animals (Scientific Procedures) Act 1986. Animals were housed in accordance with
Home Office regulations, given access to food and water ad libitum and had a 12
hour light/dark cycle.
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Figure 2.1 Diagram illustrating the creation of a-/y-synuclein double
null mutant mice
Diagram illustrates the one in sixteen chance of creating a double mutant
from heterozygous parents and shows all the other possible genotypes. The
litters produced on average followed the classic Mendelian distribution for
two non-linked alleles which is indicated numerically below
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2.3.5 Genotyping transgenic animals
Genotyping was an essential part of maintaining each colony, as every effort was
made to minimise the number of mice utilised and also to determine the genotypic
status of the animals used. In order to collect a DNA sample from each mouse, a
small tail biopsy was taken from each animal under a general anaesthetic
(Flurothane). At the same time each animal was given a numbered ear tag to
accurately identify the animal and match it to the correct genotype. Tail biopsies
were transferred to labelled eppendorf tubes, numbered corresponding to the ear tags
and refrigerated until needed.
To extract and purify DNA from these samples, a kit-based protocol was utilised
following the manufacturer's (Qiagen Ltd.) instructions. Initially, 200pl of a
Proteinase K in lysis buffer solution was added to each tissue sample and digested at
56°C overnight. This tissue lysate was vortexed and put through the column-based
purification system as per the instructions.
2.3.6 Polymerase chain reaction (PCR)
In order to amplify the correct alleles in each case, a combination of primers was
chosen and mixed in the same reaction to assay either the presence or absence of the
wild-type or mutated allele of a- or y-synuclein. Primers were chosen within the
wild-type and mutated loci as well as a primer that was common to both wild-type
and mutated alleles for each gene.
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The following primers were used to assay the wild-type and mutated y-synuclein
alleles:
SAUP: 5'-AGT CCT GGC ACC TCT AAG CA-3'
GDN: 5'-GGG CTGATG TGT GGC TAT CT-3'
Neo B: 5'-GAA GAA CGA GAT CAG CAG CC-3'
The primer named SAUP is the common primer to both alleles; NeoB binds the
mutated allele and GDN only the wild-type allele.
The following primers were used to assay the wild-type and mutated a-synuclein
alleles:
Neo A: 5'-GAA GAA CGA GAT CAG CAG CC-3'
AKoC: 5'-CAG CGA AAG GAA AGC CGA GTG
ATGTAC T-3'
aS-ups: 5'-CAG CTC AAG TTC AGC CAC GA-3'
The primer named aS-ups is the common primer to both alleles; NeoA binds the
mutated allele and AKoC only the wild-type allele.
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The primers were diluted to a working concentration of 15pM/pl and aliquoted so a
fresh vial could be used for each session. The following were combined to create a
master mix solution according to the number of samples to be genotyped. Ifn=l and
was to be genotyped for y-synuclein then the following would be combined;
• PCR buffer 5 pi
• GDN lpl
• SAUP lpl
• Neo B 1 pi
• dNTP's (25mM each) 0.5pl
• ddH20 31 pi
• MgCl2 10pl
• Taq polymerase 0.7pl
50pl of the mix was added to 2pl of purified sample DNA, pre-aliquoted into a thin
walled 0.5ml PCR tube and inserted into a thermal cycler and taken through the
following program for 45 cycles before being transferred to 4°C:
• 95°C 45 seconds
• 56°C 30 seconds
• 72°C 60 seconds
The optimal conditions for these reactions were elucidated previously by Dr. N.
Ninkina.
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2.3.7 Agarose gel separation of PCR products
To visualise the results, agarose gels were used to separate the amplified DNA
fragments. 1.2g of agarose was melted in 100ml of TAE buffer containing ethidium
bromide (0.5pg/ml). This was mixed and heated in a microwave until boiling, then
allowed to cool. When the solution had cooled sufficiently it was poured into a gel
mould, a plastic comb inserted and the gel allowed to set. After approximately 30
minutes the combs were removed and the gel transferred into a gel tank filled with
the TAE buffer so the buffer just covered the surface of the gel. lOpl of each PCR
sample was mixed with 2pl of 6X loading buffer to aid sample loading into
individual wells in the gel. A 120mA current was the passed through the gel to
separate any DNA fragments by size. 2pl of a DNA ladder loaded at each side of the
gel. This ladder contained DNA fragments of known size which allow the accurate
estimation of fragment size when imaged. Once the dye front of the gel had neared
the end of the gel, it was imaged under UV light. PCR analysis of animals resulting
from intercrosses in the y-synuclein null mutant colony yielded two distinct bands.
The mutated allele produced a 397bp fragment amplified between the NeoB and
SAUP primers in comparison with the WT allele with a band at 490bp. In the case of
a-synuclein, the WT band measured 520bp and the mutated allele 450bp. These
reactions were carried out separately for double null mutant animals. A typical result
of y-synuclein mutant colony genotyping is shown in Chapter 3 (Fig. 3.10).
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2.4 Northern hybridisation
2.4.1 Preparation and isolation of RNA for northern blotting
Tissue was taken via dissection and immediately frozen in liquid nitrogen. The tissue
was then ground into a fine powder using a pestle and mortar and kept cold with
liquid nitrogen. 500pl of guanidine buffer was added gradually as the tissue was
ground further, ensuring the lysed tissue and buffer became well mixed. Only then
were lysates allowed to thaw and transferred to an eppendorf tube.
Following this, 50pi 2M sodium acetate (pH 4.0) was added and the samples
vortexed thoroughly, before adding 500pl of acidic phenol and again vortexing the
solution. The samples were placed on ice and 100pi of chloroform was added to each
sample and vortexed intensively and then spun in a bench top centrifuge at 13,000
rpm for 10 minutes. The aqueous phase of each sample was carefully removed to a
fresh tube and the RNA precipitated for 24 hours at -20°C by adding 500pl of
isopropanol. After this precipitation period, the samples were spun for 20 minutes at
13,000 rpm, the supernatant removed and the resulting pellet washed in 70% ethanol.
These pellets were allowed to dry in a fume hood until the ethanol had evaporated,
before being re-suspended in 400pl of guanidine buffer. The process of extraction
was repeated to enhance purification. Following the second phenol/chloroform
extraction, samples were spun at 13,000 rpm for 10 minutes and 2.5 times the
volume of ethanol were added to precipitate RNA from the supernatant over a 24
hour period at -20°C. The pellets were collected by spinning samples for 20 minutes
at 15,000 rpm and washed with 70% ethanol before finally being dried under vacuum
in a speed vac for approximately 25 minutes at 45°C.
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In order to load equivalent amounts of RNA into each lane on the gel, the relative
RNA content was estimated in each case. Initially the size of each sample pellet was
estimated relative to the smallest, designated as 1 unit. Then 7pl MOPS, 14pl
formamide/ formaldehyde solution for every 1 unit of pellet size was added to each
sample. The RNA samples were then incubated between at 60°C for 10-15 minutes
before being placed on ice and 2pl of the loading dye was added. The samples of
RNA extracted from the retina were loaded onto an agarose gel. After 30 minutes
running at 1000mA the gel was observed under UV light and relative amounts of
RNA in samples were estimated from the intensities of rRNA bands. These estimates
were used to normalise amounts of RNA in samples before loading a preparative gel
for Northern blot analysis.
2.4.2 Preparation of a formaldehyde agarose gel
For the gel, 2g of agarose was added to 88ml of distilled water, boiled in a
microwave and allowed to cool to 55°C. 32ml of 5X MOPS buffer and 40ml of 38%
formaldehyde were pre-warmed to 55°C and combined with the cooling gel. This
was poured into a gel tray with combs and allowed to set. The combs were removed
and formaldehyde/IX MOPS buffer mixture 1:3 was used to fill the wells. The tank
was subsequently filled with IX MOPS buffer to the top of the gel. Samples were
loaded and run on the gel at 100mA until the dye front had travelled to the bottom
the gel and an image was captured. Before blotting the gel was washed in 20X SSC
for approximately 40 minutes, changing the solution twice.
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2.4.3 Filter preparation
A piece of Hybond N+ membrane was cut to the size of the gel and rinsed in boiling
ddfbO. The membrane was cooled and washed in 2X SSC before being placed in
contact with the gel ensuring there were no air bubbles present. This was placed in a
tank containing 2X SSC. A 2.5cm pile of absorbent paper was placed on top of the
membrane to draw fluid through the gel carrying the RNA onto the filter and a
weight was placed onto of this stack to keep it stable. After approximately 12 hours,
the filter was removed, washed in 2X SSC, allowed to air dry and was finally baked
in an 80°C oven under vacuum. The RNA was cross-linked to the filter via exposure
to 354nm UV light. The filter was then ready for hybridisation.
2.4.4 Probe DNA labelling with 32P
In order to label a cDNA probe, a nick translation reaction was performed. During
this reaction a DNAse made nicks in the dsDNA causing damage which is
subsequently repaired by the DNA polymerase, thus incorporating P labelled
cytosine into the particular DNA sequence. As radioactive materials were being used
full safety precautions were observed at all times in accordance with university
regulations.
The nick translation reaction mixture contained the following:
• a[32P] dCTP (lOmCi/ml) lOpl
• cDNA (O.lmg/ml) O.lpl
• ddH20








The above reaction was mixed and allowed to run for 30 minutes at 16°C. The
efficacy of incorporation was then tested by placing a sub pi aliquot onto a small
piece of GF/B filter paper. The level of activity was measured using a Geiger counter
then the paper was washed with trichloroacetic acid (TCA). The activity level was
re-measured and if it had not diminished significantly (i.e. no more than 60% after
washing), the reaction was stopped by adding STES buffer to make up the reaction
volume to 150pl. However, the probe purification was necessary before it could be
used in a hybridisation. A standard G50 Sephadex nick-column was used for the
desalting and gel filtration of the probe. The cap was removed from the column and
the buffer drained and discarded, before being washed through twice with 3ml
washes of STES buffer and again the flow-through discarded. 150pl of the reaction
mixture was loaded onto the column. The column was washed with 400ml of STES
and the resulting flow-through checked for absence of radioactivity before being
discarded. Another 400pl of STES buffer was added onto the column and the flow-
through collected into an eppendorf tube. The presence of the probe in this fraction
was assessed using a positive radioactivity signal and reserved. lOpl tRNA (lOmg/ml)
was added to the purified probe fraction to act as a carrier for the effective
precipitation of the DNA. In addition, 1/20 probe volume of 3M sodium acetate (pH
5.5) and 1ml 100% ethanol were added. The contents of the tube were mixed and
kept at -20°C for 12 hours to allow the DNA to precipitate out fully. Following this
period, it was spun at 13,000 rpm for 5 minutes, the ethanol removed and the pellet
dried then re-suspended in lOOpl of sterile d^O. The probe was then denatured by
adding 5pi volume 10M sodium hydroxide and incubating for 10 minutes at 68°C.
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This separated double stranded DNA into single stranded DNA. The probe was
neutralised with 50pi of 1M acidic Tris before it was added to a hybridisation buffer.
2.4.5 Hybridisation
The fdter membrane was placed in a secure tube inside the hybridisation oven and
allowed to pre-hybridise in buffer for 2-3 hours at 42°C. The buffer was refreshed
and the probe added and allowed to hybridise with the filter for 48 hours at 42°C.
Following this hybridisation, the waste buffer was disposed of in accordance with the
university regulations for the disposal of radioactive waste.
The filter was then rinsed in 2X SSC at room temperature and washed in 2X SSC
containing 0.2% SDS at 68°C for 1 hour, changing the buffer twice. The filter was
then wrapped in cling film and transferred to a cassette for exposure with X-ray film.
The membrane was placed in contact with the film and both were sandwiched
together between two phospho-luminescent screens inside the cassette, which was
then transferred into -70°C. After 12-16 hours, the film was developed and if
necessary, fresh film replaced in the cassette for a longer exposure. In order to re-
hybridise the membrane with a different probe, the membrane was boiled in a
striping solution (0.1X SSC/ 0.1% SDS). This allowed for probes to a- and P-
synuclein and the house keeping gene glyceraldehydes-3-phosphate dehydrogenase




The same process was used in each case irrespective of the tissue however the
volume of buffer was adjusted to maintain an approximately equal protein
concentration independent of the size of collected tissue samples. Tissues were taken,
frozen and ground down in liquid nitrogen and homogenised in Laemmli lysis buffer,
using a syringe in an eppendorf tube. Once homogenised, the samples were spun at
10,000 rpm for 10 minutes and supernatants boiled for 5 minutes to denature proteins.
2.5.2 Gel Preparation
Running buffer solution was prepared prior to the gel pouring, and the equipment
cleaned thoroughly and assembled as per manufacturer's (BioRad) instructions.
Stacking Gels Separating Gel (12.5%)
Acrylamide 1ml 4.13ml
Tris pH 8.8 — 3ml
Tris pH 6.8 0.6ml —
SDS (10%) 150pl lOOpl
ddH20 4.3ml 2.5ml
Amonium persulphate 10% 150pl lOOpl
TEMED lOpl lOpl
The separating gel was poured and allowed to set prior to the pouring of the stacking
gel on top, and again left to set. The gel plates were then placed into the running tank
and filled with running buffer. 12pl of sample solutions were then loaded into
individual wells using duck-billed tips. The apparatus was then run at 200V for
approximately 45 minutes or until the dye front reached the bottom of the gel.
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Four pieces of 3MM paper were cut per gel and one piece of Hybond-P nylon
membrane pre soaked in methanol. The paper, membrane and sponges in the blotting
apparatus were equilibrated in transfer buffer. The gels were removed carefully from
between the glass plates and placed in contact with the nylon membrane. The
blotting apparatus was assembled in accordance with manufacturers' instructions
(Biorad) and run at 26v for 90 minutes. After the completion of the transfer process
the nylon membrane was removed and intensively washed in PBS before being
blocked in 10% skimmed milk powder in PBST (PBS + 0.1% Tween) for 1 hour at
room temperature on a rocker.
The primary antibody dilution was made in a 3% milk/PBST solution, applied to the
membrane and incubated for 12-18 hours at 4°C again on a rocker. The membrane
was then washed several times with fresh PBST for 1 hour prior to the application of
an appropriate HRP-conjugated secondary antibody diluted in the same 3%
milk/PBST solution, for 1 hour at room temperature shaking gently. After washing
thoroughly with PBST, the blot was incubated with 2ml of enhanced
chemiluminescence (ECL) solution (1ml A + 1ml B; ECL kit). The solution was
discarded and the membrane wrapped in cling film and placed in a cassette in contact
with Kodak p-max hyperfilm for between 1-20 minutes. The film was then
developed allowing protein bands to be visualised.
2.6 Histology
2.6.1 Sample collection
Animals were prepared following standard Schedule 1 protocols; CO2 in rising
concentration until dead or by cervical dislocation. To remove the brain, the skull
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was exposed and an incision was carefully made along the midline beginning at the
rostral cervical vertebrae and extending along the sagittal suture, perpendicular to
which transverse cuts were made. In all animals, brains were excised after breaking
the parietal and temporal bones and cutting the cranial nerves, placed into a tissue
cassette and directly into an appropriate fixative for immersion fixation.
Embryonic tissue we immersed whole or decapitated and only the head placed inside
the immersion cassette. Spinal cord tissue taken for dorsal root ganglion (DRG)
analysis was dissected out from post-natal animals, leaving rib roots as reference
makers for the identification of L6 DRG. No perfusion was employed at all during
the course of this work.
2.6.2 Optimisation
Prior to each different immunohistochemical investigation, an optimisation trial was
carried out, as the same antibody can give widely differing results depending on
which fixation technique is employed. For instance, Carnoy's solution is alcohol
based and can cause substantial damage to cell membranes, hence antibodies raised
against cell surface antigens may prove ineffective. Conversely, formaldehyde-based
fixatives such as paraformaldehyde (PFA) or neutral buffered formalin (NBF) can
cross-link proteins, masking antigens and therefore require an antigen unmasking
step to be included in the processing discussed below. Therefore, four widely used
fixatives were tested with each new antibody:
1. Carnoy's solution (60% ethanol, 30% chloroform, 10% glacial acetic acid)
2.10% neutral buffered formalin (NBF) as stock
3. FAA 18% NBF, 62% alcohol, 4% glacial acetic acid, 16% ddH20)
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4. 4% Paraformaldehyde (PFA) in PBS
2.6.3 Sample processing
Before the tissues were embedded in paraffin wax, all traces of fixative were
removed. In the case of formalin-based fixatives, this was achieved by using two
hour long changes of distilled water before overnight dehydration at room
temperature in 75% ethanol. This step was not required for alcohol-based fixation as
the further dehydration in a graded alcohol series was employed. This involved three
10 minute long changes of 96% ethanol followed by two 30 minute changes of 100%
ethanol. As the paraffin wax, which was the ultimate destination for these tissues, is
not miscible with alcohol, this was replaced with chloroform. The samples were
taken through one change of 1:1 alcohol/chloroform before being immersed in
chloroform for one hour then, changing the solution, left for 24 hours. Following this
period, the samples in their respective cassettes, were taken through three 1 hour long
changes of molten, filtered paraffin wax maintained at 58°C. Following removal
from the cassettes, brain samples were transferred into a mould and the wax was
allowed to solidify around them. This was performed at 4oC as it lends a finer
crystalline structure to the wax compared to room temperature cooling.
The solid sample blocks were then trimmed and cut to a thickness of 8 pm on a
microtome (Microm 310), with the wax strips floated out onto a 55oC water bath and
collected onto microscope slides (Ultrastick, Gold Seal). The cut sections were then
allowed to dry for a period of no less than 24 hours at 37°C to ensure maximum
adherence.
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Sections were floated out onto slides in one of two fashions. If more than one
staining technique needed to be applied to one particular structure, the substantia
nigra for example, strips were alternated between two slides, creating two sets (Fig.
2.2a). This allowed us to directly compare consecutive sections stained in different
ways. Conversely, if the entire sample was to be stained uniformly then consecutive
strips were mounted on single slides (Fig. 2.2b).
A common protocol was followed during all paraffin-based histology to remove all
traces of wax and prepare the sections for incubation with a specific primary
antibody or the application of other histological stains. Initially, slides were placed
in stainless steel racks and taken through solutions in 350ml glass troughs. The initial
step was two 5 minute changes of fresh Xylene, to remove all traces of wax from the
sections. It was essential to remove all traces of this organic solvent so that water-
based solutions could be applied subsequently. This was accomplished by taking the
slides through a graded alcohol series, first two changes of 100% absolute alcohol of
5 minutes each, then a further 3 minutes in both 96% and 70%, respectively. The
sections were then introduced into distilled water for 5 minutes, removing all traces
of alcohol prior to a further 5 minute wash in PBS.
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Figure 2.2 Differential positioning of sections for histology
(a) Illustration of section layout for immunohistochemistry when two sets
of slides were required; one for marker and another for target protein.
Adjacent sections can be compared.
(b) Section layout for histology using one staining technique or antibody.





The next stage in the processing depended on the fixative used and future staining, as
antigen retrieval may be required. As mentioned, formalin-based fixation has the
effect of cross-linking proteins masking antigens hence interfering with the staining
process. The chosen method for antigen retrieval was a microwave based technique
in a 0.1 M citric acid solution (pH 6.0). Slides were transferred to a plastic rack and
incubated for approximately 10 minutes before being placed in the microwave. The
rack in solution was heated to 90°C over a period of 10 minutes and boiling of the
solution was avoided.
If a DAB reaction was to be carried out for the visualisation of a primary-secondary
complex via the avidin-biotin system, a quenching solution was required to quench
the endogenous peroxidase activity in the tissue. This quench consisted of a 70%
methanol solution in PBS, 3% hydrogen peroxide, and slides were immersed in the
solution for 20 minutes at room temperature. After PBS washing, the slides were
transferred into the Sequenza staining system. Slides were then incubated in 100pi of
blocking solution (10% serum in PBS containing 0.4% triton XI00) for no less than
60 minutes at room temperature.
The species from which the serum was chosen was dependent on the species in
which the secondary antibody was raised in order to minimise non-specific
interactions. A primary antibody(ies) were diluted in the same solution and applied to
the slides. Incubations were carried out at 4°C for 12-16 hours.
Primary Antibody Working Dilution
Anti-Tyrosine Hydroxylase 1:200
SK23 rabbit anti-y-synuclein 1:50
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If a fluorescent secondary antibody was to be used then the sections were washed in
PBS thoroughly then the fluorophore applied for approximately 60 minutes and the
slides once again washed before being mounted in Vectamount and sealed with clear
nail varnish.
If a DAB protocol was being followed the procedure was more complicated. After
incubation with a biotinylated secondary antibody for 60 minutes, the sections were
washed with PBS and the Vector Labs ABC reagent was applied, having been
prepared 30 minutes prior to use. The ABC system relies on the affinity of the
glycoprotein avidin for the vitamin biotin for its action. The biotinylated secondary
antibody forms a complex with the primary, bound to the antigen, to which the
avidin in the ABC solution can bind. This was rinsed off with PBS after 30 minutes
and the DAB applied for a maximum of 5 minutes until the coloured precipitate was
produced, the peroxidase catalysing the transformation of DAB into an insoluble
compound. The slides were then immersed in distilled water and taken backwards
through the alcohol series and again through two changes of xylene prior to being
mounted in DPX and left for 24 hours to dry.
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2.7 Production of an affinity purified antibody and
Immunohistochemistry
2.7.1 Production and purification of GST-fusion recombinant proteins from E.
coli
A plasmid in which the full length coding region of mouse y-synuclein was cloned in
frame with glutathione S-transferase (GST) was produced in the laboratory earlier.
BL21 bacteria were transformed with this plasmid as this particular strain has very
low protease activity, allowing good protein yield. Protein production was induced
by the addition of ITPG into a 500ml culture, grown over 12-16 hours. Protein was
harvested after the lysis and sonication of the bacteria, allowing the protein to be
recovered from the centrifuged lysate. The recovered GST-y-synuclein was then
purified using a G-sepharose bead column.
2.7.2 Affinity column preparation
To purify the antibody from the antiserum, a Hi-Trap affinity column (Supelco,
Sigma-Aldrich Co.) with immobilised antigen was prepared.
The column was first washed 3 times with 2ml of ice cold ImM HC1. Immediately
following this, lmg of purified recombinant protein was loaded onto the column and
allowed to equilibrate for 30 minutes at room temperature. Before the antiserum
could be loaded it had to be purified to remove any large particles and desalt it. This
was achieved using a PD10 gel filtration column. The antiserum was washed through
the column with 25ml of PBST and collected, and was now ready for loading onto
the prepared affinity purification column.
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2.7.3 Antibody purification
The purification began with the column being washed with 3ml of PBST before
being equilibrated 3ml of elution buffer (glycine, pH 2.6), followed by a second
wash with 10ml of PBST. The antiserum was pumped through the column twice at a
rate of 0.5ml/minute collecting the flow through. The column was then rewashed
with 10ml of PBST before 3ml of elution buffer was used to elute the bound
antibody fraction. The column was washed again, ready for the next cycle of
purification which was repeated a total of 4 times, yielding 4 antibody fractions. On
collection, the antibody fractions were carefully transferred into dialysis bags and
allowed to dialyse initially in PBS for 48 hours at 4°C and then in a 50% glycerol/
PBS solution at 4°C for 36 hours, changing the solution at 24 hour intervals. The
addition of glycerol increased the stability of the antibody, which was then frozen in
lOOp.1 aliquots at -80°C until ready for use.
2.7.4 Tyrosine Hydroxylase (TH) staining of dopaminergic neurones
Before experimental samples were stained, an optimisation trail was carried out to
determine the optimal dilution of commercial anti-TH primary antibody for
immunohistochemistry on paraffin sections of mouse brains fixed with Carnoy's
solution. A 1:50 dilution was found to be optimal. A 1:200 dilution of a biotinylated
horse anti-mouse antibody was used as a secondary in conjunction with ABC
amplification/detection system as described above (section, 2.6.4). A boundary
between SNpc and VTA when assaying neuronal number was drawn after consulting
anatomical atlases (Fig. 2.3). Cells were counted using the fractionator stereology
method, described below (section 2.8.2).
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Figure 2.3 Drawing boundaries between the SNpc and VTA in TH
stained sections
(a) Shows the first TH positive dopaminergic cells of the rostral aspect of
the SNpc in parsagittal section. Counting began with these cells.
(b) As you progress caudally through the SNpc, the cell number increases
and the characteristic elongated wing-like shape (outlined in red) of the
structure appears (black arrow) in parasagittal section. The fibres leaving the
cell bodies run out parallel to the long axis of the structure. This is highlighted
(box). The line represent where the boundary between the SNpc and the
VTA was drawn. VTA cells (red arrow) have fibres running off perpendicular
to those of the SNpc. The line was drawn through the sparse fibrous region,
largely devoid of cell bodies, separating the two structures. It is this region
coupled with fibre direction which decides the boundary.
(c) Caudally, the medial lemniscus (ML) passes through the SNpc, this is
not to be confused with the fibrous area separating the SNpc and VTA. Once
again SNpc cells (black arrow) are separated from those of the VTA (red
arrow) by both the fibrous gap and fibre direction.
(d) The cells of the SNpc become sparser until finally only the VTA is left.
The boundary becomes more defined as you move caudally.
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2.8.1 Identification of sensory neurones using Cresyl Fast Violet
The L6 dorsal root ganglion (DRG) and the trigeminal ganglion (TG) were the
sensory structures chosen to investigate protein localisation and assay any changes in
neuronal number in sensory structures at E12, E15 and P2 in the mouse. Embryos
were dissected from the uterus following schedule 1 procedures and placed directly
into tissue processing cassettes. For samples taken for TG investigations, heads were
removed and processed separately. The spinal columns from P2 mice were fixed and
embedded as described above (section 2.6.3). Serial 8pm thick longitudinal sections
were cut and mounted onto poly-lysine coated slides. The specimens were cut into
sagittal as well as coronal sections. In the case of whole embryo sections, it was not
possible to obtain true coronal sections throughout the entire CNS due to the curved
position of the embryo.
Slides were taken down to water as described above (section 2.6.3) and two drops of
glacial acetic acid were added to the 250ml ofwater in the staining jar. The 0.5%
cresyl violet stain was made up following the manufacturers' instructions (Raymond
A Lamb) 24 hours in advance of use. 250ml of stain were filtered and acidified with
3 drops of glacial acetic acid and the slides immersed for 20-25 minutes until
staining was at the required intensity. The staining was then rapidly dipped into 70%
then 96% ethanol until differentiated as required. This was followed by two 30
second immersions in 100% ethanol and two 5 minute changes of xylene and the
slides were mounted in DPX mounting medium.
97
Lumbar L6 DRGs were identified by virtue of the Nissl substance and their large,
round, pale-stained nuclei (Konigsmark, 1970). Neurones in the L6 DRG displaying
a prominent nucleolus were counted on every eighth section. Neuronal number was
quantified using a digital stereology system that employed a combination of the
optical dissector and volume fraction Cavalieri methods (Kinetics Imaging,
Bromborough, UK). All counts were carried out blind to animal genotypes.
To identify the TG, anatomical atlases were utilised (Theiler, 1989; Kaufman, 1992;
Altman and Bayer, 1995; Paxinos and Franklin, 2001; personal communication Prof
A. Davies). Cells were counted in an identical manner to the DRG.
2.8.2 Cell Counts
All of the cell counts made herein were conducted using the fractionator
stereological method. Stereology is the histometrical technique by which quantitative
information on the volume, surface area and/or particle numbers of objects within a
two or three-dimensional structure is obtained from one- or two-dimensional data
(Bancroft and Stevens, 1996). The fractionator method was used as only particle
numbers or cell numbers were required in this case. Described by Gundersen in 1986,
it provides a direct estimate of particle number, independent of the volume of the
structure the particles form or are part of (Gundersen, 1986). In this context, the
number of dopaminergic neurones in the substantia nigra could be estimated
accurately without calculating the volume of the structure in advance.
The greatest advantage of this technique is that bias is not introduced due to
shrinkage of the tissue. This shrinkage is an inevitable consequence of the fixation,
processing, de-paraffination and staining procedures, despite all care being taken.
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The removal of paraffin wax alone is said to cause a collapse of up to 60% of the
tissue sections height (Reed and Howard, 1998). Such changes are impossible to
account for under normal circumstances, hence a method that is as independent of
such errors is highly desirable. Every effort was taken to collect experimental tissues
together, in an attempt to ensure all aspects of fixation, processing and staining were
as near chemically and chronologically identical as possible.
When DAB is used as a substrate for the peroxidase detection reaction the TH
antibody stained the cell body with a dark brown precipitate leaving a clear nucleolus,
thus we were able to count the large clear space surrounded by this dark stain. These
cells were counted on every tenth section. Every cell in the section that lay within the
determined boundaries of the SNpc and the VTA was counted.
As the cell body is thicker than the plane of section the same cell will be present in
more than 1 section. To minimise the error which this introduces into cell counts
Abercrombie's correction was applied.
Abercrombie's correction states that,
P = A x M / (L + M)
P being the true number of cells, A the crude number counted, M the section
thickness (8pm) and L, the mean nuclear diameter.
In order to calculate L, the diameter of 100 nuclei per animal per structure were
measured with the aid of a microscope, CCD camera system and the appropriate
software (Axiovision, Carl Zeiss Ltd.). A mean was calculated for each animal and
the correction applied. In order to make L as accurate as possible, the nuclei were
chosen randomly and the distance measured was the horizontal length as they
appeared on screen.
2.9 MPTP treatment
6-8 week old male C57B16/J mice, were weighed and treated daily with 30mg/kg
doses of MPTP for 5 days, six animals from each genotypic group were present in
each group. The MPTP was diluted in PBS to a concentration of 1 mg/ml and
introduced via intraperitoneal (i.p.) injections. Control animals were injected with
equivalent volumes of sterile PBS.
Due to the highly toxic nature of MPTP (Chapter 4, section 4.4.1), animals were
housed separately from the general population of the facility. Full protective clothing
was worn and any waste disposed of only after treatment with a bleach solution for
three days. As urine of the subject animals must also be considered as toxic for 10
days post final injection, the bedding was also treated in this manner. 14 days after
the final injection, brains were taken for histological evaluation of neurone number in
both the SNpc and VTA, using the tyrosine hydroxylase immunohistochemistry
method outlined above (section 2.7.4). Safety procedures were taken in accordance
with published data/guidelines (Przedborski, Jackson-Lewis, Naini, Jakowec,
Petzinger, Miller and Akram, 2001).
2.10 Evaluation of basic behavioural functions
2.10.1 Assessment of motor behaviour
Experimental mice were first given three training periods on a Ugo Basile (2100)
accelerating rotorod.
In training sessions, a steady speed of 12 revolutions per minute (rpm) was
maintained and each mouse introduced to the rotating rod and allowed to run for a
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maximum of three minutes. The mice were then subsequently tested in 2 different
trials. The first trial was at a constant speed of 24 rpm and the time recorded when
the mouse either fell from the rod or was deemed to loose control of its movement on
the apparatus. Each mouse was given 4 runs and the best three times were averaged.
The lowest result was discarded in an attempt to eliminate any accidental slips which
may have introduced error into these data, as excreta expelled during the test can
cause slippage. Finally the mice were placed on the unit revolving at 4 rpm, and left
on the rod for a maximum of 5 minutes as it accelerated to 40 rpm smoothly over that
period. The same criteria as in the previous test for measuring the animals'
performance on the rod were applied.
2.10.2 Assessment of general activity
General levels of activity were measured using movement in defined space over a 2
hour period. Experimental mice were introduced into a behavioural assessment
chamber (Ugo Basile) for 2 hours. The activity was measured as the number of infra¬
red beam breaks the mouse made every 10 minutes during this period. A number of
these beams cross the chamber in the x and z axis. After the time has elapsed the
mouse is returned to its cage and the data taken from the machine. This test allows
for the evaluation of the general activity of these mice in a foreign environment.
2.11 HPLC analysis of dopamine and its metabolites in the
striatum
This work was carried out by J. Sharky and P. Jones of the Fujisawa institute of
neuroscience.
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Brains of 9 adult wild-type or mutant male mice on C57B16 background were
dissected, the striatum removed on ice, snap-frozen and kept at 70°C until assayed.
95pL of 0.4 M HC104 and 5pL of 40 lg/mL N-co-5-HT (internal standard) was added
to each thawed sample prior to sonication for 3 seconds by an ultrasonics
homogenizer with a 3mm tip. The samples were centrifuged at 20,000 g on a bench
top centrifuge for 25 minutes at 4°C. The pellet was frozen for protein quantification,
which was carried out using a standard BCA protein assay reagent kit (Pierce,
Rockford, IL, USA). Then, 50pL of the supernatant were injected onto the high
performance liquid chromatography (HPLC) column through a Rheodyne injection
valve connected to a 20pL loop. A BAS PM-80 solvent delivery system and BAS
LC-4 ECD was used to detect dopamine (DA) and its metabolites (DOPAC, HVA
and 5-H1AA). Isocratic mobile phase (75 mM sodium dihydrogen phosphate, 1.7mM
octanosulphonic acid sodium salt, lOOpL/L triethylamine in 90% ddfBO water, 10%
acetonitrile, pH 3.0) was used to carry the samples through a reverse phase ESA
column (120 A C18 150 • 3.2 mm column packed with 3-lm particles). Flow rate was
set at 0.6mL/min and the detector was at 0.7V.
2.12 Primary neurone culture
Trigeminal ganglia from P2 C57B16 mice were dissected in LI5 media and incubated
with 0.05% trypsin in Ca2+/Mg2+"free HBSS for 25 minutes at 37°C. After
trypsinisation, most of the enzyme solution was removed and the ganglia washed in 2
x lOmls Hams F12 medium containing 10% heat-inactivated horse serum to remove
and inactivate any residual trypsin. After washing, the ganglia were then dissociated
into a single-cell suspension by trituration using a fire polished siliconised glass
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pipette. Neurones were plated at low density in neurobasal medium with B27
complement, on 35 mm culture dishes containing a 12mm by 12mm square, coated
with poly-L-ornithine and laminin (Davies, Lee and Jaenisich, 1993).
In most cases the initial count of neurones attached within this square was carried out
3 hours after plating.
In experiments with proteasome inhibitors and metal ions, the initial count was
carried out 24 hours after plating. In all cases drugs were added to cultures
immediately after the initial count. The number of surviving neurones in the same
area was counted 24 and 48 hours later and was expressed as a percentage of the
initial count.









10 pM cytosine arabinoside [AraC]
10 pM Etoposide)
JNK signaling pathway inhibitor
20 pM SP600125
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ERK signaling pathway inhibitor
20 pM PD98059
Phosphatidylinositol 3-kinase signaling pathway inhibitor
20 pM LY294002
Chapter 3: RESULTS (I)
3.1 Distribution of y-synuclein within the murine nervous system
Previous work has demonstrated the high level of y-synuclein mRNA expression in
peripheral sensory neurones in addition to spinal and cranial motoneurones in both
rat and mouse (Buchman et al., 1998). Experiments were undertaken to describe the
gross overall expression pattern of y-synuclein protein in the nervous system and
investigate the intracellular localisation of y-synuclein within certain distinct
neuronal populations.
3.2 Affinity purification of mouse y-synuclein specific (SK23)
antibody
An antibody specific for mouse y-synuclein had been previously produced and
described (Buchman et ah, 1998). However large quantities of the highly specific,
affinity purified antibody were required to complete expression studies. Thus the
antibody was purified from rabbit immune serum by affinity chromatography on a
column with matrix immobilised recombinant mouse y-synuclein.
3.2.1 Production and purification of GST-fusion mouse y-synuclein
The initial step was to produce and purify the GST-fusion mouse y-synuclein
(Chapter 2, section 2.7). BL21 E. coli were transformed with a recombinant
expression plasmid carrying mouse y-synuclein cDNA cloned in-frame with
glutathione-S-transferase. This plasmid was prepared previously by Dr V. Buchman.
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In order to purify the fusion protein, bacteria carrying the expression plasmid were
cultured in 1L of the culture medium and expression of the fusion protein was
induced by adding the induction agent IPTG into the culture up to a final
concentration of 0.5mM. The GST-y-synuclein was then purified on Glutathione-
Sepharose as described previously (Chapter 2, section 2.7.1). This process yielded
approximately lOmg of pure fusion protein.
3.2.2 Preparation of the affinity purification column
2mg of the GST-y-synuclein was dialysed against coupling buffer and applied to the
prepared Hi-Trap column (Chapter 2, section 2.7.2). The protein concentration in the
flow through fraction revealed that 50% of the loaded GST-y-synuclein did not bind
to the column matrix. This was assessed by measuring the optical density of the
column flow-through. Therefore the resulting affinity purification column must have
carried lmg of the recombinant GST-y-synuclein protein attached to the matrix.
3.2.3 Affinity purification of anti-mouse-y-synuclein antibody from SK23
antiserum
To avoid any blockage of the affinity column with precipitous material often present
in serum samples, 10ml of antiserum were first run through a PD10 gel filtration
column as described above (Chapter 2, section 2.7.3). The free volume column
fractions were loaded onto the GST-y-synuclein Hi-Trap affinity column. The flow-
through fraction was retained for further repeat rounds of purification. The bound
antibody was eluted (Chapter 2, section 2.7.3) and the column re-equilibrated. Three
further rounds ofpurification took place using the flow-through from the column,
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until elution with the low pH buffer yielded only traces of protein, again as judged by
measuring the optical density of the elutant.
Each of the four eluted fractions was then dialysed against 50% glycerol in PBS
overnight to increase the stability of the protein when freezing for storage. Each
fraction was checked for efficacy using both recombinant and endogenous y-
synuclein present in homogenised spinal cord lysate on western blots (Chapter 2,
section 2.5) Fractions 1-4 were used individually as primary antibodies to
specifically detect y-synuclein protein on separate western blots. Four acrylamide
gels were poured and samples loaded. After running the gel and transfer of proteins
to the PDVF membrane, a 1:200 dilution of each fraction was applied for the
required period before the washing, application of secondary anti-rabbit antibody and
ECL as described above (Chapter 2, section 2.5.2). It was clear on developing the
blot film that fraction 1 gave the best signal (Fig. 3.1). As expected, the efficacy
dropped off the more times the flow-through was passed through the column. This
can also be seen as the y-synuclein signal appears to be fainter in fraction 2 then 3
then 4, although the same amount of protein was loaded on each blot (Fig. 3.1).
3.2.4 Optimisation of immunohistochemical detection of y-synuclein using
affinity purified antibody
As described in Chapter 2, four fixatives were tested to elucidate which was most
suitable for the detection of endogenous y-synuclein on histological sections of
mouse tissue using the affinity purified anti mouse-y-synuclein antibody and which
antibody dilution was optimal for each of the fractions. Four mouse brains were
dissected and fixed with one of either Carnoy's solution, Paraformaldehyde (PFA),
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FAA or neutral buffered formalin (NBF) (10%) (Chapter 2, section 2.6.2). Brains
were sectioned as described (Chapter 2, section 2.6.3) and 20 midbrain sections from
each brain were taken for immunostaining. In addition to a negative control where no
primary antibody was applied, four dilutions (1:50, 1:100, 1:250 and 1:500) of each
antibody fraction were incubated on the slide before all were processed through to
completion in the same way as described (Chapter 2, section 2.6.4). The best results
were achieved using tissue fixed in Carnoy's with primary antibody from purification
fraction 1 at a dilution of 1:50 (Fig. 3.2).
Figure 3.2(a) illustrates the specific immunostaining of endogenous y-synuclein in
the midbrian of adult wild-type C57B16 mice, using the antibody described above.
Expression was clearly visible in the region of the SN, where intense neuropil
immunostaining was evident. A negative control section taken from the same region
of a y'1' mouse confirmed the complete absence of the staining (Fig. 3.2b). No further
negative control images will be shown and the absence of y-synuclein from our null
mutant animals will be discussed below (section 3.5).
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Figure 3.1 SK23 affinity purified y-synuclein antibody fractions for use
in western blotting
Each of the 4 affinity purified y-synuclein antibody fractions (1-4) were
applied to western blots as primary antibodies at 1:200 dilution (a-d) to
assess antibody specificity and relative concentration. Each blot contained 3
lanes, recombinant y-synuclein (Ry), homogenate of a wild-type mouse spinal
cord containing endogenous y-synuclein (Ey) and homogenate of spinal cord
from y-synuclein null mutant mice (y'~) as a negative control. Each filter was
re-probed with anti-actin antibody to demonstrate that similar amounts of total
proteins from wild-type and null mutant mice are present on each filter.
Fraction 1 was found to have the highest antibody protein concentration with
each subsequent fraction displaying less.
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Figure 3.2 Specificity of the SK23 y-synuclein antibody stain
(a) y-synuclein staining in the midbrain of an adult wild-type mouse. Intense
neuropil staining can be seen in the SN (arrow).
(b) The same antibody applied to a section taken from a y-synuclein null
mutant mouse illustrates the specificity of the affinity purified SK23 anti-y-
synuclein antibody, as no staining is seen above a very little background.
The nigral region is marked (arrow). The lower panel is the adjacent section
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At El2 the TG neurones were found to be intensely stained for y-synuclein, showing
both axonal and cell body staining (Fig. 3.3a). This was also found to be the case at
El5 (Fig. 3.3b) and P2, by which time neuronal populations have stabilised (Fig.
3.3c). Significantly, no changes were observed in the pattern of expression or in
protein compartmentalisation during the studied period of development. All cells
within the TG appear to express y-synuclein rather than discrete populations of cells.
In the DRG similar observations were made. At El2 y-synuclein expression was
observed in the perikarya and also in the nerve fibres of the dorsal root (Fig 3.4a). At
El 5 the expression pattern was unchanged, with axonal and cytoplasmic staining still
clearly visible (Fig 3.4b). At P2 again the pattern was consistent with intense
immunostaining in both the cytoplasm and nerve fibres of the DRG (Fig 3.4c).
3.3 Developmental changes in y-synuclein compartmentalisation
in sensory neurones
3.3.1 y-synuclein mRNA expression
Expression of y-synuclein mRNA and protein has been shown previously in sensory
neuronal populations such as the trigeminal ganglion (TG) and the dorsal root
ganglion (DRG) (Buchman et al., 1998). In the TG this expression begins at E10 and
at El4 has reached a level which is maintained throughout subsequent development.
The increase of expression level in TG between El 0-12 coincides with the period of
mouse embryonic development at which the earliest axons are growing to their target
fields (Buchman et al., 1998).
It was necessary to verify that the protein expression does indeed match the mRNA
expression pattern previously described (Buchman et al., 1998) If y-synuclein is
being expressed during this critical phase in development it may shed light on its
physiological role. It was also important to study the sub-cellular localisation in
addition to its presence or absence in certain structures.
3.3.2 y-synuclein protein localisation in sensory neurones
An immunohistochemical investigation was performed using the highly specific
affinity purified anti-y-synuclein antibody to detect endogenous y-synuclein on
coronal and sagittal sections of mouse embryos at different developmental stages;
thus allowing us to study any changes in protein localisation that may occur during
development. This work was carried out in collaboration with Dr. Oliver Schmidt as
described above (Chapter 2, section 2.6).
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Figure 3.3 y-synuclein expression in mouse trigeminal sensory
neurones
(a) E12 mouse trigeminal motor nuclei (TMN) and the sensory trigeminal
ganglia (TG) stained with affinity purified anti-y-synuclein antibody showing
the intensely positive cell bodies (CB) and axons (AX) of the TG in addition to
those of the TMN. Arrowheads denote positively stained axons of the
trigeminal motor nucleus. Scale bar represents 100pm.
(b) E15 mouse trigeminal motor nuclei (TMN) and the sensory TG stained
with affinity purified anti-y-synuclein antibody showing the intensely positive
CB and axonal fibres (arrow) of the TG in addition to those of the TMN
(arrowhead) and the root of the trigeminal nerve (rTN). Scale bar represents
200pm.
(c) Mouse P2 TG, CBs stained positive for y-synuclein, in addition the AX
staining of the trigeminal nerve (TN). Scale bar represents 100pm.
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Figure 3.4 y-synuclein expression in mouse dorsal root ganglion
sensory neurones
(a) E12 mouse dorsal root ganglion (DRG), stained with affinity purified anti-
y-synuclein antibody showing the intensely positive cell bodies (CB) and
axons. Scale bar represents 100^m.
(b) E15 mouse DRG stained with affinity purified anti-y-synuclein antibody
showing the intensely positive CB and axonal fibres (AX) of the dorsal root.
Scale bar represents 200|Lim.
(c) P2 mouse DRG CB staining positive for y-synuclein. Positive staining of
the fibres in the dorsal root (DR) is indicated. Scale bar represents 20|am
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3.4 Developmental changes in intracellular compartmentalisation
of y-synuclein in substantia nigra neurones
3.4.1 y-synuclein in the substantia nigra
Previous in situ hybridisation experiments have shown that y-synuclein mRNA is
expressed in the substantia nigra (SN) of adult mice (Kholodilov et al., 1999;
Abeliovich et al., 2000). In addition to this, the neuropathological link of the
synucleins to disorders impacting on the SN make it critical that protein expression
be examined. To investigate y-synuclein protein expression/distribution during
development, the affinity purified anti-y-synuclein antibody described above (section
3.2) was used for immunohistochemistry on coronal and sagittal paraffin sections of
murine midbrain at different developmental stages. Anti-tyrosine hydroxylase
antibodies were used to identify the dopaminergic neurones making up this structure
(Chapter 2, section 2.7.4).
3.4.2 Embryonic expression of y-synuclein in the substantia nigra
At El 5 the dopaminergic cells making up the primordium of the SN begin to
synthesise dopamine and hence have also produce tyrosine hydroxylase (TH). Thus,
antibodies to TH were used to identify the SN and adjacent sections were stained for
y-synuclein (Chapter 1, section 1.6.2).
We have clearly demonstrated that at El 5 y-synuclein is expressed in both neuronal
cell bodies and axons of the dopaminergic neurones making up the developing SN
(Fig. 3.5a, b). Interestingly however three days later, at El8, the previously strong
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neuronal cell body staining disappears, and is replaced with the dotted neuropil
staining (Fig. 3.6a). The axonal staining however still remains prominent (Fig. 3.6b).
3.4.3 Postnatal expression of y-synuclein in the substantia nigra
At P2 anatomical separation between functionally distinct substantia nigra pars
compacta (SNpc) and ventral tegmental area (VTA) is possible. Drawing a boundary
between the two structures was done arbitrarily as described above (Chapter 2,
section 2.7.4). In both these structures, the diffuse pattern of neuropil staining
persisted with no y-synuclein immunoreactivity evident within the perikarya of the
neuronal cells (Fig. 3.7a). However, other structures in the same region of the
midbrain continued to display intense immunostaining with our affinity purified y-
synuclein antibody. Such structures included the red nucleus which displays
prominent immunostaining in the perikarya (Fig. 3.7). Also visible were the nerve
fibres of the medial lemniscus (Fig. 3.7).
3.4.4 Expression of y-synuclein in the adult substantia nigra
The pattern of y-synuclein expression was studied in adult animals over four months
old using identical methods to those described above. The SNpc revealed an irregular
pattern of cells staining positive for y-synuclein. These cells were distributed in a
haphazard fashion and numbers varied from animal to animal. No such cells were
observed in the VTA. To prove that the y-synuclein positive cell was truly a
dopaminergic neurone of the SNpc, double immunofluorescence detection of two
proteins on the same section was performed (Fig. 3.8a, b). The affinity purified rabbit
polyclonal anti-y-synuclein antibody was used in conjunction with a TRITC-
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conjugated secondary anti-rabbit antibody and mouse monoclonal anti-TH antibody
in conjunction with a FITC-conjugated secondary anti-mouse antibody. In the
postnatal brain, punctate neuropil staining was detected in the striatum indicating y-
synuclein may not only be located in axons but at presynaptic regions of the
dopaminergic neurones of the SNpc (Fig. 3.9).
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Figure 3.5 Sagittal section of E15 mouse brain showing the
primordium of the substantia nigra stained with anti^y-synuclein
antibody
(a) Sagittal section showing the primordium of the SN in E15 mouse brain.
The three arrowheads denote the fasciculus retroflexus, a critical landmark in
positive identification of the nigra. The arrow indicates the nigro-striatal tract,
while the arrowhead identifies the primordium of the SN positively stained for
y-synuclein. Scale bar represents 500pm.
(b) Individual positively stained cell bodies of the primordial SN at higher
magnification. Scale bar represents 20pm.
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Figure 3.6 Sagittal section of E18 mouse brain showing the
distribution pattern of y-synuclein in the primordial substantia nigra
(a) The three arrowheads denote the fasciculus retroflexus, in addition the
landmarks that are the third (III) and fourth (IV) ventricles are also highlighted.
The large arrow indicates positively stained cells in the SN. Scale bar
represents 500pm.
(b) The SN is shown at higher magnification but in contrast to that seen at
E15, at E18 cell body staining has been replaced with dotted neuropil





Figure 3.7 Coronal section of P2 mouse brain at the level of the
substantia nigra
(a) Shows the region of the substantia nigra stained with anti-y-synuclein
antibody. The cell bodies of the neurones of the red nucleus (RN) and the
fibres of the medial lemniscus (ML) can be seen to stain positive for y-
synuclein, providing a positive internal control as well as a landmark. Note
the lack of cell body staining within the substantia nigra pars compacta (SNpc)
and the ventral tegmental area (VTA). (Scale bar 50pm).
(b) Shows the consecutive paraffin section to that shown in (a) stained with
anti-TH antibody to delineate the SNpc and VTA. (Scale bar 200pm).
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Figure 3.8 Dopaminergic cells of the adult SNpc express y-synuclein
(a) A SNpc neurone stained with rabbit polyclonal anti-y-synuclein antibody
with a TRITC- conjugated secondary anti-rabbit antibody.
(b) SNpc neurones stained with mouse monoclonal anti-TH antibody with
FITC-conjugated secondary anti-mouse antibody.
128
 
Figure 3.9 y-synuclein expression in the adult striatum
(a) The striatum of a wild-type adult mouse stained with the affinity purified y-
synuclein antibody. Note the neuropil appearance of the stain surrounded by
the black oval. Neuropil staining is defined as the complex net of axonal,
dendritic, and glial branching that forms the bulk of the central nervous
system grey matter.
(b) A higher power image of y-synuclein neuropil staining in the striatum. This
staining is specific and above background.
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3.5 The generation and maintenance of a y" colony
3.5.1 Chimera generation
Production of the first chimeric animal carrying the mutated-synuclein allele was
successfully completed and is described previously (Chapter 1, section 1.8.1). The
initial crossing of a male chimera with wild-type C57B16 females produced the F1
generation of animals with brown coat colour, a sign of successful germline transfer
of the ES cell genotype in the chimera. Theoretically, a proportion (50%) of these
animals should have been heterozygous for the mutated y-synuclein allele. Selection
of animals carrying this mutation for further use was based on results of genotyping
using polymerase chain reaction (PCR) with specifically designed primers (Chapter 2,
section 2.3.6).
3.5.2 Genotypic verification
Establishing a reliable and efficient method of genotyping animals was the most
critical step in producing experimental null mutant animals. Primers were designed
using appropriate sequences from both the wild-type and mutant alleles, and the
optimal PCR reaction was established by Dr. N. Ninkina before this project started.
DNA was extracted from ear or tail biopsies for use in genotyping reactions (Chapter
2, section 2.3.5). Established protocols for PCR amplification and subsequent
agarose gel analysis of the reaction products, detected a 490bp fragment in the
presence of the wild-type y-synuclein allele and a 379bp fragment in the presence of
the null mutant allele. The presence of both these fragments indicated a heterozygous
animal (Fig. 3.10).
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3.5.3 Purification of genetic background
The initial chimera was the product of a 3.5 day old C57B16 blastocyst injected with
genetically modified 12901a ES cells. Germline transfer therefore only occurred if
gamete-producing cells of a chimera were formed from these 12901a cells. A male
chimera could mate with a wild-type female C57B16 and if the resulting litter had a
mottled coat it indicated successful germline transfer. The resulting pups however
were on a mixed genetic background. Different mouse strains such as C57B16 and
12901a have been shown to have very different behavioural, physiological and even
morphological features. The inter-strain differences are not predictable or regulated
in offspring, hence any investigation into behaviour, physiology or morphology
would be flawed and any data gleaned inaccurate. To overcome this, the colony was
backcrossed in order to ensure that all experimental animals would be on a pure
genetic background. This was achieved by mating heterozygous male animals with
wild-type C57B16 female animals (Fig. 3.11a). This process was repeated until the
F6 generation was reached, the minimum level on which behavioural and
morphometric experiments were carried out.
3.5.4 Experimental animals
When the F6 generation was reached, experimental animals were generated. This
was achieved by inter-crossing heterozygous male and female littermates in order to
produce a heterogeneous litter. This litter should contain wild-type (y+/+), null mutant
(y"/~) and heterozygous (y+/") animals, all of F6 generation (Fig. 3.11b). Genotyping,
as described above using PCR amplification (Chapter 2, section 2.3.6), revealed that
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animals were born in normal Mendelian ratios indicating that y~'~ animals were
equally as viable as y+/" or y+/+ animals.
3.5.5 Proving absence of y-synuclein mRNA and protein
Genotyping conclusively showed that both alleles were mutated in the first y""
animals. To ensure that the introduced mutation resulted in complete inactivation of
the gene, we compared y-synuclein mRNA expression in retinas of y~~ and y+/+
animals. This tissue was chosen because expression of all three synucleins has been
demonstrated previously in the retina (Surguchov, McMahan, Masliah and
Surgucheva, 2001). Therefore any compensatory changes in the expression of the
remaining synucleins could be assessed simultaneously. y" ~ and y+/+ animals were
sacrificed by appropriate Schedule 1 method, retinas were dissected and total mRNA
extracted and separated on a 1.2% agarose gel then transferred onto a nylon
membrane (Chapter 2, section 2.4.1).
Northern hybridisation was performed, using a highly specific full length y-synuclein
cDNA probe (Chapter 2, section 2.4.4). Figure 3.12(a) clearly shows the complete
absence of y-synuclein mRNA in retina of yv~ mice as compared directly with wild-
type retina showing definite expression.
Under the hybridisation and moderate stringency washing conditions the y-synuclein
cDNA probe cross-hybridised with the (3-synuclein transcript, producing an aberrant
band (Fig. 3.12a*). High stringency washes completely eradicated this leaving the y-
synuclein hybridisation signal in wild-type samples unchanged (Fig. 3.12a).
The same blot was stripped and re-hybridised with a specific 3' UTR probe
accurately designed to exclusively detect (3-synuclein mRNA. This band coincided
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with an aberrant band detected when probing for y-synuclein, hence was identified as
a (3-synuclein cross-hybridisation. No changes were detected in the level of (1-
synuclein mRNA in y~'~ (Fig 3.12a).
Once again the blot was stripped after the {3-synuclein hybridisation and re-probed
with an a-synuclein specific 3' UTR probe, and again no changes were seen in the
level of a-synuclein mRNA expression in y'~ mice (Fig 3.12a).
Finally the blot was striped once more and re-hybridised with a specific probe for the
housekeeping gene GAPDH, which ensured equivalent levels of total RNA in each
sample were present on the filter (Fig. 3.12a).
The absence of y-synuclein protein in tissues from the null mutants was confirmed by
Western blotting as described above (Chapter 2, section 2.5). Spinal cord tissue was
dissected from adult y~'~ and y+/+ mice. Tissue was homogenised in loading buffer,
total protein concentration in homogenate was measured and equal amounts were
loaded onto a 15% polyacrylamide gel. Separated proteins were transferred onto a
PVDF membrane and probed with the affinity purified, highly specific y-synuclein
antibody described above. The result shown in Fig. 3.12(b) confirmed that no y-
synuclein protein was present in the y~'~ mice.
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Figure 3.10 PCR analysis of genotype
Image of a typical agarose gel illustrating the genotyping of animals from an
intercross litter from the y~'~ colony. The presence of both y+l+ 490bp band and
y~'~ 397bp mutant allele band can be seen indicating the presence of two
heterozygotes (y+/"), a y+/+ and a y~'~ animal.
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Figure 3.11 Diagram illustrating the process of transfer of the y-
synuclein transgenic colony onto a pure genetic (C57BI6) background
(a) Illustrates the process of genetic purification of the y-synuclein colony.
Heterozygous male animals are mated with standard C57BI6 females from
Charles River. (*) denotes a male animal which can be used to produce the
next generation.
(b) Illustrates the production of an experimental cohort of littermates, for
experimental use, once F6 had been reached. The intercrossed litter retain
the same F6 status.
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a
F1 Male WT Female
F2 Generation
b
F6 Male F6 Female
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Figure 3.12 Expression of synucleins in adult mice by Northern and
Western blot
(a) Expression of mRNAs encoding members of the synuclein family in the
retinas of y+/+ and f'~. Results of Northern hybridisation with a full-length
mouse y-synuclein cDNA probe, a mouse (3-synuclein-specific probe, a
mouse a-synuclein-specific probe, and a GAPDH probe are shown. *
indicates that under the hybridisation and washing conditions used, the y-
synuclein cDNA probe cross-hybridised with (3-synuclein transcript. High-
stringency washes completely eradicated this hybridisation signal, with no
effect on hybridisation with y-synuclein transcript.
(b) Western blot with 10 pg of total spinal cord protein lysates per lane was
probed with an anti-y-synuclein. Wild-type (+/+) sample shows high levels of













3.5.6 Production of experimental a-synuclein null mutant mice
During the course of our investigations a-synuclein null mutant mice were obtained
from the laboratory of A. Rosenthal (Genentech). These mice have been described in
detail previously (Abeliovich et al., 2000). The mice were on a mixed
12901a/C57B16 genetic background and hence were backcrossed as described above
(Chapter 2, section 2.3.2). This ensured that all experimental animals were on the
same genetic background, allowing for accurate comparisons to be made between the
different genotypes, in this case a'1' and y~'~.
3.5.7 Production of experimental a /y double null mutant mice
Once both y''~ and a'~ mutant mice had been backcrossed to equivalent genetic
backgrounds suitable for intercrossing (F6), it was feasible to create an a'~/y~1'
synuclein double null mutant strain (Chapter 2, section 2.3.3). This colony would
allow us to compare the cumulative effect of the null mutations alongside the single
mutant animals on an identical genetic background.
Interbreeding a1' and y ' animals produced a litter of double heterozygous animals, in
effect a+/" / y+/" animals. Interbreeding these offspring yielded a 1:16 chance of a litter
containing a double null mutant mouse. These a'~l y~'~ mice could then be interbred to
enlarge the colony.
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3.6 Initial characterisation of y-synuclein null mutant mice
3.6.1 Y-synuclein null mutant mice
Identification of the first y~'~ mouse in an intercross litter indicated this mutation was
non-lethal during gestation. As further litters were produced, it became obvious that
development was not restricted, as y~'~ animals appeared at approximately the
expected mendelian frequency. y~'~ mice developed normally and phenotypically it
was not possible to distinguish them from y+ + and y+/" littermates. A study of the
gross morphology of the brain and other organs carried out by Dr. O. Schmidt also
failed to reveal obvious differences between y+/+ and y~'~ mice. Male and female y~'~
animals were interbred and regular size litters of y'~ mice were successfully produced
proving y~'~ animals were fertile as well as viable. The average weight of y_/" juvenile
and adult animals was no different from their y+/+ and y+/" littermates. This is
illustrated by the comparison of 4 month old male animals (Fig. 3.13).
3.6.2 General level of activity displayed by y"" mice
To assess the level of general activity displayed by y" in comparison with y+/+ mice
an open field camera (Ugo Basile) was used. The average number of infrared beam
breaks was recorded at 10 minute intervals over a 2 hour test period. Adult male
animals were used, as hormonal changes in female mice can alter behaviour patterns,
especially significant in a new environment such as the camera.
Studies of these animals in an open field camera revealed no significant differences
in the general levels of activity between y~'~ and y+/+ mice (Fig. 3.14).
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Figure 3.13 Average weight of 4 month old male of y-, a- or a/y-
synuclein null mutant mice compared to wild-type mice
The average weight of 4 month old male y-, a- or y/a - synuclein null mutant
mice was compared to wild-type mice. No statistically significant differences
were observed. n=8 for each genotype.
■ +/+ / +/+a / y
□ a+/+ / y1'
m a~'~ / y+/+










Figure 3.14 Assessment of general activity using an open field camera
The general level of activity of y-synuclein null mutant mice (y"/_) was tested in
comparison with that of wild-type (y+/+) littermates. The mean number of
beam breaks in a given time was recorded and no significant differences





3.7 Neuronal number of dorsal root ganglion (DRG) and the
trigeminal ganglion (TG) of y+/+, y~'~ and a'1' animals
3.7.1 y-synuclein in sensory ganglia
We have shown that y-synuclein expression begins during embryonic development
and is maintained throughout the postnatal period into adulthood. In contrast to y-
synuclein, a-synuclein has been shown to be radically different, being expressed
heterogeneously throughout the CNS with immuno-positive structures being
punctuate with a neuropil appearance (Totterdell et al., 2004). Expression however
begins at approximately the same point during development, E12 (Hsu et al., 1998).
Peripheral sensory neurones display one of the highest levels ofy-synuclein
expression in the entire nervous system (Buchman et al., 1998). Therefore in the
absence of any gross anatomical or behavioural changes in y"", it was logical to
investigate any effects of this loss in an area of high expression. At P2 the period of
natural cell death (NCD) has ended and the neuronal population stabilised both in the
DRG and TG, therefore this is a suitable time point for analysis (Chapter 1, section
1.6.3). a-synuclein is also expressed in these neurones, although at a lower level.
Therefore a-synuclein null mutants were also included in the study. Double a^'/y'1'
were not available at the time of this experiment hence not included in the study.
3.7.2 Assaying sensory neuronal populations
Neuronal populations of the trigeminal ganglia (TG) and L6 dorsal root ganglia
(DRG) were assayed in P2 mice. Tissues were dissected and processed for histology
as described above (Chapter 2, section 2.6) Longitudinal sections of the lumbar
region of the spinal cord and transverse sections of the head were stained with Cresyl
148
Fast Violet to facilitate the identification and assessment of these neuronal
populations (Chapter 2, section 2.8.1).
Cell counts were carried out using a stereology system as described previously
(Chapter 2, section 2.8.2).
No statistically significant differences were found in the mean number of neurones
per ganglia in the TG of wild-type, y_/~ and a"'" mice, with all genotypes containing
approximately 30,000 neurones per ganglion (Fig 3.15a).
Identical results were observed in the L6 DRG, where again no statistically
significant differences were observed in the mean number of neurones per ganglion
in the DRG ofwild-type, y'1' and a'~ mice, all having approximately 2,500 neurones
per ganglion (Fig. 3.15b). These results clearly indicate that the absence of either a-
or y- synuclein does not have any direct effect on the development of sensory
neuronal populations of either the TG or DRG.
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Figure 3.15 Sensory neuronal number assayed in the trigeminal and
dorsal root ganglia of wild-type (a+/+/Y+/+), y-synuclein null (y"'") and a-
synuclein (a"'") null mutant mice
(a) Comparison of the mean (± SEM) number of neurones in the TG of
a+/+/y+/+, y"'" and a1' P2 mice. Means were taken from at least 10 ganglia for
each genotype. There were no significant differences in the neuronal number
irrespective of genotype (p > 0.6, Kruskal-Wallis one-way ANOVA analysis of
variance).
(b) Comparison of the mean (± SEM) number of neurones in the L6 DRG of
a+/+/y+/+, y~'~ and a'~ P2 mice. Means were taken from at least 10 ganglia for
each genotype. There was no significant difference in the neuronal number
irrespective of genotype (p > 0.6, Kruskal-Wallis one-way ANOVA analysis of
variance).

































3.8 Survival in culture of peripheral nervous system neurones of
wild-type and synuclein null mutant mice
3.8.1 Primary neuronal cultures
Although no differences in neurone numbers in DRG or TG ofwild-type, a-
synuclein or y~'~ were found, it was feasible to check whether neurones with an
incorrect balance of synucleins are more sensitive to various stresses than wild-type
neurones. For this we compared the survival of neurones from the trigeminal ganglia
of a'' and y~'~ and a''/ y'' mice in dissociated primary cultures. It has been shown
previously that certain types of cells with modified expression of synucleins,
particularly dopaminergic neurones over-expressing a-synuclein, have normal
survival characteristics under optimal culture conditions but are substantially more
susceptible to stresses (Ostrerova-Golts, Petrucelli, Hardy, Lee, Farer and Wolozin,
2000; Petrucelli et al., 2002).
To determine whether the absence of y-synuclein renders neurones more sensitive to
various toxic insults, we cultivated P2 trigeminal neurones in the absence of
antioxidants or in the presence of DNA-damaging agents, proteasome inhibitors,
heavy metal ions or inhibitors of major intracellular signalling pathways in the
medium. Cultures from trigeminal ganglia were prepared and maintained in
neurobasal medium with B27 complement as described above (Chapter 2, section
2.12). The number of neurones attached to each culture dish within a 12 by 12mm
square was counted 3 hours after plating and was taken as the initial number of
neurones, the 100% value. In all cases, drugs were added to cultures immediately
after the initial count. The number of surviving neurones in the same area was
counted at 48 hours and was expressed as a percentage of the initial count.
3.8.2 Neuronal survival in dissociated culture
Firstly, the survival characteristics of a-synuclein and y-synuclein deficient neurones
were studied in the presence and absence of nerve growth factor (NGF). In both
cases, the survival of these neurones was indistinguishable from those of wild-type
neurones. They survived similarly well in the presence of NGF and failed to survive
equally in its absence (Fig. 3.16a).
A selection of pharmaceutical agents were chosen to apply to cultures on the basis of
their known neurotoxicity or because of putative interactions of a-synuclein and
proteins involved in certain signalling pathways discussed in greater details above
(Chapter 1, section 1.3).
In the presence of the proteasome inhibitors MG-132 and PSI and the heavy metal
ions Cu2+ and Zn2+ no significant differences in survival were observed in the
absence of y-synuclein; equal reductions were observed for both genotypes alike, in
the presence of these neurotoxic agents (Fig. 3.16b).
In the absence of antioxidants or the presence of the cytotoxic agents AraC and
etopicide equivalent observations were made i.e. no significant differences in
survival were observed in the absence of y-synuclein (Fig. 3.16c).
Finally in the presence of inhibitors of the JNK signalling pathway SP600125, ERK
signalling pathway PD98059, or phosphatidylinositol 3-kinase signalling pathway
LY294002 no statistically significant differences in survival were observed in the
absence of y-synuclein (Fig. 3.16d.)
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Figure 3.16 Survival of P2 mouse trigeminal ganglion neurones in
dissociated primary culture
Bar charts illustrate survival of neurones 48 hours after initial count and
addition of drugs. The number of surviving neurones is expressed as a
percentage of the initial count. Means ± SEM of data obtained from analysis
of at least six culture dishes for each genotype in two independent
experiments are shown.
(a) Both a-synuclein deficient (a"/") and y-synuclein deficient (y"/_) neurones
have the same survival rate as wild-type (a+/+/y+/+) neurones in the presence
of nerve growth factor (NGF) and are unable to survive in its absence (P <
0.8, Kruskal-Wallis one-way ANOVA).
(b) Proteasome inhibitors MG-132 or proteosome inhibitor I [PSI]) and heavy
metal ions Cu2+ or Zn2+ were added to cultures after the initial count.
(c) Neurones were plated in neurobasal medium supplemented with B27
without antioxidants or in the presence of DNA-damaging agents cytosine
arabinoside [AraC] or Etoposide.
(d) Inhibitors of the JNK signalling pathway P600125, ERK signalling
pathway PD98059, or phosphatidylinositol 3-kinase signalling pathway
Y294002 were added to cultures after the initial count.
No statistically significant differences were revealed between wild-type and





3.9 Summary of results
An antibody specific to the C-terminal peptide of mouse y-synuclein has been
successfully purified and has been shown to be effective and specific for use in both
western blotting and immunohistochemistry. This antibody was used to perform
protein expression studies confirming previous mRNA data. In sensory neurones,
axonal and cytoplasmic expression was found to be maintained from El2 into
adulthood in both the trigeminal and dorsal root ganglia.
In the SN at El5 both axons and cell bodies are stained however, at El 8 this begins
to change with the appearance of dotted neuropil staining, which by P2 has replaced
the cytoplasmic staining in most cells. In adult animals this replacement is total
except in a small number of haphazard immunopositive cell bodies.
Experimental y_/", a1' synuclein null mutant and a 7y_/"synuclein double mutant mice
were successfully produced using the animals produced by Dr V. Buchman and
gifted from Prof A Rosenthal (Genentech). Once on a sufficiently pure genetic
background (F6) animals were intercrossed to produce experimental litters. The
production of these animals took considerable time so that some experimentation
could only be carried out with certain available genotypes.
The loss of a- or y-synuclein was found to have no effect on the neuronal populations
of either the trigeminal or dorsal root ganglia, with no significant differences being
found in neuronal number. The population of the cranial motor nuclei was also found
to be unchanged in the absence of y-synuclein.
Furthermore, y~A neurones have been shown to be equally sensitive to neurotoxic
insult as wild-type cells in dissociated primary culture.
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In the light of these findings it was decided to focus our efforts on the neuronal
populations of the SN. The involvement of synucleins in pathological conditions
makes the SN an important target in understanding the role of synucleins in disease.
The transgenic models we have developed are excellent tools for gathering valuable
information as to the physiological function of this novel protein family.
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Chapter 4: RESULTS (II)
4.1 Assaying dopaminergic neurone number
4.1.1 Tyrosine hydroxylase as a dopaminergic marker
To assay the number of dopaminergic (DA) neurones within the substantia nigra (SN),
we stained histological sections with a specific antibody to tyrosine hydroxylase (TH)
(Chapter 2, section 2.7.4). TH is the rate limiting enzyme in the dopamine synthesis
pathway, catalysing the hydroxylation of tyrosine to L-3,4-dihydroxyphenylalanine (L-
dopa). The importance of TH to murine physiology is underlined by mid-gestational
lethality in mice lacking TH (Kobayashi, Morita, Sawada, Mizuguchi, Yamada,
Nagatsu, Hata, Watanabe, Fujita and Nagatsu, 1995). Other catecholamines such as
adrenalin and noradrenalin have been shown to be severely reduced to <0.5% in TH null
foetuses, while tissue levels of dopamine were only reduced to 42% ofwild-type levels
(Kobayashi et al., 1995). While it is acknowledged that TH is a major enzyme in the
dopamine (DA) synthesis pathway, it is not the sole pathway. L-dopa can also be
produced from dopaquinone via the oxidation of tyrosine by tyrosinase, part of the
melanin synthesis pathway (Riley, 1995). Nevertheless, dopaminergic populations of the
SN predominantly utilise the TH synthesis pathway. Therefore this is a good marker for
these neurones.
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4.1.2 Deficit of dopaminergic neurones in y-synuclein null mutant (y~/_) mice
The number of mesencephalic dopaminergic neurones were assayed at two different
points during development (El 8, P5) and in adult animals, in both wild-type (y+/+) and y-
synuclein null mutant (y"") mice (Chapter 2, section 2.7.4) These two time points were
chosen as they span the period of developmental apoptosis which peaks at P2, as
discussed (Chapter 1, section 1.6.2) (Jackson-Lewis et al., 2000). As expression of y-
synuclein begins during development at approximately El2, it is reasonable to
hypothesise that the protein has a role to play during normal development. Were y-
synuclein to have a role in apoptosis then a difference between the two genotypes may
be observed in neuronal number as development progresses.
To investigate this hypothesis, total numbers of dopaminergic cell bodies were counted
i.e. substantia nigra pars compacta (SNpc) plus ventral tegmental area (VTA), as
embryonic anatomy prevented accurate topographical discrimination between SNpc and
VTA. A specific antibody to TH was chosen that clearly labels the perikarya of
dopaminergic neurones to enable accurate counting in histological sections.
El8 embryos were dissected from uteri and brains removed, following Schedule 1
protocol. Histological samples were processed and serial coronal sections through the
midbrain region were stained with an anti-TH antibody for analysis using fractionator
stereology (Chapter 2, section 2.8.2). This method provided an accurate measurement of
neuronal number. All experimental data collection was carried out in blind manner to
prevent bias.
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Analysis of the TH stained sections revealed that no statistically significant differences
existed in the total number of dopaminergic neurones present in the primordial SN of
y+/+ and y7"animals (Fig. 4.1).
To assess the number of dopaminergic neurones remaining in the SN and VTA of y-
synuclein null mutant mice following the wave of developmental apoptosis at P2, the
brains of P5 y+/+ and y'~ mice were dissected and processed for immunohistochemistry,
as described previously (Chapter 2, section 2.6.3) . In contrast to El8, a small yet
significant deficit was observed in the number of TH positive midbrain dopaminergic
neurones in y1' mice at P2 (Fig. 4.1). The mean number of neurones in y " (6100 ± 200)
being 19% ± 3.2% fewer than the y+/+ mice.
To assess whether or not this deficit persisted into adulthood, identical histological
methods were applied to the brains of adult y~'~ and y+ + mice. A 19% ± 2.4% deficit in
the number of dopaminergic neurones of the SN and VTA observed at P5 was still
evident in adult y~'~ mice (6200 ± 150) as compared to y+/+ mice (7600 ± 170; Fig. 4.1).
4.1.3 Effects of the y-synuclein null mutation on dopaminergic neuronal number
in the SN pars compacta (SNpc) and ventral tegmental area (VTA)
In adult animals (15-20 weeks old), neurodevelopment is complete and a reliable
accurate distinction could be made between the SNpc and VTA (Chapter 2, section
2.7.4). In order to ascertain which of these dopaminergic structures displayed a neuronal
deficit, a second investigation was carried out to analyse the SNpc and VTA of adult
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mice as separate structures. The boundary between the two structures was drawn
applying consistent criteria (Chapter 2, section 2.7.4).
Adult brains were dissected following Schedule 1 protocols and processed for
immunohistochemistry as described previously. Sections were again stained with the TH
antibody to specifically label dopaminergic neurones and stereology was applied to
quantify neuronal number.
Within the SNpc, we observed a very similar statistically significant 14.5% ± 5.2%
reduction in the number of TH-positive neurones in the brains of adult y~'~ mice (3619 ±
188) in comparison to y+/+ (4233 ±211) mice (Fig. 4.2).
Unlike the SNpc, the VTA of adult y~'~ mice (3881 ± 183) displayed no significant
change in dopaminergic neuronal number in comparison to y+/+mice (3786 ± 257; Fig.
4.3). These results demonstrate that the developmental deficit described earlier is due to
a specific loss of SNpc dopaminergic neurones arising at a point in development
between E18 and P5.
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Figure 4.1 Number of dopaminergic neurones in midbrain of wild-type
and y-synuclein null mutant mice
This histogram shows the mean ± SEM number of TH-positive neurones in
SN + VTA of E18, P5 and adult mice. No difference was found in E18 (p > 0.5,
Student's f-test; n = 6 for each genotype) but P5 and adult y-synuclein null
mutant mice (y_/~; n = 8 and 6, respectively) have significantly less (*p < 0.05,
Student's f-test) neurones than adult wild-type mice (y+/+; n = 9). The figure
shows that between E18 and P5 a 15-20% deficit arises in the total number of
























Figure 4.2 Comparison of number of dopaminergic neurones in the
substantia nigra pars compacta (SNpc) of y-, a- or y/a - synuclein null
mutant mice compared to wild-type mice
Histogram shows mean ± SEM number of TH-positive neurones in SNpc of wild-
type (a+/+ / y+/+), y-synuclein null mutant (a+/+/ y_/"), a -synuclein null mutant (a1'/
y+/+) and double null mutant (a1' / y~'~) mice. Neurones were counted separately in
left and right structures of at least seven animals for each genotype. Statistical
analysis (Kruskal-Wallis one-way anova) showed a significantly reduced number
of neurones in SNpc (*p < 0.01) of all three types of mutant mice when
compared to wild-type mice. These results clearly show that the developmental
deficit in midbrain dopaminergic neurone number exists in the SNpc.








Figure 4.3 Comparison of the number of dopaminergic neurones in the
ventral tegmental area (VTA) of y-, a - or y/a - synuciein null mutant mice
compared to wild-type mice
Histogram shows the mean ± SEM number of TH-positive neurones in VTA of
wild-type (a+/+/ y+/+), y-synuclein null mutant (a+,+1 y~'~), a-synuclein null mutant (a
y+/+) and double null mutant y~'~) mice. Neurones were counted
separately in left and right structures of at least seven animals for each
genotype. Statistical analysis (Kruskal-Wallis one-way anova) showed no
difference in VTA (p > 0.3) in any mutant mice when compared to wild-type
mice. These results clearly show that the developmental deficit in midbrain
dopaminergic neurone number is restricted the SNpc and not seen in the VTA.












4.1.4 Effects of an a-synuclein null mutation on dopaminergic neuronal number
in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA)
In the light of the SNpc specific deficit in the number of DA neurons in y"/_ mice an
identical study was carried out using a-synuclein null mutant (a~/~) mice which became
available to us (Chapter 2, section 2.3.2).
Brains were dissected from adult a'1' mice following Schedule 1 methods and processed
for immunohistochemistry. Neuronal number was assayed by counting cell bodies
stained positive for TH (Chapter 2.7.4).
We observed a statistically significant 17.8% ± 4.4% reduction in the number of SNpc
DA neurones in a'1' (3479 ± 186) as compared to wild-type (a+/+/y+/+) mice (4233 ±211;
Fig. 4.2). This reduction was almost identical to that seen in y"A mice. As in ymice, we
observed no significant differences in the neuronal number in the VTA of a"" (3468 ±
183) as compared to a+/+/y+/+ mice (3786 ± 257; Fig. 4.3).
4.1.5 Effects of a double a-/y-synuclein null mutation on dopaminergic neuronal
number in the SNpc and ventral tegmental area (VTA)
A statistically significant difference in the number of dopaminergic SNpc neurones was
observed in both a'~ and y_/" mice. Following the generation of double a-/y-synuclein
double null mutant animals (a~/7y~/~) (Chapter 2, section 2.3.3), an identical investigation
was carried out to elucidate whether or not any cumulative effects of the mutations
would occur, producing a larger deficit in the SNpc or perhaps precipitating one in the
VTA, where previously no differences were observed.
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Identical histological methods were applied to brains of a~/7y~/~ mice, dissected according
to Schedule 1 protocols. A statistically significant 20.1% ± 5.3% reduction was observed
in the dopaminergic neurones of the SNpc of a" 7y~/_ mice (3382 ± 179) as compared to
a+/+/y+/+ mice (4233 ±211), such that no cumulative effects from the double null
mutation were observed (Fig. 4.2). The same pattern as previously seen was observed in
the VTA i.e. no significant differences existed in DA neuronal number between a" 7y""
(3460 ± 204) and a'+/y+l+ mice (3786 ± 257; Fig. 4.3).
As these data were collected in three independent studies, it is worth noting that each
genotype was compared to wild-type (a+/+/y+/+) animals individually. As no differences
were observed in the numbers of neurones in a+/+/y+l+ animals, the data could be
combined.
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4.2 Motor performance assessment in synuclein null mutant mice
The role of the SN in motor control is now well characterised (Chapter 1, section 1.6.1).
Therefore, it was logical to assess the motor performance of synuclein null mutant mice
to investigate whether or not the neuronal deficit observed could translate into a
deleterious phenotype in the form of a deficit in motor performance.
4.2.1 Motor performance of synuclein null mutant mice at constant speed
Groups of adult male a+/+/ y+/+, a+/+/ y~A, a~/7 y+/+ and a~ / y1' animals were assessed for
motor performance using an Ugo Basile rotarod. Animals were given three two minute
long training periods on the equipment before experimental data were recorded. Animals
were placed onto the rotating rod in individual compartments and time measured until
the animals fell from the rod as described above (Chapter 2, section 2.10.1).
At a speed of 24 revolutions per minute (rpm), wild-type performance was taken as the
mean 100% performance value. Single null mutant a+,+ / y1' and a_/7 y+/+ mice showed
no observable significant differences in motor performance compared to wild-type
animals (Fig. 4.4). The double null mutant a'~ / y'~ mouse group, while perhaps the most
likely group to show a retarded motor performance, also showed no observable
differences in performance when compared to a+l+ / y+/+ or single null mutant a+/+ / y'~
and a_/7 y+/+ mice (Fig. 4.4).
171
4.2.2 Motor performance of synuclein null mutant mice in an accelerating trial
The animals described above were again placed on the rod in individual compartments.
However in this accelerating trial the rod was initially stationary but accelerated steadily
to 40 rpm over five minutes and the clock was stopped when the animal fell from the
rod.
Once again, results followed the pattern of the previous experiment, with no significant
differences in performance being observed between a+l+ / y+/+ mice and the synuclein
null mutant a+/+ / y~7", a"7" / y+/+and a"7" / y~7~ mice (Fig. 4.5).
We concluded from these investigations that the developmental neuronal deficit within
the SNpc of synuclein deficient mice does not translate into impaired motor function.
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Figure 4.4 Performance of wild-type and synuclein null mutant mice in
constant speed rotorod tests
Histogram shows mean ± SEM of time intervals from the test start to animal fall
from the rotating rod. Results of 3 minute test with constant 24 rpm. Statistical
analysis (Kruskal-Wallis one-way anova) showed no significant difference in the
performance of wild-type and mutant mice (p > 0.4).





□ a1' / y~'~
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Figure 4.5 Performance of wild-type and synuclein null mutant mice in
accelerating rotarod tests
Histogram shows mean ± SEM of time intervals from the test start to animal
falling from the rotating rod. Results of 5 min accelerating rotation test are
shown. Statistical analysis (Kruskal-Wallis one-way anova) showed no
significant difference in performance of wild-type and mutant mice in both tests
(p > 0.4).




□ a"'" / y+/+
□ a'1' / y~'~
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4.3 Assaying levels of dopamine and its metabolites in the striatum of
synuclein null mutant mice
4.3.1 Assaying levels of dopamine and its metabolites via HPLC analysis
To assess the effect of the synuclein null mutation and the reduction in dopaminergic
neuronal number on the levels of dopamine and its metabolites, the striatum was
dissected from nine month old male mice. High performance liquid chromatography
(HPLC) analysis was used to measure dopamine (DA), 5-hydroxyindolacetic acid (5-
HIAA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels
in the extract of each of individual striatum. The HPLC analysis itself was carried out by
Paul Jones and John Sharkey of the Fujisawa Institute ofNeuroscience, Edinburgh and
as in other experiments, performed blindly and is described above (Chapter 2, section
2.11).
Brains of nine month old male a+/+/y+/+, a+7+/y"A, a_/7y+/+ and a"77y"7" mice were dissected
and snap frozen for storage prior to analysis on an HPLC column. Samples were later
defrosted and homogenised before extracts were injected onto the column.
Levels of all four neuro-chemicals studied, DA, HIAA, DOPAC and HVA were
analysed and a+/+ / y+/+ levels normalised as 100% for comparison against a+/+/ f'~, a"7"/
y+/+ and a"7" / y~7" samples. The synuclein null mutant samples showed no significant
reductions in the striatal level of either dopamine or its metabolites HIAA, DOPAC or
HVA (Fig. 4.6 and Fig. 4.7). These results indicated that the reduction in neuronal
number caused by these null mutations was not significant enough to precipitate a drop
in levels of striatal dopamine.
Figure 4.6 Dopamine and its metabolite 5-hydroxyindolacetic acid levels
in striatum of wild-type and synuclein null mutant mice
Striatal concentrations (ng/mg protein) of (a) dopamine (DA) and (b) 5-
hydroxyindolacetic acid (5-HIAA) in mutant animals were normalised to
corresponding mean values for wild-type animals (100%) in each experiment.
Mean ± SEM for nine animals per genotype from two separate experiments are
shown. Statistical analysis showed no significant difference between wild-type
and mutant mice for either of the neurochemicals (p > 0.1, one-way anova with
posthoc Newman-Keuls test).
■ +/+ / +/+a ly






Figure 4.7 Levels of dopamine metabolites 3,4-dihydroxyphenylacetic
acid and homovanillic acid in striatum of wild-type and synuclein null
mutant mice
Striatal concentrations (ng/mg protein) of (a) 3,4-dihydroxyphenylacetic acid
(DOPAC) and (b) 5-hydroxyindolacetic acid (HVA) in mutant animals were
normalised to corresponding mean values for wild-type animals (100%) in each
experiment. Mean ± SEM for nine animals per genotype from two separate
experiments are shown. Statistical analysis showed no significant difference
between wild-type and mutant mice for either of the neurochemicals (p>0.1,
one-way anova with posthoc Newman-Keuls test).













4.4 Changes in sensitivity to neurotoxic insult of dopaminergic
neurones in synuclein null mutant mice
4.4.1 l-Methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)
The biological effects of the potent neurotoxin MPTP (l-Methyl-4-phenyl-l,2,3,6-
tetrahydropyridine) were first noted in July of 1982 in northern California (Langston,
Ballard, Tetrud and Irwin, 1983). MPTP had been ad-mixed with MPPP (l-Methyl-4-
phenyl-4-propionoxypiperidine) and sold as synthetic heroin in this limited region of the
United States. Initially, one female and three male patients were admitted to hospital
with severe Parkinson-like symptoms, having taken between 5-20g of the drug
intravenously over a period of days. All patients became symptomatic within one week
of taking the drug. They began with visual hallucinations, jerking and generalised
muscle stiffness and dyskinesia which continued to develop despite the discontinued use
of the drug. After 6 weeks, each of the patients was found to be all but immobile with
generalised increase in muscle tone, fixed stare and constant drooling. All patients were
found positive in the Glabellar tap test and displayed the classical pill rolling tremor, in
addition to general bradykinesia. All individuals did however respond to Levodopa and
Carbidopa therapy although none displayed any sign of remission (Langston et al.,
1983). Following these cases, it became apparent that this compound could prove a
useful tool in the development of an in vivo model in primates and rodents to investigate
Parkinson's disease (PD) (Kolata, 1983). It was found that MPTP is initially metabolised
by type B monoamine oxidase (EC 1.4.3.4, MAO-B), predominantly glial in origin, into
the intermediate l-methyl-4-phenylpyridinium (MPDP+) (Ramsay and Singer, 1986). In
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a further oxidation, the final four-electron oxidation product, the actual toxic molecule,
1-methyl-4-phenylpyridinium (MPP+), is produced. The toxic intracellular accumulation
of MPP+ occurs as it is a high affinity substrate for the dopamine transporter (DAT) due
to the structural similarities between itself and dopamine (Fig. 4.7) (Javitch, D'Amato,
Strittmatter and Snyder, 1985).
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Figure 4.8 1 -Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Line diagrams showing the chemical structure of 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and its toxic metabolite 1-methyl-4-phenylpyridinium










4.4.2 Dopaminergic neurones of single and double synuclein deficient mice are
resistant to MPTP toxicity
To address the question ofwhether the absence of synucleins might alter the sensitivity
of dopaminergic neurones to specific neurotoxic insults, we treated a+/+/y+l+, a1', y'1' and
a'/y'1' null mutant mice with MPTP, a neurotoxic drug that predominantly affects
dopaminergic neurones. A protocol of MPTP administration (Chapter 2, section 2.9) that
results in the apoptotic death of dopaminergic neurones was chosen (Tatton and Kish,
1997). This protocol allowed for the identification of animals more sensitive as well as
less sensitive to the neurotoxic effect of the drug because it causes only a moderate
reduction, approximately 40%, in the number of dopaminergic neurones of the SNpc of
wild-type mice. The deficit precipitated is not accompanied by reductions in the level of
striatal dopamine.
The experimental cohort of mice that were to be given the course of i.p. MPTP
injections were separated from the general population 1 week prior to the first injection
of the drug, for health and safety reasons and to ensure control animals were not
contaminated. Five daily 30mg/kg doses of MPTP, injections at lOmg/ml were
administered to the experimental group and sterile PBS given to the control (vehicle)
group. Twenty one days after the last injection, brains were dissected following
Schedule 1 procedures, and were processed for histology as described above. An
antibody to tyrosine hydroxylase (TH) was used to stain the dopaminergic neurones of
the SNpc (Chapter 2, section 2.7.4).
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Wild-type animals demonstrated the expected reduction in TH-positive neuronal number
following the MPTP injection regimen. 64.7 ± 11.1% of neurones remained in the
MPTP-treated group; 100% was the mean of neurone numbers in a vehicle treated group
of wild-type animals (Fig. 4.9). All other data are expressed as a percentage survival as
compared with the vehicle injected equivalent genotype and not compared to wild-type.
Interestingly, no statistically significant reductions were observed within the synuclein
null mutant cohorts. a_/" animals retained 88.1 ± 4.7% of neurones in the MPTP-treated
group as compared with vehicle injected animals (Fig. 4.9). y" mice retained 95.3 ±
7.4% of neurones in the MPTP-treated group as compared to vehicle injected y"" mice
(Fig. 4.9). a''/y" animals again showed no cumulative effects of the mutation, retaining
85.9 ± 6.6% of neurones following MPTP treatment (Fig. 4.9).
4.4.3 Effect of chronic MPTP treatment on the motor performance of wild-type
and synuclein null mutant mice
The same experimental cohort of animals used in the experiment described above were
tested two weeks following administration of MPTP or saline vehicle in an accelerating
rotorod trial as described previously (Chapter 2, section 2.10.1).
No significant differences in motor performance were observed in the a+/+/ y+/+ group in
either MPTP or saline injected groups (Fig. 4.10). Furthermore, none of the a'~, y"A or
the a','/y'1' groups revealed any differences in motor performance between the MPTP
treated animals in comparison with their saline injected control group (Fig. 4.10).
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Figure 4.9 Effect of chronic MPTP treatment on wild-type and synuciein
null mutant dopaminergic neurones of the SNpc
The number of dopaminergic neurones in SNpc of wild-type and synuciein null
mutant treated with MPTP or vehicle. Neurones were counted separately in left
and right SNpc of at least six animals for each experimental group. Statistical
analysis (*p<0.2, Kruskal-Wallis one-way anova and Student's f-test separately
for each genotype) showed a significant reduction in the number of neurones






Figure 4.10 Effect of chronic MPTP treatment on the motor performance
of wild-type and synuclein null mutant mice
Performance of wild-type (a+/+/y+/+), y-synuclein null mutant (a+/+/y"/_), a-synuclein null
mutant (a_/7y+/+) and double null mutant (a"/7y"/") mice in 5 min accelerating rotarod test
before and 2 weeks after MPTP treatment. No significant differences in motor





4.5 Synuclein expression in the midbrain of null mutant mice
4.5.1 Assaying synuclein protein level
The relative expression level of the remaining un-mutated synuclein proteins were
investigated in the three synuclein null mutant colonies. This also allowed us to verify
the total absence of a- and y-synuclein protein from our double null mutant mice.
Midbrain tissues were dissected from adult male f'\ a'1', a1'If1' and a+/+/y+/+ mice and
homogenised in Laemmli lysis buffer as described above (Chapter 2, section 2.5.1).
lOpg of total midbrain protein lysate from each genotype were loaded into separate
lanes on three agarose gels prepared and run as described previously (Chapter 2, section
2.5.2). The separated proteins were transferred onto 3 nylon membranes which were
then probed with antibodies to a-, (3- and y-synuclein. The filter probed with an anti-|3-
synuclein antibody was stripped and re-probed with an anti-a-tubulin antibody to ensure
equivalent amounts of total protein were loaded.
The f~ tissue showed a complete absence of y-synuclein protein as expected and the
level of a-synuclein expression was equivalent to the a+/+/y+/+ control sample (Fig. 4.11).
However, the level of p-synuclein protein expression appeared to be elevated in
comparison with the a+/+/y+/+ control sample (Fig. 4.11).
Similarly, the a1' tissue showed a complete absence of a-synuclein protein as expected
and the level of y-synuclein expression was equivalent to the a+/+/y+/+ control sample
(Fig. 4.11). Again, an increase in P-synuclein expression was detected (Fig. 4.11).
The a.'1'If1' tissue confirmed the absence of both proteins from these animals as expected
and again an increase in P-synuclein protein expression was observed (Fig. 4.11). In
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both the single and double null mutant animals, there was an equivalent increase in p-
synuclein expression.
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Figure 4.11 Western blot showing synuclein protein expression in
midbrain of wild-type and synuclein null mutant mice
Each of the three identical western blots with 10^xg of total midbrain protein
lysates per lane were probed with antibodies against a-synuclein, p-synuclein
and y-synuclein. The filter probed with p-synuclein was stripped and re-probed
with anti-a-tubulin as a control (lower panel). Midbrains of adult male y~'~, a'~, a'~







4.6 Summary of results
A 15-20% developmental deficit in the total number of dopaminergic neurones in the
SNpc and VTA was detected at P5 in y~'~ mice. We have shown this deficit must arise
between El8 and P5 as at El8 there were no significant differences. The reduction was
also seen in adult animals.
To identify the source of this reduction, a study was carried out in adult y'\ a'~ and a'~ /
y" mice animals to identify which structures were responsible for the reduction as a
distinction was now possible between the SNpc and the VTA. The 15-20% reduction in
neuronal number was restricted to the SNpc of all mutant mice studied, with no effects
observed in the VTA of any group.
In light of the neuronal deficit displayed by the null mutant animals in the SNpc, an area
associated with motor behaviour, we tested these animals on a rotorod looking for any
signs of impaired motor function. Two tests were carried out, one at a constant speed of
24 rpm and another accelerating from 0 to 40 rpm over the 5 minute duration of the test.
No statistically significant differences were observed between any mutant groups and
their wild-type littermates.
The levels of striatal dopamine and its metabolites 5-hydroxyindolacetic acid, 3,4-
dihydroxyphenylacetic acid and homovanillic acid were assayed using HPLC analysis to
detect whether or not the reduction in dopaminergic neurones seen in the SNpc
translated into a reduction in striatal dopamine levels. However, no statistically
significant differences were observed between the three null mutant groups and their
wild-type littermates.
MPTP is a DA specific neurotoxin which has become a widely used to create models of
Parkinson's disease in rodents and primates. So, we tested the sensitivity of a"", y~A and
a~/7y"/" mice to the potent neurotoxin MPTP. a++/y+/+animals showed the typical 40%
reduction seen with our chosen dose regimen as compared to vehicle injected controls.
All three mutant groups however showed complete insensitivity to the drug as no
changes in neurone number were observed in comparison with a vehicle injected control
group of the same genotype.
These same animals showed equivalent performance in an accelerating rotorod trial with
no differences being observed between genotypes or MPTP and control injected
controls.
Western blotting analysis of midbrain tissue confirmed the absence of a- and y-synuclein
protein from our a_/7y~" mice. In addition an increase in P-synuclein expression was
detected in all synuclein mull mutant strains in comparison with a+/+/y+/+animals.
The synuclein null mutants generated in the laboratory have allowed us to generate a
wealth of data, which will doubtless contribute to the elucidation of the physiological
function of this novel protein family.
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Chapter 5: Discussion
Compelling evidence implicates the synuclein family of proteins in various
neurodegenerative conditions such as Parkinson's disease and dementia with Lewy
bodies. The focus of synuclein research to date has largely been directed towards a-
synuclein, which has been shown to be neurotoxic and involved in proteosomal
protein degradation.
The findings presented herein are an attempt to redress this imbalance; to this end we
focused our attention initially on y-synuclein and its sub-cellular localisation within
certain neuronal populations and the effects of a null mutation on murine physiology
and development. To begin these investigations an antibody specific to mouse y-
synuclein was purified to assess the distribution of y-synuclein in structures
throughout the nervous system.
5.1 Affinity purified anti y-synuclein antibody
An antibody to the C-terminal peptide of mouse-y-synuclein was successfully raised
in rabbit and the antiserum generated was purified via a GST-fusion protein column.
It was crucial to create our own unique highly specific antibody as no commercial
alternative was available and having such a tool was essential to our investigations.
The antibody that I have purified has been shown to be effective for use in Western
blotting at a dilution of 1:200 for the detection of y-synuclein protein in mouse
tissues. We have clearly demonstrated using y-synuclein null mutant (y~") mouse
tissue that the antibody was specific for the detection of y-synuclein only, showing
no cross-reactivity with either a- or 0- synuclein. In addition, the antibody was used
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for the specific detection of y-synuclein protein in immunohistochemistry and
immunofluorescence studies.
This antibody was used in histological studies to confirm that protein distribution
was consistent with previous data localising y-synuclein mRNA in several structures
throughout the developing nervous system (Buchman et al., 1998; Lavedan et al.,
1998a; Abeliovich et al., 2000). This revealed the subtleties of intracellular
compartmentalisation of y-synuclein in various neuronal populations at distinct
points during development. The importance of the specificity of the antibody cannot
be overstated as previous protein localisation studies, such as those by Li and
colleagues used an antibody raised against complete recombinant human y-synuclein,
applying them to rat brain (Li et al., 2002). This is undesirable as y-synuclein
exhibits the lowest degree of interspecies homology of the three synuclein proteins
(Lavedan et al., 1998a). As the immunogenic peptide was full length human y-
synuclein, the antibody produced may also react to regions of the N-terminal which
is highly conserved between all synucleins; hence cross reactivity becomes a
concern. The antibody that we have purified is unique and specific for a region
within the C-terminal of mouse y-synuclein. Using this antibody, we were able to




5.2.1 Localisation of y-synuclein in sensory neurones
High levels of y-synuclein were detected via immunohistochemistry in the sensory
populations of the dorsal root ganglia (DRG) which arise from neural crest tissue and
trigeminal ganglia (TG) which arise from the placode. The conclusions drawn from
these investigations were from findings of consistent staining patterns observed in at
least 4 animals; these criteria were maintained for all expression studies.
At El 2, this expression was present in both the neuronal cell bodies and axons of all
neurones within both these structures. This expression was maintained throughout
embryonic development into the postnatal period at the same high level. At this time,
neuronal populations have matched the requirement of their target field for
innervation and following a period of natural cell death, maturation can proceed. Any
changes in compartmentalisation related to potential changes in function are likely to
have occurred by this time, around P2. However, we observed no such changes. We
may have observed changes in localisation if the role of y-synuclein was changing
during development; however this did not appear to be the case in either the TG or
DRG.
Damage to the sensory neurones in the DRG can cause abnormal pain processing. As
y-synuclein expression is abundant in DRG, it was of interest to examine whether y-
synuclein was involved in a hypersensitive state following damage to these primary
afferent neurones. Thus, in a parallel study, y~'~ mice underwent a model of peripheral
nerve injury to induce a neuropathic pain state. This manifests as a behavioural
sensitisation that is recorded as an increase hind paw withdrawal reflex response to
sensory stimuli. Prior to injury, y"/_ mice had the same response as wild-type
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littermates indicating that y-synuclein does not play a role in normal nociceptive
processing. At the time of maximal behavioural sensitisation resulting from nerve
injury, y~'~ mice had the same expected sensitised responses as their wild-type
littermates in tests for both a noxious thermal stimulus and an innocuous mechanical
stimulus (Ninkina et al., 2003). This indicates that y-synuclein does not play a role in
the abnormal pain processing that occurs following nerve injury, thus neuronal
function was not significantly affected.
Several null mutant animal models have been shown to evoke changes in neuropathic
sensitivity; RI-P the regulatory subunit of PKA for example (Malmberg, Brandon,
Idzerda, Liu, McKnight and Basbaum, 1997). The high level of y-synuclein
expression in the DRG made this model an excellent test of in-vivo neuronal
function. Initial in-situ hybridisation studies revealing embryonic expression of
mRNA in the DRG appear to show a decreasing gradient of expression moving
caudally down the spinal cord (Buchman et al., 1998). Logically then the DRG L4-6
innervated by the sciatic nerve may not be the most sensitive region to target,
however the nature of the model places restrictions on testing regions of greater
expression.
Significantly, a different trend in y-synuclein localisation was observed in a
complementary study carried out in our laboratory by Dr. O. Schmidt, into y-
synuclein expression in the cranial motor nuclei arising from the medial and lateral
parts of the basal lamina. In the hypoglossal, facial, trochlear, oculomotor and
trigeminal motor nuclei at El 2 the pattern ofy-synuclein expression mirrored exactly
that seen in sensory neurones, i.e. intense cell body and axonal staining (Ninkina et
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al., 2003). However, at El 8 this pattern began to change with the appearance of
dotted neuropil staining at the cell periphery, which replaced the cytoplasmic
staining in most cells by P2. In adult animals, this replacement was total except in the
facial nuclei, which retained several haphazard immunopositive cell bodies. In the
other structures, only axons and nerve terminals displayed staining (Ninkina et al.,
2003).
These findings are in contrast to those of Li and colleagues who report the presence
of y-synuclein-positive cell bodies in the motor nuclei of adult rats (Li et al., 2002). It
is unlikely that these differing observations are a result of interspecies differences
between rodents and, given the high degree of homology between proteins, it is also
unlikely they are performing different functions in rats and mice. As mentioned
previously, the antibody used by Li et al (2002). was raised against recombinant
human y-synuclein and tested for specificity against the same human protein.
Significantly, this antibody was not validated for rat y-synuclein or on null mutant
negative control tissue.
It is unknown why a sub-population of cells within the facial nuclei display the same
expression pattern as sensory neurones, however two distinct groups are present both
ofwhich express high levels of y-synuclein. We believe that our investigation is
robust and the findings provide an accurate picture of y-synuclein expression in
murine sensory and motoneurones. It is conceivable then, that y-synuclein is
interacting with different proteins or performing different functions in these two
distinct populations, although it must be remembered these techniques only allow us
a snapshot of the behaviour of the molecule.
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5.2.2 Localisation ofy-synuclein in the substantia nigra
High levels of y-synuclein mRNA expression have been previously reported in the
substantia nigra (SN) (Lavedan et al., 1998a; Abeliovich et al., 2000).
Thus, we investigated the expression of y-synuclein protein in the SN to determine
whether or not these cells also displayed a change in sub-cellular localisation of y-
synuclein.
We saw the characteristic embryonic pattern of intracellular distribution at El 5, i.e.
both cell bodies and axons were stained positive for y-synuclein. However, as in
motoneurones, the staining of the perikarya was replaced by dotted neuropil staining
by El 8 with axonal staining persisting. The term neuropil is not ideal to use as it is
quite non-descript, however its definition "A dense intricate feltwork of interwoven
fine glial processes, fibrils, synaptic terminals, axons, and dendrites interspersed
among the nerve cells in the grey matter of the central nervous system" makes it the
most appropriate term to describe our observations. By P2 a reliable distinction
between the SN and the ventral tegmental area (VTA) was possible and both the SN
and VTA were found to display the same pattern of y-synuclein expression.
These findings support those reported by Galvin et al. who observed a similar
change in intracellular localisation ofy-synuclein in human embryos (Galvin et al.,
2001b). Significantly though, a restricted number of neurones in adult animals did
display y-synuclein expression in the perikarya echoing the pattern seen in the cells
of the facial nucleus. While not revealing any further information about the exact
function of the synucleins, these findings do support the argument that although their
expression begins during development and maturation of synapses, synucleins may
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have a different function in maintaining normal synaptic function after development
has ceased.
The striatum, which receives projections from the SN, also displays this neuropil
staining suggesting that axonal and presynaptic expression of y-synuclein is
maintained in adult animals.
Once again these findings are in direct contrast to those of Li and colleagues who
reported high levels of y-synuclein staining in the cell bodies of the SN, both the pars
reticulata and pars compacta (SNpc) (Li et al., 2002). Interestingly however we did
observe positive staining in the perikarya in the cells of the red nucleus, in the same
region as the SN, confirming the observation made by Li et al. This provided a useful
internal positive control, validating our immunostaining methods.
We have proved the specificity of our anti-y-synuclein antibody, utilising y~'~ mouse
tissue and with no primary antibody assays serving as a negative control. We again
suggest a reason for the apparent discrepancy between our expression profile and that
of Li et al. (2002). Only in the arcuate nucleus of the hypothalamus, did Li et al.
detect y-synuclein as the sole synuclein present in that structure but with no
verification of antibody specificity (Li et al., 2002). Thus the findings presented here
give a more accurate analysis of y-synuclein expression in the murine SN.
5.3 Synuclein null mutant mice
5.3.1 y-synuclein null mutant mice
The generation of a true y-synuclein null mutant was critical for studying the normal
function(s) ofy-synuclein. This allowed us to investigate the hypothesis that y-
synuclein has an important role in the development and correct functioning of the
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neuronal populations in which it is expressed. If this was the case, then its absence
could lead to developmental and physiological abnormalities. It is important to
acknowledge the fact that null mutant models are limited in their usefulness as they
can only hint at a protein's endogenous function.
The successful generation of a y-synuclein null mutant mouse strain has been
discussed in detail previously and the absence of the wild-type allele, mRNA and
protein in these animals has been confirmed by polymerase chain reaction, Northern
and Western blotting respectively.
The colony was backcrossed onto a pure C57B16/J background prior to detailed
characterisation of the mutant strain. The C57B16 animals used were sourced from
Charles River, not Harlan. This is significant as a spontaneous a-synuclein null
mutation was discovered in a strain of C57B16/S mice propagated in the UK Harlan
facility (Specht and Schoepfer, 2001).
The y-synuclein null mutant mice were viable and fertile and displayed no
observable phenotype. A survey of gross brain morphology also showed that there
were no phenotypic differences (Dr O. Schmidt, personal communication).
Adult y-synuclein null mutant mice weighed the same as their wild-type littermates
and displayed identical levels of activity in an open field camera, indicating that
there was no obvious motor/perambulatory dysfunction. This test was applied during
daylight hours at the same time. As mice are naturally more active at night, this
would have been a more appropriate time to study this behaviour.
These observations echo those noted in four assessments of independently produced
a-synuclein null mutant mice which also displayed no gross phenotypic
abnormalities (Abeliovich et al., 2000; Specht and Schoepfer., 2001; Cabin et al.,
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2002; Schluter et al., 2003). All but the mice described by Specht and Schoepfer,
were created via homologous recombination as our y-synuclein null mutant has been,
while their mutant animal arose spontaneously as a result of commercial inbreeding.
Specht and Schoepfer have concluded that as no significant increase in (1- or y-
synuclein was detected via immunoblotting in these animals, compensation does not
occur within the family. This is contradictory to our own findings and without
looking in greater detail at the distribution of the remaining proteins and other
combinations of synuclein null mutant I feel it is not possible to make such a
statement.
Interestingly, it has recently been reported that (3"/_ and of'VP" "null mutant mice
produced by Thomas Sudhof and colleagues also show no obvious phenotype
(Chandra, Fornai, Kwon, Yazdani, Atasoy, Liu, Hammer, Battaglia, German,
Castillo and Sudhof, 2004).
5.3.2 a-synuclein null mutant mice
The mice gifted to us by Prof A. Rosenthal (Genentech) were described as viable and
fertile, exhibiting intact brain architecture and possessing a normal complement of
dopaminergic cell bodies, fibres and synapses (Abeliovich et al., 2000). However,
they exhibited an increased release of dopamine from nigrostriatal terminals in
response to paired stimuli that could be mimicked by elevated Ca (Abeliovich et
al., 2000). These mice were of mixed 129sv/j / C57B16 background and experimental
animals were only the F2 generation. These findings therefore may not be accurate as
inter-strain differences can introduce unknown genetic variables making any
comparisons unsound.
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The a-synuclein null mutant mice were backcrossed onto the same pure C57B16
background as our y-synuclein null mutant mice prior to any experimental use. With
these strains of null mutant mice we could directly compare any effects of the
absence of both a- and y-synuclein. In addition, these true C57B16 single mutant
mice were interbred to create double heterozygotes. These heterozygous littermates
were then interbred to create a strain of cf'Vy"7" -synuclein double mutant mice. This
was a lengthy procedure as mice are not sexually mature until 5-6 weeks of age. It
takes two months for each generation to pass and our experimental animals were at
least the F6 generation. Therefore experimental double null mutant animals were not
available for use in every part of this study.
5.4 Assay of sensory neurone populations
We have shown that the sensory neurones of the TG and DRG express high levels of
y-synuclein. The assessment of the number of sensory neurones in the DRG and TG
of postnatal mice using Cresyl fast violet stained paraffin sections revealed no
statistically significant differences in either the L6 DRG or TG in a'' and y_/~ mice as
compared to their wild-type littermates. Interestingly, in a parallel study in the
laboratory, no statistically significant differences were observed in the populations of
cranial motoneurones (Ninkina et al., 2003).
These two different populations display a crucial difference in their expression
pattern i.e. the shift in compartmentalisation seen in the majority of motoneurones
during the peri-natal period discussed above. Despite high levels of expression and
differences in sub-cellular localisation, no effects on these populations were observed
in the absence of either a- or y-synuclein (Ninkina et ah, 2003). Thus, the absence of
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either a- or y-synuclein is not sufficient to disrupt the key developmental processes
of neuronal migration, proliferation, differentiation or apoptosis in these studied
ganglia.
However until all three synucleins are deleted and in each permutation, the true
relationship between these proteins and development will not be revealed. The highly
homologous nature of these proteins and their developmentally regulated expression
strongly suggest a role lies within these processes. The absence of these proteins may
only become detrimental to neuronal survival in old age, explaining their
involvement in neurodegeneration. This would be of interest for future studies.
5.5 Survival of synuclein-deficient neurones in primary culture
It has been shown previously that certain types of cells, most notably dopaminergic
cells, with modified synuclein expression, in particular a-synuclein over-expression,
have normal survival characteristics under optimal culture conditions but are
substantially more susceptible to stresses (Ostrerova-Golts et al., 2000; Petrucelli et
al., 2002). Here we show that under optimal culture conditions (i.e. with NGF) there
were no observable differences in the survival of neurones from y-synuclein null
mutant mice. We next tested the hypothesis that the absence of either a- or y-
synuclein may render cultured trigeminal neurones more susceptible to neurotoxic
insult. We observed that both a- and y-synuclein-deficient neurones survived equally
poorly as cells taken from wild-type mice in the absence ofNGF from the culture
media.
It has been proposed that a-synuclein may be intrinsically neurotoxic as over-
expression of mutated and endogenous a-synuclein has been shown to cause cell
death in culture (Saha et al., 2000; Zhou et al., 2000). These findings gave rise to the
hypothesis that P- and y-synuclein may act synergistically with a- protecting the cell
from the toxic effects of a-synuclein. If this was the case in TG neurones, one might
expect to have seen an increased level of cell survival in its absence. Conversely, in
the absence of the negative regulation of y-synuclein, the neurotoxic a-synuclein may
have led to decreased survival under optimal conditions in y-synuclein null mutant
neurones.
The sensitivity of y-synuclein null mutant neurones to direct neurotoxic insult was
tested further. Proteosome inhibitors, metal ions, mutagens and JNK pathway
inhibitors were all applied to cultures. Neurones from y-synuclein null mutant mice
displayed equivalent sensitivity to the toxic effects of these drugs as wild-type
neurones.
We have shown previously that there are high levels of synuclein expression in
sensory neuronal populations hence synucleins are likely to have a role in the normal
function and development of these cells. However, disruption of the intracellular
balance of synucleins did not lead to an alteration in sensitivity to neurotoxic insult
in culture, which may indicate that synucleins are not essential to the processes
which support neuronal survival. Indeed, the overlapping expression of these
proteins could suggest that functional redundancy within this family exists, but the
production of a triple synuclein null mutant would be necessary to answer this
question.
The studies indicating that increased a-synuclein expression in dopaminergic cells in
vitro causes neurotoxicity may not have revealed the true picture as it has recently
been shown that glial derived trophic support in the form of glial derived
209
neurotrophic factor (GDNF), is critical for normal dopaminergic neuronal survival
(Barroso-Chinea, Cruz-Muros, Aymerich, Rodriguez-Diaz, Afonso-Oramas,
Lanciego and Gonzalez-Hernandez, 2005). This factor was not taken into account in
the culture of DA neurones in either study, hence a decreased level of neuronal
survival may have been exacerbated by the lack of trophic support coupled with the
increased levels of a-synuclein present (Ostrerova-Golts et al., 2000; Petrucelli et al.,
2002).
5.6 Developmental deficit of midbrain dopaminergic neurones
Mesencephalic dopaminergic neurones have been shown to express high levels of y-
synuclein mRNA and have also been described as the most vulnerable population to
changes in the balance of synuclein expression (Lavedan et ah, 1998a; Abeliovich et
ah, 2000; Hashimoto et ah, 2001; Kruger and Schulz, 2002; Dev, Hofele, Barbieri,
Buchman and van der Putten, 2003). With this in mind, we expanded our studies and
assayed the dopaminergic neuronal populations of the SN at El 8, P5 and in adult y-
synuclein null mutant mice. Total TH positive neurone number was taken, counting
SN and the ventral tegmental area (VTA) as distinction between the embryonic SN
and VTA was not possible. These investigations revealed a 15-20% deficit in the
number of TH-positive neurones arising between El 8 and P5, persisting at the same
level into adulthood. Significantly, this deficit arises during the same peri-natal
period as the shift in compartmentalisation occurring in motor and SN neurones. This
loss of neurones occurs at approximately the same time as the major period of
developmental apoptosis within the SN. This loss is biphasic in nature, peaking at P2
followed by a smaller peak at P14 (Burke, 2003). This cell death is regulated in vivo
by feedback from the target field, namely the striatum (Burke, 2003). While the
controlling growth factor supplying these growing neurones with support is
unknown, current evidence suggests that GDNF has a major role in preventing
apoptosis during this period (Burke, 2003).
Our findings suggest that in the absence of y-synuclein, mesencephalic dopaminergic
(DA) neurones could have a reduced ability to utilise GDNF-derived neurotrophic
support and hence are less able to survive this period of cell death. Conversely,
alterations in the balance of synuclein proteins may make these cells more
susceptible to neurotoxic insult.
To investigate this neuronal deficit and apportion it correctly to either the SN or the
VTA, a second study was undertaken in adult animals. It was at this point in the
study that a-/y-synuclein double null mutant mice (a"/7y"/") became available for use.
TH positive neurones were counted as previously described in the SN and VTA and
this revealed not only that this deficit was specific to the SN, but it was present in a''
and a" 7y"/_ mutant mice in equal measure. As no cumulative effects of the double
mutation on neuronal number were seen, it is reasonable to hypothesise that a
compensatory mechanism exists to limit the effects of their absence. P-synuclein
therefore becomes a candidate for this function due to its homology with the other
synuclein proteins and their overlapping expression pattern. These data cast doubt on
the hypothesis that y-synuclein acts as a negative regulator of the toxic a-synuclein
as no further losses are seen in the absence of y-synuclein and no recovery to wild-
type levels was observed in a'' mice. It is possible that a distinct neuronal sub-
population exists within the SNpc that are particularly vulnerable to a disruption in
synuclein balance.
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5.7 Basic motor function
In light of the neuronal deficit displayed by all three null mutant animals in the
SNpc, a structure associated with motor behaviour, we tested these animals on a
rotorod to look for any signs of impaired motor function. Two tests were carried out,
one at a constant speed of 24 rpm and another accelerating from 0 to 40 rpm over the
5 minute duration of the test. No statistically significant differences were observed
between any mutant groups and their wild-type littermates. It is likely that this deficit
was insufficient to impact striatal DA levels to the extent which would precipitate a
disturbance in motor control. In Parkinson's disease for example, clinical signs
relating to the loss of motor control become apparent following a 70-80% reduction
in striatal dopamine levels precipitated by a 40% reduction in mesencephalic
dopaminergic neurones (Bezard et al., 2001). The neuronal deficit we report herein
would not necessarily be great enough to precipitate a reduction in motor
performance that could be detected using these methods. However as part of the
overall phenotypic characterisation of these null mutants we felt it was important to
test the animals as there may be other abnormalities leading to motor effects that
were overlooked. The tests applied were as discriminating as the available equipment
would allow.
5.8 Assaying striatal dopamine
The levels of striatal dopamine and its metabolites 5-hydroxyindolacetic acid, 3,4-
dihydroxyphenylacetic acid and homovanillic acid were assayed using HPLC
analysis, to detect whether or not the reduction in dopaminergic neurones seen in the
SNpc translated into a reduction in striatal dopamine. No statistically significant
differences were observed between the three null mutant groups and their wild-type
littermates. This was not unexpected as no disturbance of motor function was
observed. These findings are in contrast to observations made in a"/7(3"/" animals in
which, a 20% decrease in striatal dopamine levels were recorded, while no
differences were seen in single mutant animals (Chandra et al., 2004). Other changes
in this model included selective alterations in the levels of signalling and vesicular
associated proteins; complexins and 14-3-3 proteins (Chandra et al., 2004). It has
been proposed that these changes in vesicular proteins are the result of compensation
for the loss of synucleins, due perhaps to a functional relationship between
synucleins and these molecules which may exist in vivo. This could result from either
the molecules acting in the same pathways or possibly direct interactions between
these proteins (Chandra et al., 2004).
5.9 Compensatory changes in synuclein expression
It has been hypothesised previously that due to the high degree of homology shared
by the synuclein proteins there may be a functional redundancy in the absence of one
or more of these proteins. Here, we show significant evidence that supports this
hypothesis, whereby all three of our synuclein null mutants displayed an increase in
(3-synuclein expression. This increase was similar in all strains i.e. no greater increase
was seen in the absence of either a- and y-synuclein. A 50% increase in y-synuclein
has also been reported in cf 'VP"'" animals lending greater support to this hypothesis
(Chandra et al., 2004). Together these findings suggest that the synucleins are of
great importance to normal neurodevelopment of certain populations. Hence, this
compensatory mechanism has evolved to protect the endogenous physiological
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functioning of the proteins which are still unknown. To further test this hypothesis
siRNA techniques could be employed in different ratios in the different null mutants
to attempt to exacerbate and rescue neuronal loss. Dopaminergic neurone culture
would be an ideal model system to test cell survival under these conditions and
would take experiments away from snapshots to a wider picture. A conventional (3-
synuclein knock-in to exacerbate the overproduction in the existing null mutant
cohorts may produce a rescue of the dopaminergic neurones of the SNpc, which
would strongly indicate that redundancy exists between the synucleins and their
involvement in normal cell survival. A detailed investigation of the localisation of (3-
synuclein, using a highly specific antibody must be undertaken. Only then could any
changes in compartmentalisation be identified. This may occur concurrently with the
increased level of expression seen in our null mutants as potentially it may be
replacing the function of the missing proteins.
5.10 Sensitivity of mesencephalic dopaminergic neurones to MPTP
MPTP is a potent dopaminergic specific neurotoxin which is widely used to create
models of Parkinson's disease in rodents and primates. It is metabolised into the
initial two-electron product 1 -methyl-4-phenylpyridinium (MPDP+) by type B
monoamine oxidase (EC 1.4.3.4, MAO-B) (Ramsay and Singer, 1986). In a further
oxidation, the final four-electron oxidation product, the actual toxic molecule, 1 -
methyl-4-phenylpyridinium (MPP+), is produced. The toxic intracellular
accumulation of MPP+ occurs as it is a high affinity substrate for the dopamine
transporter (DAT) with which a-synuclein can interact (Javitch et al., 1985; Lee et
al., 2001). The structural similarity between MPP+ and dopamine is the reason
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behind the specificity of the neurotoxin. Having been selectively taken up into the
dopaminergic neurone, MPP+ selectively inhibits NADH-ubiquinone oxioreductase
(Complex I) of the mitochondrial respiratory chain. This inhibition leads to a failure
of ATP production and hence cell death (Chan et al., 1991).
We tested the sensitivity of our synuclein null mutant mice to MPTP. Wild-type
animals showed the expected 40% reduction in dopaminergic neurones for our
chosen MPTP dose regimen when compared to vehicle-injected controls. In contrast,
all three null mutant groups showed complete insensitivity to MPTP in comparison
with a vehicle-injected control group, with no observable changes in neuronal
number. Independent studies have confirmed that other null mutations for a-
synuclein provide some degree of protection from the toxic effects of MPTP, with a
reduced decrease in striatal dopamine being recorded (Schluter et al., 2003; Drolet et
al., 2004). In the initial report of this protective effect it was proposed that in the
absence of a-synuclein, MPTP could not inhibit Complex I thus eliminating the toxic
potential (Dauer et al., 2002). Commercially available spontaneous a-synuclein
deficient mice display no such reduction in sensitivity (Schluter et al., 2003).
However, these animals lack several other genes that could easily account for this
insensitivity. These data, ours included, suggest that MPTP toxicity is not directly
coupled to any interactions of synuclein with proteins that are involved in mediating
this toxic effect but that these proteins do influence the mechanism in some mouse
strains. Stimulation of expression, post-translational modification and aggregation of
a-synuclein in the neurones of the SNpc by MPTP is well documented, but it is less
clear how these correlate with neuronal death (Kowall et al., 2000; Vila et al., 2000;
Przedborski et al., 2001; Meredith et al., 2000; Kuhn et al., 2003). Studies of
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dopaminergic neurones that over-express different forms of human a-synuclein
produced contradictory results with either increased (Richfield et al., 2002) or
unaltered (Rathke-Hartlieb et al., 2001; Dong et al., 2002) sensitivity to MPTP
toxicity. Results showing a resistance to MPTP toxicity are more consistent for mice
with targeted inactivation of the a-synuclein gene. The neuroprotective effect of (3-
synuclein over-expression has recently been demonstrated in in vitro experimental
systems (da Costa, Masliah and Checler, 2003). In cultured neurones cells the over-
expression of P-synuclein has been shown to inhibit the expression of p53 thereby
protecting cells from staurospaurine-induced cell death. It is feasible therefore to
suggest that any compensatory increases in P-synuclein levels in midbrain neurones
that we have shown here could render these neurones less sensitive to certain
neurotoxic insults by preventing the cell entering apoptosis. Again, it would be
interesting to examine the sensitivity of these neurones in the absence of all three
synucleins and to see if this insensitivity remains in the absence of the potential
compensatory effect of P-synuclein. The same experimental cohort was tested prior
to tissue collection using the accelerating rotorod trial described previously, having
been given training prior to any substance administration. This procedure was to
ensure that no deleterious effects on motor performance were produced by the drug
acting on other neuronal populations concerned with controlling motor function. As
no neuronal deficits were observed within the SN, no significant differences were
expected. Thus it was not surprising that no differences were observed between
either drug or control injected or genotypic groups.
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5.11 Conclusions
Several synuclein transgenic models, including our own have demonstrated that the
absence of a-, (3- or y-synuclein individually or a-/p-, a-/y- combined, does not lead
to any gross changes in the morphology or physiology of the nervous system. We
have shown here using null mutant models that deficits arise in specific neuronal
populations in the absence of certain synucleins, indicating that they play a role in
normal neurodevelopment. Our findings do not directly support the widely held
hypothesis that a-synuclein is intrinsically neurotoxic as we did not observe any
increased neuronal survival in its absence in vitro or in vivo. However our study has
focused mainly on developing and early adult animals in an attempt to gain
information relating to their normal function. As the pathologies associated with the
synuclein proteins tend to arise at later ages, perhaps later time points would have
been more suitable to challenge these synuclein deficient populations in our
experimental models. Perhaps introducing tests of learning and memory may also
yield results, as tests currently available for motor behaviours are not sensitive
enough to detect phenotypes in our null mutant cohorts, if indeed they exist.
The weight of evidence however does still indicate that fibrillated a-synuclein is
cytotoxic under certain physiological conditions. The role of P-synuclein must be
investigated further as it has been shown to act synergistically with a-synuclein.
Also, as we have shown here in the absence of a- and y-synuclein, the expression of
P-synuclein is increased, perhaps to maintain some endogenous function of the
synucleins, which still eludes us.
The production and characterisation of a complete synuclein null mutant is underway
in collaboration between Prof. V. Buchman and Prof. T. Sudhof. It will be interesting
to learn whether the changes we report here are exacerbated in the absence of all
three synucleins and hopefully more concrete evidence will emerge as to the
mechanisms in which synucleins are involved. As mentioned above the insensitivity
to MPTP we report, may be lost in the absence of all three proteins, which should
conclusively prove that some functional redundancy does exist between the
molecules. Also, the dopaminergic cell loss in the SNpc may also be exacerbated by
the complete loss of synucleins. Culturing of dopaminergic neurones taken from the
transgenic cohorts would provide a useful tool as they could be grown in
combination with different synuclein siRNA to knock-down the remaining
synucleins in the different null mutants. The effects of these manipulations would
hopefully demonstrate the differing contributions the synucleins make towards
dopaminergic cell survival. Very recently it has been shown that null mutant mice
lacking trkB and trkC, the receptors for dopaminergic growth factors brain derived
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) respectively, also exhibit an
approximate 20% reduction in the number of TH positive neurones in the SNpc in
addition to increased expression of a-synuclein in the remaining cells of aged mice
(von Bohlen, Halbach, Minichiello and Unsicker, 2005). If this increase in a-
synuclein expression is a direct result of reduced trophic support for the remaining
cells then it implicates the synucleins in mediating trkB and trkC signalling and
would help to explain the developmental deficit in midbrain dopaminergic neurones
we report here. However the authors of this paper did not comment on this possibility
and propose that a-synuclein is accumulating as cells begin the deterioration that
occurs with age.
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In summary, the evidence for synergistic action between the three synuclein proteins
continues to mount yet the vast majority of studies overlook the existence and
possible significance of P- and y-synuclein. I feel that this may be a potential cause
for some of the conflicting data that has arisen in this field of study.
The precise role of this protein family is still unclear, with recent data implicating
them in the regulation of cell survival. Whether they are cytotoxic, protective in
nature or function in synergy as a distinct regulator of cell survival will not be
determined until the details of their endogenous function are elucidated in isolation
from one and other.
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Homologous recombination in ES cells was employed to generate mice with targeted deletion of the first
three exons of the y-synuclein gene. Complete inactivation of gene expression in null mutant mice was
confirmed on the mRNA and protein levels. Null mutant mice are viable, are fertile, and do not display evident
phenotypical abnormalities. The effects of y-synuclein deficiency on motor and peripheral sensory neurons
were studied by various methods in vivo and in vitro. These two types of neurons were selected because they
both express high levels of y-synuclein from the early stages of mouse embryonic development but later in the
development they display different patterns of intracellular compartmentalization of the protein. We found no
difference in the number of neurons between wild-type and null mutant animals in several brain stem motor
nuclei, in lumbar dorsal root ganglia, and in the trigeminal ganglion. The survival of y-synuclein-deficient
trigeminal neurons in various culture conditions was not different from that of wild-type neurons. There was
no difference in the numbers of myelinated and nonmyelinated fibers in the saphenous nerves of these animals,
and sensory reflex thresholds were also intact in y-synuclein null mutant mice. Nerve injury led to similar
changes in sensory function in wild-type and mutant mice. Taken together, our data suggest that like
a-synuclein, y-synuclein is dispensable for the development and function of the nervous system.
Several neurodegenerative diseases have been recently coa¬
lesced into a distinct group named synucleinopathies (12, 16,
20, 53). Although they are diverse in symptoms and clinical
signs, these diseases share a common histopathological
feature, i.e., formation of large intracellular inclusions whose
principal component is an aggregated small protein,
a-synuclein. Neither the normal cellular function of a-
synuclein nor the exact mechanism of its involvement in neu-
rodegeneration is clearly understood; possible scenarios are
discussed in many recent reviews (see, for example, references
10, 28, 33, 34, and 43). Even less clear are the normal functions
and roles in neurodegeneration of the other two members of
the synuclein family. Both (3-synuclein/PNP 14 (24, 35) and
y-synuclein/BCSGl/persyn (7, 26, 29) have a very high degree
of amino acid similarity with a-synuclein within the N-terminal
KTK repeat region of the protein molecule, and this is re¬
flected in such common features of synucleins as a native
unfolded state in physiological solutions, reversible binding to
lipid vesicles, and localization in presynaptic terminals (13, 25,
31). However, the C-terminal regions of synucleins, although
all highly acidic, are rather different (7, 29, 52). It is perhaps
this structural diversity that leads to differences in the behavior
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of synucleins in vitro and in various in vivo model systems.
Consistent with the finding that (3-synuclein and y-synuclein
are much less fibrillogenic than a-synuclein (4, 47, 55), aggre¬
gates of these two proteins are not constituents of Lewy bodies
or other histopathological hallmarks of synucleinopathies, al¬
though abnormal (3- and y-synuclein-positive structures have
been observed in several cases (15, 17, 49). Recent in vitro
studies have also shown that both (3- and y-synuclein are able
to inhibit fibrillation of a-synuclein (40, 55). In transgenic mice
overexpression of p-synuclein reduces the severity of neurode¬
generative alterations and the number of a-synuclein-positive
interneuronal inclusions caused by a-synuclein overexpression
(23). Changes of expression of all three synucleins in brain
areas affected in neurodegenerative diseases have been re¬
ported (44). Previously we demonstrated that overexpression
of a-synuclein, but not y-synuclein, kills sensory neurons in
primary cultures (6, 45). Moreover, it has been shown that
y-synuclein is able to block JNK signaling, a pathway whose
activation is commonly associated with induction of apoptosis
(39). These observations suggest that the correct balance of
synucleins might be important for survival of at least some
populations of neurons and that decreased expression of
y-synuclein might have a proapoptotic effect. The obvious way
to investigate this is to assess whether the absence of
y-synuclein affects neurons that normally express these two
proteins. In different vertebrate species, high levels of
y-synuclein mRNA are detected from the early stages of em¬
bryonic development in two neuronal populations, motoneu¬
rons and peripheral sensory neurons (7, 52), and a-synuclein is
also expressed in these neurons (18, 32, 52; our unpublished
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FIG. 1. Targeted inactivation of the mouse y-synuclein gene, (a) Scheme for deletion of exons I, II, and III and promoter region of the mouse
y-synuclein gene by homologous recombination. The organizations of the wild-type genomic locus (top), targeting vector (middle), and resulting
knockout locus (bottom) are shown. Restriction endonuclease sites: E, EcoRI; B, flam III; Xb, Xbcil; K, A/ml; Bg, Bglll. Hybridization probes a
and b, which were used for the analysis of homologous recombination, are also shown, (b) Examples of analysis of homologous recombination in
ES cell lines by Southern hybridization. DNAs from four neomycin-resistant ES cell lines were digested with EcoRI and hybridized with either
probe a or probe b. Only a 20-kb wild-type band is revealed in two clones with random insertion of a PGK-neo cassette, and the homologous
recombination in two other clones results in the appearance of a 17-kb band. Similar results were obtained when DNA was digested with flam I II
and hybridized with probe c. (c) Example of PCR-based genotyping of mice from a litter of two heterozygous parents, (d) Expression of mRNAs
encoding members of the synuclein family in the retinas of wild-type and y-synuclein null mutant mice. Results of Northern hybridization with a
full-length mouse y-synuclein cDNA probe, a mouse fi-synuclein-specific probe, a mouse a-.sym«:/em-specific probe, and a GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) probe are shown. Note that under the hybridization and washing conditions used, the y-synuclein cDNA probe
cross-hybridized with p-synuclein transcript (upper panel). High-stringency washes completely eradicated this hybridization signal, with no effect
on hybridization with y-synuclein transcript, (e) A Western blot of 10 p,g of total spinal cord proteins of wild-type and y-synuclein null mutant mice
was probed with mouse y-synuclein-specific SK23 antibody.
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a-synuclein leads to pathological changes in spinal and brain
stem motoneurons (19, 30, 56), suggesting that these neurons
are susceptible to changes in the metabolism of synucleins.
Therefore, we studied populations of motoneurons and pe¬
ripheral sensory neurons in y-synuclein null mutant mice,
which we produced.
MATERIALS AND METHODS
Generation of y-synuclein null mutant mice. To generate a targeting vector, a
1.2-kb Xbal-Xbal fragment from lambda genomic clone PS92 (2) was cloned as
a short arm into an Xbal site of the pPNT vector (54) between PGK-TK and
PGK-neo cassettes. The resulting plasmid was digested with foe83871, blunted
with the Klenow fragment of DNA polymerase I, further digested with Xhol, and
used as a vector for ligation with a long arm. DNA of lambda genomic clone PS91
(2) was digested with Bglll, blunted with Klenow fragment of DNA polymerase
I, and further digested with Sail, and a 4-kb fragment was used as a long arm in
our targeting vector (Fig. la). For electroporation of 12901a mouse ES cells
(clone E14Tg2a; a gift of A. Smith, Centre for Genome Research, University of
Edinburgh), DNA of the resulting targeting vector was linearized by digestion
with Notl. After electroporation and selection, G418- and ganciclovir-resistant
ES cell clones were checked for correct homologous recombination by Southern
hybridization analysis of EcoRI-digested (for probes a and b in Fig. la) or
ZfamHI-digested (for probe c) DNA. Suitable clones were injected into blasto¬
cysts of C57B16J mice (Charles River). All procedures involved in generation of
mutant mice were carried out according to the United Kingdom Animals (Sci¬
entific Procedures) Act (1986) and other Home Office regulations under specific-
pathogen-free conditions. The presence of a mutant allele in animals was
checked by PCR analysis of DNA extracted from mouse tail biopsies. A common
upstream primer (5'-AGTCCTGGCACCTCTAAGCA-3') and primers specific
for the wild-type allele (5'-GGGCTGATGTGTGGCTATCT-3') and the PGK-
neo cassette in the mutant allele (5'-GAAGAACGAGATCAGCAGCC-3') were
used for amplification. Forty cycles of 45 s at 95°C, 30 s at 56°C, and 60 s at 72°C
were carried out. The presence of 480-bp (for the wild-type allele) and 397-bp
(for the mutant allele) amplification products in the reaction mixture was
checked by electrophoresis in a 1.5% agarose gel. Heterozygous animals were
used for at least six further generations of backcrosses with C57BL6J mice before
null mutant, wild-type, and heterozygous littermates were produced for further
studies by breeding heterozygous males and females. The mutant mouse strain
was registered in the Mouse Genome Information database under the official
name (B6-TgHSNCG,m,VLB).
ot-synuclein null mutant mice. Generation of a-synuclein mutant mice was
described previously (1). We backcrossed these mice with C57B16J mice for at
least six generations before setting up intercrosses to produce null mutant,
wild-type, and heterozygous littermates.
Expression studies. Extraction of RNA from mouse tissues, Northern blotting,
and preparation of labeled probes were carried out as described previously (7,
36).
Affinity-purified polyclonal rabbit SK23 antibody generated against a C-ter-
minal peptide of mouse -y-synuclein (persyn) was used at a 1:500 dilution for
Western blotting and enhanced chemiluminescence detection of this protein in
total cell lysates as described earlier (7, 36). For immunohistochemistry, adult
mouse brains and embryonic day 12 (E12), E15, and E18 embryos were fixed in
4% paraformaldehyde-phosphate-buffered saline (PBS) or Carnoy's fixative
(60% ethanol, 30% chloroform, 10% glacial acetic acid) at 4°C overnight fol¬
lowing dehydration in alcohol series and embedding in paraffin blocks. Eight-
micrometer-thick sections were cut with a Leica or Microm microtome and
mounted on SuperFrost slides (BDH, Poole, United Kingdom) for conventional
staining or on Gold Seal slides (Gold Seal Products, Portsmouth, N.H.) for
immunostaining. The paraffin sections were cleared in xylene and rehydrated
through a graded alcohol series. Endogenous peroxidase activity was quenched
by incubating the slides in 3% H20 in methanol for 20 min. After being washed
with PBS, the tissues were blocked in 10% horse or goat serum and 0.4% Triton
X-100 in PBS for 1 h at room temperature. Incubation with a 1:40 dilution of
SK26 anti-mouse y-synuclein antibody was carried out at 4°C overnight. Detec¬
tion of immune complexes with biotinylated anti-rabbit antibody and avidin-
peroxidase complex from the Vectastain ABC kit (Vector Laboratories, Peter¬
borough, United Kingdom) and diaminobenzidine (Fast 3,3'-diaminobenzidine
tablet sets; Sigma, St. Louis, Mo.) as a substrate was carried out according to the
manufacturer's instructions. Motor nuclei were identified by staining of alternate
sections with hematoxylin-eosin (Raymond A Lamb, London, United Kingdom)
and a goat antibody against choline acetyltransferase (Chemicon, Temecula,
Calif.) at a 1:100 dilution. In the latter case, anti-goat secondary antibody was
used for detection.
Whole-mount immunofluorescence. Mouse triangularis sterni muscle was dis¬
sected in PBS and fixed in 4% paraformaldehyde-PBS for 20 min, followed by
incubation with AlexaFluor 647-conjugated p.-bungarotoxin (5 pg/ml in PBS) for
30 min. After washing in PBS and blocking and permeabilization for 1 h in 1%
bovine serum albumin-0.4% lysine-0.5% Triton X-100 in PBS, samples were
incubated overnight with primary antibodies diluted in the same buffer at 4°C.
Mouse monoclonal anti-neurofilament M (clone 2H3; Developmental Studies
Hybridoma Bank, Iowa City, Iowa) and anti-synaptic vesicles (clone SV2; De¬
velopmental Studies Hybridoma Bank) antibodies were used at a 1:200 dilution,
and rabbit polyclonal SK23 antibody was used at a 1:40 dilution. After several
washes, incubation with l:200-diluted secondary antibodies (fluorescein isothio-
cyanate-conjugated goat anti-rabbit immunoglobulins and tetramethyl rhoda-
mine isocyanate-conjugated goat anti-mouse immunoglobulins, both from Jack¬
son ImmunoResearch Laboratories, West Grove, Pa.) was carried out for 3 h at
room temperature, followed by extensive washing and mounting in Vectashield
(Vector Laboratories, Burlingame, Calif.). Images were obtained with a Zeiss
LSM 510/Axioplan 2 confocal microscope.
DRG neuron counts. The spinal columns from P2 mice were fixed and em¬
bedded as described above. Serial 8-fxm-thick longitudinal sections were cut,
mounted on SuperFrost slides (BDH), cleared in xylene, rehydrated through a
graded alcohol series, and stained with 0.1% cresyl violet acetate (Sigma). Lum¬
bar L6 dorsal root ganglia (DRG) were identified by using characteristic tissue
landmarks on sections. Neurons were identified by virtue of the Nissl substance
and their large, round, pale-stained nuclei (27). Neurons in the L6 DRG dis¬
playing a prominent nucleolus were counted on every eighth section. The neu¬
ronal number was quantified by using a digital stereology system that employs a
combination of the optical dissector and volume fraction-Cavalieri methods
(Kinetics Imaging, Bromborough, United Kingdom). All counts were carried out
blindly by a person unaware of animal genotypes.
Motoneuron counts. Adult mouse brains were fixed and processed as de¬
scribed above for expression studies. The whole brain stem was sectioned into
8-p.m-thick sections, which were mounted on SuperFrost slides. Rehydrated
sections were stained in a 1% solution of neutral red (Raymond A Lamb) in
distilled water for 30 min, followed by dehydration and mounting as described
above. A stereological fractionator method (22), which allows estimation of the
number of particles independent of the volume of the structure that the particles
are part of and is not affected by tissue shrinkage during processing, was used to
assess the number of motoneurons in five motor nuclei of the brain stem. Large
(~20 p,m in diameter) neurons displaying a prominent nucleolus were counted
in total on every fifth section throughout the nucleus; the first section for count¬
ing was randomly chosen from the first five sections that included this nucleus.
Nerve fibers counts. Anesthetized animals were transcardially perfused with
heparinized saline and then 2.5% glutaraldehyde-2% paraformaldehyde-0.1 M
sodium cacodylate buffer (pH 7.3)—1 mM CaCl2 for 5 min. The saphenous nerve
was removed and fixed for 2 h in the same fixative, postfixed in Os04, and
embedded in araldite. One-micrometer resin sections were prepared and stained
with toluidine blue for light microscopy to measure the area of the nerve cross-
section. Ultrathin 80-nm transverse sections were stained with uranyl acetate and
lead citrate, mounted onto copper slot grids, and examined on a transmission
electron microscope (Phillips BioTwin; FEI, Cambridge, United Kingdom). My¬
elinated A-fibers and unmyelinated C-fibers were identified and counted as
described previously (57). The densities of both types of fibers were calculated
after counting of 12 to 15 randomly chosen electron microscope images and
multiplied by the area of the nerve cross-section.
Primary neuronal cultures. Cultures from trigeminal and superior cervical
ganglia were prepared as described previously (42) and maintained in neurobasal
medium with B27 complement (Invitrogen, Carlsbad, Calif.). The number of
neurons attached to each culture dish within a 12- by 12-mm square was counted
3 h after plating and was taken as the initial number of neurons (100%). In
experiments with proteasome inhibitors and metal ions, the initial count was
carried out 24 h after plating. In all cases drugs were added to cultures imme¬
diately after the initial count. The number of surviving neurons in the same area
was counted 24 and 48 h later and was expressed as a percentage of the initial
count.
Behavioral tests. All experiments were carried out in accordance with the
United Kingdom Animals (Scientific Procedures) Act (1986). Behavioral testing
was carried out prior to surgery to establish a baseline for comparison to post¬
surgical values, as described in detail previously (5,11). The procedure of chronic
constriction injury (CCI) to the sciatic nerve was modified for mice from a
procedure described previously for rats (3). In brief, adult male mice (90 to
120 g) were anaesthetized with sodium pentobarbital (Sagatal; Rhone Merieux,
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FIG. 3. y-Synuclein in postnatal mouse sensory and motoneurons. y-Synuclein is localized in the cytoplasm of cell bodies of mouse P2 DRG
(a) and trigeminal ganglion (b) neurons as well as in nerve fibres in the dorsal root (DR), spinal nerve (SN), and trigeminal nerve (TN). In P2
oculomotor nucleus (c), only y-synuclein-negative cell bodies (arrowheads) are seen on the background of neuropil staining, whereas in P2
trigeminal motor nucleus (d), cytoplasmic staining can be detected in some neurons (arrows). Bars, 100 p,m (a and c) and 20 p,m (b and d).
Essex, United Kingdom) (0.06 ml/100 g, intraperitoneally) supplemented with
halothane-02 (Zeneca, Cheshire, United Kingdom). Under aseptic conditions,
the right sciatic nerve was exposed proximal to the trifurcation, at mid-thigh
level, and three chromic cat gut ligatures were tied to loosely constrict the nerve.
The overlying muscle and skin were closed with sutures, and the animals were
allowed to recover before reflex testing recommenced. Thermal hyperalgesia was
monitored by using noxious radiant heat (30 to 55°C) (Hargreaves' thermal
device; Linton Instruments, Diss, United Kingdom) applied to the mid-plantar
glabrous surface of the hind paw. The withdrawal response latency was charac¬
terized as a brief paw flick, and a standard cutoff latency of 20 s prevented tissue
damage. Mechanical allodynia was measured as the threshold for paw withdrawal
in response to graded mechanical stimuli applied to the mid-plantar glabrous
FIG. 2. y-Synuclein in embryonic mouse sensory and motoneurons. Anti-y-synuclein staining of E12 (a) and E15 (b) trigeminal motor nuclei and
trigeminal ganglia and of E18 trigeminal motor nucleus (c), E18 oculomotor nucleus (d), E18 trochlear nucleus (e), E18 facial nucleus (f), and E18
hypoglossal nucleus (g) is shown. All nuclei contain labeled neuronal cell bodies, but dotted neuropil stain becoming also obvious in all ganglia at E18.
Arrowheads show y-synuclein-positive axons of E12 and E15 motoneurons of the trigeminal motor nucleus (TMN). Sensory neurons of the trigeminal
ganglion (TG) are also intensively stained, as is the root of the trigeminal nerve (rTN). Bars, 100 p,m (a, c, e, and f), 200 gm (b and g), and 50 |xm (d).
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FIG. 5. Average total numbers of motoneurons in brain stem motor nuclei of wild-type (+/+) and y-synuclein null mutant (-/-) adult mice.
Means and standard errors from data obtained from analysis of at least 10 nuclei for each genotype are shown. Statistical analysis (two-tailed,
unpaired Student's t test) showed no significant difference in cell numbers between the two genotypes for all nuclei (P > 0.5).
surface of the hind paw with calibrated von Frey filaments (Stoelting, Wood
Dale, 111.). The threshold was defined as the pressure (force per unit area) that
caused foot withdrawal five times in every 10 applications, repeated at 1- to 2-s
intervals. The pressure applied to the hind limb by the von Frey filaments is
calibrated as force (millinewtons) divided by the area over which it is applied
(square millimeters).
RESULTS
Generation of y-synuclein null mutant mice. Mouse strains
with a targeted deletion of the first three exons of the mouse
y-synuclein gene (Fig. 1) were generated from three indepen¬
dent ES cell clones as described in Materials and Methods.
Two of these strains were used in this study, and because the
results were identical, the experimental data obtained with
both strains were combined. Mice lacking the y-synuclein gene
were viable and fertile and did not show any obvious abnor¬
malities in development, behavior, or gross morphology of the
nervous system (data not shown). Western blotting (Fig. le)
and immunohistochemistry (not shown) with an antibody spe¬
cific to the C-terminal peptide of mouse y-synuclein showed a
complete absence of the protein in all tissues of null mutant
mice. Northern hybridization of RNAs from various tissues
confirmed complete inactivation of y-synuclein gene function
in null mutant mice, which was not accompanied by compen¬
satory increases of a- or 3-synuclein mRNA levels (Fig. Id and
data not shown).
In the absence of an obvious phenotypic manifestation of the
null mutant genotype in y-synuclein knockout mice, we carried
out comparative studies of several neuronal populations with
wild-type and null mutant mice. Motoneurons and peripheral
sensory neurons were chosen because both populations nor¬
mally express high levels of y-synuclein mRNA (7) but, as
shown below, display different intracellular compartmentaliza-
tion of y-synuclein.
Developmental changes of y-synuclein compartmentaliza-
tion in motoneurons. Previously we have demonstrated by in
situ hybridization high levels of y-synuclein mRNA expression
in spinal and cranial motoneurons from early stages of mouse
and rat embryonic development (7). However, neither the
abundance nor the intracellular localization of y-synuclein pro¬
tein in these neurons has been studied. Using a specific anti¬
body which recognizes the C-terminal peptide of mouse
y-synuclein, we now demonstrated that the protein expression
pattern follows the mRNA expression pattern but that dra¬
matic changes in compartmentalization of y-synuclein within
motoneurons take place during postnatal development. Immu¬
nohistochemistry was performed on sagittal as well as coronal
paraffin sections of mouse embryos of different developmental
stages and adult mouse brains. To identify oculomotor, troch¬
lear, facial, hypoglossal, and trigeminal motor nuclei, adjacent
sections were stained with hematoxylin-eosin and an antibody
against choline acetyltransferase, a motoneuron marker (see
Materials and Methods). From the early stages (E12) and
throughout the embryonic development, y-synuclein is local¬
ized in both motoneuron cell bodies and axons (Fig. 2 and data
not shown). However, at E18, in addition to cytoplasmic stain¬
ing, a dotted neuropil staining became evident in all studied
motor nuclei (Fig. 2c to g). The pattern is completely different
in motor nuclei of postnatal, particularly adult, mouse brain.
FIG. 4. y-Synuclein in adult mouse motoneurons. (A) -y-Synuclein in motor axons and nerve terminals at the neuromuscular synapse. Triple
immunofluorescent staining of whole-mount preparations of mouse traingularis sterni muscle is shown. y-Synuclein (Ai, green) is colocalized with
neurofilaments in the axon and SV2 in presynaptic terminals (Aiii, red) but not with acetylcholine receptors on postsynaptic membrane (Aii, blue
[stained with AlexaFluor 647-conjugated |x-bungarotoxinj). Three images are merged in panel Aiv. (B) -y-Synuclein in oculomotor nuclei
(arrowheads) and the root of oculomotor nerve (rON). A higher magnification shows axonal staining in the nerve root (panel Biv), the absence
of -y-synuclein in cell bodies of motoneurons, and positive staining of neuronal cell bodies in the median Edinger-Westphal nucleus (E-Wn, panel
Bii). (C) -y-Synuclein in trochlear nuclei (arrowheads in panel Ci) and the root of trochlear nerve (arrow in panel Ciii and rTN in panel Civ). A
higher magnification shows intense staining of motoneuron axons in the nerve (Civ) and only a dotted neuropil staining in the nucleus (Cii).
(D) -y-Synuclein in facial nuclei (arrowheads) and the facial nerve. Axonal staining is evident in the internal genu (IgFN) and the root (rFN) of
the nerve (panel Diii). A higher magnification reveals -y-synuclein in the cytoplasm of a few motoneurons (open arrowhead in panel Dii).
(E) -y-Synuclein in hypoglossal nuclei (arrowheads in panel Ei and HN in panel Eii) and the root of hypoglossal nerve (rHN in panel Eii). A higher
magnification shows positive staining of the nerve root and neuropil staining in the nucleus (Eii). (F) -y-Synuclein in the trigeminal motor nucleus
(TMN) and the spinal trigeminal tract (STT). Neuronal cell bodies are not stained; only dotted neuropil staining is evident at the highest
magnification (Fiii).
































FIG. 6. Numbers of sensory neurons and nerve fibers in wild-type and null mutant mice, (a and b) Average total number of neurons in
trigeminal ganglia (a) and L6 lumbar DRG (b) of wild-type (+/+), y-synuclein null mutant (y~/_), and a-synuclein null mutant (a~/_) P2 mice.
Means and standard errors of data ohtained from analysis of at least 10 ganglia for each genotype arc shown. Statistical analysis (Kruskal-Wallis
one-way analysis of variance) showed no significant difference in cell numbers between all three genotypes for both ganglia (P > 0.6). (c and d)
Average total numbers of myelinated A-fibers (c) and unmyelinated C-fibers (d) in adult mouse saphenous nerves. Means and standard errors of
data obtained from analysis of at least five nerves for each genotype are shown. Statistical analysis (Kruskal-Wallis one-way analysis of variance)
showed no significant difference in numbers for both types of fibers between all three genotypes (P > 0.4).
At postnatal day 2 (P2), only neuropil staining (Fig. 3c) or very
few neurons with y-synuclein-positive cytoplasm on the back¬
ground of neuropil staining (Fig. 3d) are evident in these
nuclei. In adult brain all motor nuclei (with the exception of
the facial nucleus, where a few neurons still display positive
cytoplasmic staining) show a complete absence of y-synuclein
in the cytoplasm of neuronal cell bodies, but axons in all stud¬
ied motor nerve roots display intense y-synuclein immunore-
activity (Fig. 4). Using immunofluorescence, we clearly dem¬
onstrated that y-synuclein is present not only in axons but also
in presynaptic terminals of motoneurons in neuromuscular
junctions (Fig. 4A).
Intracellular localization of y-synuclein in mouse sensory
neurons. As in motoneurons, in sensory neurons of embryonic
peripheral ganglia y-synuclein is distributed throughout the
cytoplasm of cell bodies and axons (Fig. 2 and data not shown).
However, in contrast to the case for motoneurons, y-synuclein
compartmentalization in sensory neurons does not change dur¬
ing late embryonic and postnatal development. Postnatal neu¬
rons of DRG and cranial sensory ganglia display intensive
immunostaining of their cell bodies as well as nerve fibers with
anti-y-synuclein antibody (Fig. 3a and b and data not shown).
Numbers of motoneurons in cranial nuclei of wild-type and
y-synuclein null mutant mice. Serial coronal sections of adult
mouse brain were prepared and stained, and motoneurons
were counted in five cranial nuclei as described in Materials
and Methods. In neither of these ganglia were statistically
significant differences in the number of neurons between wild-
type and y-synuclein null mutant mice found (Fig. 5).
Numbers of sensory neurons in DRG and trigeminal ganglia
of wild-type and null mutant mice. The number of neurons in
L6 lumbar DRG and trigeminal ganglia was assessed in P2
mice, after the period of physiological cell death in these gan¬
glia. Serial longitudinal sections of the lumbar part of the
spinal column and transverse sections of the head were stained
and neurons were counted as described in Materials and Meth¬
ods. Figure 6a and b show that the absence of y synuclein docs
not have an effect on the number of neurons in both sensory
ganglia. Similarly, no effect of the absence of a-synuclein on
the neuronal complement in these ganglia was found. Mice
with a targeted inactivation of the a-synuclein gene have been
described previously (1), but for this work they were further








FIG. 7. Survival of P2 mouse trigeminal ganglion neurons in dissociated primary culture. Cultures were prepared and treated with drugs as
described in Materials and Methods. Bar charts illustrate survival of neurons 48 h after initial count and addition of drugs. The number of surviving
neurons is expressed as a percentage of the initial count. Means and standard errors of data obtained from analysis of at least six culture dishes
for each genotype in two independent experiments are shown, (a) Both y-synuclein-deficient (y '~) and a-synuclein-deficient (ot~/_) neurons have
the same survival rate as wild-type (+/+) neurons in the presence of nerve growth factor (NGF) and are unable to survive in its absence (P > 0.8,
Kmskal-Wallis one-way ANOVA). (b to d) Various treatments have the same effect on y synuclcin deficient (--■/) neurons as they have on
wild-type (+/+) neurons (P > 0.5 for all conditions; two-tailed, unpaired Student's t test). Proteasome inhibitors (5 pM MG-132 or 10 pM
proteasome inhibitor T [PST]) or heavy metal ions (30 pM CuSO, or 75 pM ZnS04) were added to neurons after the initial count at 24 h after
plating (b) In one set of experiments neurons were plated in neurobasal medium supplemented with B27 without antioxidants (c). In other cases,
DNA-riamaging agents (10 pM cytosine arabinoside [AraC] or 10 pM Etoposide) or inhibitors of the JNK signaling pathway (20 pM SP600125),
ERK signaling pathway (70 pM POQ8059), or phosphatidylinositol 3-kinase signaling pathway (20 pM LY294002) were added to neurons after the
initial count at 3 h after plating (c and d).
Me,thods) to nhtain a colony with a genetic background similar
to that of the y-synuclein null mutant mice.
Numbers of nerve fibers in saphenous nerves of wild-type
and null mutant mice To determine whether the absence of
synucleins affected growth and myelinization of axons of sen¬
sory neurons, we examined the mouse saphenous nerve, which
contains mostly afferent sensory nerve fibers, and counted the
numbers of myelinated A-fibers and unmyelinated C-fibers. No
differences in the general ultrastructural morphology of the
fibers (not shown) or in their numbers (Fig. 6c and d) in
y-synuclein and a-synuclein null mutant mice compared to the
wild-type mice were found
Survival in culture of peripheral nervous system neurons of
wild-type and null mutnnt mice. Although no differences in
neuron numbers in DRG or trigeminal ganglia of wild-type,
y-synuclein, and ct synuclcin null mutant mice were found, it
was feasible to check whether neurons with an incorrect bal¬
ance of synucleins are more sensitive to various stresses than
wild-type neurons. For this we compared the survival of neu¬
rons from peripheral ganglia of null mutant and wild type mice
in dissociated primary cultures. Dissociated cultures of P2 tri
geminal ganglion neurons were prepared and neuronal survival
was assessed as described previously (42). Survival character¬
istics of y synuclein and a synuclcin deficient neurons were
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FIG. 8. Behavioral analysis of mice with CCI to the sciatic nerve. Data show mean (± standard error of the mean) responses taken over a period
of up to 13 days before and every 2 to 6 days following surgery in wild type mice (a and c) (n — 9) and y synuclein null mutant mice (b and d) (n
= 6). (a and b) Paw withdrawal latency (PWL) from a noxious thermal stimulus (Hargreaves' thermal stimulator) ipsilateral to CCI (O) showed
significant differences between postoperative and preoperative values (t, P < 0.05; Krusltal Wallio one way analysis of variance) and from
postoperative, contralateral (■) values (*, P < 0.05 by Student's t test) for both wild-type (a) and mutant (b) mice. No thermal hyperalgesia was
seen on the contralateral side, (c and d) Paw withdrawal thresholds (PWT) from mechanical stimulation (von Frey filaments) showed significant
differences between postoperative and preoperative values on the side ipsilateral (O) to CCI (t, P < 0.05; Dunn's method analysis of variance on
ranks) and between postoperative ipsilateral and contralateral (■) values (*, P < 0.05, Mann Whitney U tost) for both wild type (c) and mutant
(d) mice.
indistinguishable from those of wild-type neurons; they sur¬
vived similarly well in the presence of nerve growth factor and
failed to survive in its absence (Fig. 7a). Similar results were
obtained for P2 superior cervical ganglion neurons (data not
shown). It has been shown previously that certain types of cells
with modified expression of synucleins, particularly dopami
nergic neurons overexpressing oi synuclein, have normal sur
vival characteristics under optimal culture conditions but are
substantially more susceptible to stresses (37, 38, 41, 50, 51).
To determine whether the absence of y synuclein renders nou
rons more sensitive to various toxic insults, we cultivated P2
trigeminal neurons in the absence of antioxidants or in the
presence of DNA-damaging agents (Fig. 7c), proteasome in¬
hibitors, heavy metal ions (Fig. 7b), and inhibitors of major
intracellular signaling pathways (Fig. 7d) in the medium. None
of these treatments revealed differences in the survival of
y-synuctein-deficient neurons compared to wild-type neurons.
Sensory reflexes and effects of CCI in wild-type and
y synuclcin null mutant mice. The behavioral reflex responses
of adult male y-synuclein null mutant and wild-type littcrmatc
mice to noxious radiant heat and graded mechanical stimuli
were studied as described in Materials and Methods. In both
tests the behaviors of mice from these two groups were indis
tinguishable (Fig. 8). To examine the effects of sciatic nerve
injury on behavioral reflex responses, we used the CCI model
of neuropathic pain. Over 7 to 10 days following CCI, wild type
and mutant mice progressively developed marked ipsilatcral
thermal hyperalgesia (reduced paw withdrawal latency) (Fig.
8a and b) and mechanical allodynia (reduced paw withdrawal
threshold) (Fig. 8c and d). All responses from the contralateral
hind limb remained unaltered. The time courses of recovery
from the consequences of CCI were very similar for mice of
both genotypes (Fig. 8). These results suggest that degenera¬
tion and regeneration of the injured nerve and neuronal plas
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(icily in Hie spinal cord arc not compromised in y-synuclcin null
mutant mice.
DISCUSSION
We have shown that in embryonic motoneurons -y-synurlein
is uniformly distributed through the cytoplasm of cell bodies
and axons. However, with the exception of a few neurons in the
facial nucleus, the cytoplasm of cell bodies of motoneurons of
the adult cranial somato- and branchiomotor nuclei is
y-synuclein negative, whereas their axons and synaptic boutons
in neuromuscular junctions are intensively stained with anti-y-
synuclein antibody. Previously published in situ hybridization
data demonstrated high levels of y-synuclein mRNA in cranial
motor nuclei of adult brain (7). Therefore, in motoneurons
during postnatal development, y-synuclein undergoes a com-
partmentalization shift, which might reflect a functional shift.
Our results contradict recently published data (32) which dem¬
onstrated the presence of y-synuclein in cell bodies of mo¬
toneurons in brain stem motor nuclei of adult rats. This might
reflect a difference between species; however, a more plausible
explanation is the difference in the antibodies used in the two
studies. In the present study, a highly specific antibody gener¬
ated against mouse y-synuclein C-terminal peptide was used,
whereas Li et al. (32) used an antibody generated against
human recombinant y-synuclein whose specificity has been
checked with recombinant human synucleins but not with sam¬
ples from null mutant animals.
It is not clear why some neurons of the adult facial nucleus
do not follow the common rule and continue to accumulate
y-synuclein in the cytoplasm of their cell bodies. In this aspect
they resemble peripheral sensory neurons, in which no devel¬
opmental changes of intracellular compartmentalization of
y-synuclein take place and which have equally high levels of
y-synuclein in their cell bodies and processes during embryo-
genesis and postnatally. We found that both neural crest-de¬
rived DRG and placnde-derived trigeminal sensory neurons
have this unchanging pattern of y-synuclein intracellular com¬
partmentalization. Taken together, our expression studies
demonstrated that between neurons expressing the highest lev¬
els of y-synuclein throughout development, two subpopula-
tions could be specified. The first includes peripheral sensory
neurons and some motoneurons of the facial nucleus, which
localize y-synuclein in their cell bodies and axons at all devel¬
opmental stages. Most other motoneurons of the brain stem
nuclei comprise the second group, which is characterized by
the developmental shift of y-synuclein compartmentalization.
The high levels of expression suggest that y-synuclein should
have an important role in the development and function of
sensory and motoneurons. Consequently, the loss of this pro¬
tein could affect the morphology and/or physiology of animal
sensory and motor systems. To check this, we produced mutant
mice with complete inactivation of the y-synuclein gene. Sim¬
ilarly to previously reported a-synuclein null mutants (1, 8, 46,
48), these mice showed no obvious phenotypical changes. De¬
tailed studies of sensory and motoneurons in vivo and in vitro
failed to detect any difference between y-synuclein null mutant
and wild-type mice. The number of neurons is not changed in
either of the subpopulations described above, suggesting that
proliferation, migration, differentiation, or programmed cell
death is not affected by the absence of y-synuclein. Consir,
tcntly, survival of y synuclein deficient neurons in primary cul
turc is not different from survival of wild type neurons. More¬
over, the absence of y synuclein docs not render these neurons
either more or less sensitive to any of the survival-affecting
fuctors studied so far. Because mid brain dopaminergic neu
rons seem to be most vulnerable to changes of synuclein me¬
tabolism (references 10, 28, and 33 and references therein), it
is feasible that this neuronal population might be more sensi
tivc to changes in the synuclein ratio than motoneurons and
sensory neurons. We are currently testing whether the absence
of y-synuclcin affects survival of dopaminergic neurons in the
substantia nigra and ventral tegmental area of null mutant
mice.
It has been suggested previously that y-synuclein could be
involved in axonal growth and stabilization of axon architec¬
ture (6). However, we did not find differences in the morphol¬
ogy und number of myelinated or unmyelinated fibers in the
saphenous nerves of mutant and wild-type mice. Sensory reflex
thresholds were also intact in y-synuclein null mutant mice.
Nerve injury led to similar changes in sensory function in
wild-type and mutant mice. Normalization of sensory function
after nerve injury is believed to be associated with neuronal
plasticity in the spinal cord and axonal regeneration processes
in the injured peripheral nerve (9, 14, 21, 58). These processes
require remodeling of the axonal cytoskeleton, including the
neurofilament network, and involvement of y synuclein in reg¬
ulation of neurofilament network integrity has been suggested
previously (6). However, the time course of sensory recovery
after CCI in y-synuclein null mutant mice is the same as that in
wild-type mice, which suggested that neive regeneration and
plasticity of early somatosensory pathways in y-synuclein mu¬
tant mice were unaffected.
The most straightforward explanation of our results is that
despite high levels of expression, y-synuclein is not essential
for the development and function of motor and peripheral
sensory neurons. Nevertheless an alternative explanation is
also possible. This function(s) could be vital for vertebrate
organisms, and therefore effective mechanisms of protection
against its loss have been developed in evolution. The presence
of three closely related synucleins in all vertebrates and sub¬
stantial overlapping of their expression patterns readily suggest
that they are able to compensate for each other's function(s).
It is unlikely that compensation for the loss of one synuclein
function in mice is achieved by a simple increase of expression
of other synucleins. We found no difference in the levels of
mRNAs encoding the two remaining synucleins in several neu¬
ronal populations of y-synuclein null mutant mice, and the
same has been demonstrated before for a synuclein null mu¬
tant mice (1). However, it is possible that it is not necessary to
boost an already high level of synuclein expression, because
changes in compartmentalization, posttranslational modifica¬
tions, or interaction with other macromolecules could be re¬
quired and sufficient for functional compensation. Detailed
studies of these processes in synuclein null mutant mice as well
as studies of double und triplo synuclein mutants should shed
more light on this problem and finally reveal the normal func¬
tions of these proteins.
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Abstract
The growing body of evidence suggests that intermediate
products of a-synuclein aggregation cause death of sensitive
populations of neurones, particularly dopaminergic neurones,
which is a critical event in the development of Parkinson's
disease and other synucleinopathies. The role of two other
members of the family, (3-synuclein and Y-synuclein, in neu-
rodegeneration is less understood. We studied the effect of
inactivation of y-synuclein gene on mouse midbrain dopam¬
inergic neurones. Reduced number of dopaminergic neurones
was found in substantia nigra pars compacta (SNpc) but not in
ventral tegmental area (VTA) of early post-natal and adult
y-synuclein null mutant mice. Similar reductions were
revealed in a-synuclein and double a-synuclein/y-synuclein
null mutant animals. However, in none of these mutants did
this lead to significant changes of striatal dopamine or dop¬
amine metabolite levels and motor dysfunction. In all three
studied types of null mutants, dopaminergic neurones of SNpc
were resistant to methyl-phenyl-tetrahydropyridine (MPTP)
toxicity. We propose that both synucleins are important for
effective survival of SNpc neurones during critical period of
development but, in the absence of these proteins, permanent
activation of compensatory mechanisms allow many neurones
to survive and become resistant to certain toxic insults.
Keywords: development, knockout mice, MPTP, substantia
nigra, synuclein.
J. Neurochem. (2004) 89, 1126-1136.
Discovery of two point mutations in the human a-synuclein
gene associated with autosomal dominant familial form of
Parkinson's disease (Polymeropoulos et al. 1997; Kruger
et al. 1998) triggered numerous studies aimed at understand¬
ing the mechanism of a-synuclein involvement in neuro-
degeneration. Although various observations suggested a
causative role of ot-synuclein aggregation in development of
synucleinopathies (Spillantini et al. 1997, 1998a, 1998b;
Conway et al. 1998, 2000; Irizarry et al. 1998; Mezey et al.
1998; Wakabayashi et al. 1998; Arai et al. 1999; Lippa
et al. 1999; Narhi et al. 1999; Serpell et al. 2000; Takeda
et al. 2000; Mori et al. 2002), it has also been shown that
ot-synuclein could cause cell death or render cells more
sensitive to toxic insults independently of protein fibrillation
(Ostrerova et al. 1999; Hsu et al. 2000; Saha et al. 2000;
Lee et al. 2001; Gosavi et al. 2002; Lehmensiek et al. 2002;
Petrucelli et al. 2002). This apparent discrepancy was at least
partially explained when a multistep mechanism of
a-synuclein aggregation was revealed and the cytotoxicity
was attributed to soluble a-synuclein oligomers or proto¬
fibrils, rather than insoluble highly polymerized mature
fibrils (Wood et al. 1999; Stefanis et al. 2001; Voiles et al.
2001; Ding et al. 2002; Gosavi et al. 2002; Lashuel et al.
2002; Voiles and Lansbury 2002; Zhu et al. 2003).
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Overexpression of ot-synuclein does not always have
detrimental effects on the survival of cells in culture and, in
some cells, has been shown to protect them from certain
insults (Alves Da Costa et al. 2002; Lotharius et al. 2002;
Wersinger and Sidhu 2003; Zourlidou et al. 2003). This
suggests that the increase of intracellular concentration of
a-synuclein is not the sole factor that changes cell fate; the
presence and activity of certain macromolecules and/or
intracellular structures and pathways, which interact either
physically or functionally with a-synuclein are of no less
importance. Among the factors shown to affect cell survival
reciprocally with a-synuclein are free radical-producing
metabolic pathways, excitotoxicity, signal transduction path¬
ways, molecular chaperons, intracellular trafficking machin¬
ery, mitochondrial dysfunction and protein degradation
systems, primarily proteasome (for recent reviews see
Betarbet et al. 2002; Bonini 2002; Hardy 2002; Helfand
2002; Kruger et al. 2002; Lotharius and Brundin 2002;
Mattson et al. 2002; Schwartz et al. 2002; Welch and Yuan
2002; Wolozin and Golts 2002; Cookson 2003; Dev et al.
2003; Lee 2003; Voiles and Lansbury 2003).
Recently, attention was focussed on the possible role of
two other members of the family, (3-synuclein and y-synuc-
lein, in the regulation of ot-synuclein-induced neurotoxicity.
Although these two proteins are similar to a-synuclein in
their amino acid sequences, they display rather different
aggregation kinetics and do not form amyloid-like fibrils
(reviewed in Uversky and Fink 2002). No mutations/
polymorphisms have been found so far in fl-synuclein or
y-synuclein genes in association with any neurodegenerative
diseases (Lavedan et al. 1998b; Flowers et al. 1999; Lincoln
et al. 1999a, 1999b; Kruger et al. 2001). Likewise, these two
proteins have never been detected in histopathological
hallmarks of neurodegeneration, although their presence in
unusual structures or changes of their intracellular distribu¬
tion have been reported in several cases of human neuro¬
logical diseases (Duda et al. 1999; Galvin et al. 1999, 2000;
Mori et al. 2002). Most interestingly, (3-synuclein and
y-synuclein inhibit the generation of a-synuclein protofibrils
and fibrils in vitro (Uversky et al. 2002; Windisch et al.
2002; Park and Lansbury 2003), and are able to prevent
neurotoxic effects of a-synuclein at least in certain in vivo
systems (Hashimoto et al. 2001; Windisch et al. 2002; da
Costa et al. 2003; and our unpublished observations).
Taken together these suggest that correct balance of
synucleins is important for normal brain function and
imbalance of these proteins might affect survival of neurones
that normally express more than one synuclein. However,
recently we have shown that targeted inactivation of
y-synuclein gene in mice does not affect survival ofperipheral
sensory and motor neurones that express high levels of this
protein in wild-type animals (Ninkina et al, 2003). Neverthe¬
less, because of compelling evidence that midbrain dopam¬
inergic neurones are more vulnerable to changes of synuclein
metabolism than other neuronal populations (Zhou et al.
2000, 2002; Xu et al. 2002) it was expedient to study the
effects of y-synuclein gene inactivation on these neurones.
Here we demonstrate that in mouse SNpc, deficiency of
y-synuclein, a-synuclein or both of these proteins, has
negative effect on development of dopaminergic neurones,




(DAB; Sigma Fast 3,3'-diaminobenzidine tablet sets) and general
chemicals were purchased from Sigma (St Louis, MO, USA),
Vectastain ABC-kit from Vector Laboratories (Peterborough, UK),
fluorescein isothiocyanate (FITC)-conjugated anti-mouse and
TRITC-conjugated anti-rabbit immunoglobulins from Jackson Im-
munoResearch Laboratories (West Grove, PA, USA).
Generation of double y-synuclein/a-synuclein null-mutant mice
Targeting inactivation of y-synuclein gene in ES cells and
production of null mutant mice on pure C57B16J (Charles River
Laboratories, Wilmington, MA, USA) background were described
previously (Ninkina et al. 2003). A colony of a-synuclein mutant
mice on pure genetic background was established from mice
described previously (Abeliovich et al. 2000) by backcrossing with
C57B16J mice (Charles River) for several generations as described
elsewhere (Ninkina et al. 2003). Null mutant a-synuclein and
Y-synuclein mice were bred to produce double heterozygous and
consequently double y-synuclein/a-synuclein null mutant mice.
Immunoblotting
Substantia nigra and surrounding midbrain region were dissected
from adult mouse brains and homogenised in sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) loading
buffer followed by incubation of lysates for 5 min at 100°C. To
avoid the influence of individual differences and inconsistent
dissections each lysate was prepared from tissues dissected from
four brains. Samples of these lysates (10 gg of total protein) were
analysed in 18% SDS-PAGE, transferred to Hybond-P membrane
(Amersham, Arlington Heights, IL, USA) and probed with antibody
as described previously (Buchman et al. 1998; Ninkina et al. 1999).
Affinity-purified polyclonal rabbit SK23 antibody generated against
C-terminal peptide of mouse y-synuclein (persyn; Buchman et al.
1998) was used in 1 : 500 dilution, sheep polyclonal antia-
synuclein antibody (AB5334P, Chemicon, Temecula, CA, USA) -
in 1 : 1000 dilution, rabbit polyclonal anti(3-synuclein antibody
(AB5086, Chemicon) - in 1 : 3000 dilution and mouse monoclonal
antia-tubulin antibody (DM1 A, Sigma) - in 1 : 10000 dilution.
Histology
For the quantification of dopaminergic neurones in the midbrain of
wild-type and mutant animals, brains were collected from El8
embryos, post natal day 5 (P5) or adult mice. To minimize variations
between the specimens, cohorts of brains from animals of the 3amc
age group were collected, processed, embedded and stained in
parallel. Animals were killed by an appropriate Schedule 1 method
© 2004 International Society for Neurochemistry, J. Neurochem. (2004) 89, 1126-1136
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according to the UK Animals (Scientific Procedures) Act 1986. The
brains were fixed in 4% paraformaldehyde/PBS (phosphate-buffered
saline) or Camoy's fixative (60% ethanol, 30% chloroform, 10%
glacial acetic acid) at 4°C overnight following dehydration in
alcohol series and embedding in paraffin blocks. Then, 8-pm-thick
sections were cut using a HM 310 microtome (Microm Inter¬
national, Walldorf, Germany) and mounted onto Gold Seal slides
(Gold Seal Products, Portsmouth, NH, USA). The paraffin sections
were cleared in xylene and rehydrated through a graded alcohol
series. Endogenous peroxidase activity was quenched by incubating
the slides in 3% H202 in methanol for 20 min. After washing with
PBS the tissues were blocked in 10% horse or goat serum and 0.4%
Triton X-100 in PBS for 1 h at room temperature. Incubation with
primaiy antibody was carried out at 4°C overnight. A monoclonal
antibody (clone 1B5) against tyrosine hydroxylase was purchased
from Novocastra Laboratories (Newcastle upon Tyne, UK) and used
in 1 : 40 dilution. Detection of immune complexes with biotinylated
anti-mouse or anti-rabbit antibodies and avidin/peroxidase complex
from Vectastain ABC-kit, and DAB as substrate were carried out
according to manufacturers instructions. For analysis of v-synuclein
protein expression and intracellular localization sections of the
whole El5 embryos and El8, P2 or adult brains were prepared as
described above and probed with 1 : 40 dilution of an SK23
antibody. For double immunoflourescent studies, FITC-conjugated
anti-mouse and TRITC-conjugated anti-rabbit immunoglobulins
were used in 1 : 200 dilution.
Cell counts
To assess number of dopaminergic neurones in SNpc and VTA
regions of mouse brain, the first section for counting was randomly
chosen from the first 10 sections that included SNpc/VTA region.
Starting from this section, nuclei of tyrosine hydroxylase (TH)-
positive cells were counted on the every tenth section through the
whole region. The Axiovision imaging program (Carl Zeiss Vision,
Munchcn-Hallbcrgmoss, Germany) was employed to measure
diameters of nuclei of 50 randomly picked dopaminergic neurones
in the SNpc or ventral ventral tegemental area (VTA) of every
mouse brain included in this study. The average nuclear diameter for
each structure in each brain was used for Abercrombie's correction
(Abercrombie 1946) of nuclei counts to obtain an actual number of
TH positive cells in the structure. All counts were carried out blindly
by a person unaware of the genotype of the animals.
MPTP treatment
Studies were approved by the Home Office and carried out
according to the UK Animals (Scientific Procedures) Act 1986.
All procedures, which included MPTP handling were carried out in
accordance with published safety recommendations (Przedborski
et al. 2001a). Eight- to 10-week-old wild-type or mutant male mice
on C57B16 background were injected intrperitoneally (i p.) with
0.1 mL of PBS or MPTP dissolved in PBS at 24-h intervals for
5 days. Daily dose of MPTP was 30 mg/kg. Brains were collected
for histological studies 21 days after the last injection.
Rotarod testing
Seven-month-old male animals were tested thrice on a rotarod
(UGO Basil, Comerio, Italy) at constant (24 rpm) rotation speed for
180 s or in accelerating (from 4 to 40 rpm) mode for 300 s. Results
were expressed as mean ± SEM of seconds before fall for each
experimental group.
Measurement of striatal dopamine and dopamine metabolite
levels
Brains of 9-month-old wild-type or mutant male mice on C57B16
background were dissected, the striatum removed on ice, snap-
frozen and kept at -70°C until assayed. 95 pL of 0.4 m HC104 and
5 pL of 40 pg/mL N-co-5-HT (internal standard) was added to each
thawed sample prior to sonication for 3 s by an ultrasonics
homogenizer with a 3 mm tip. The samples were centrifuged at
20 000 g at a benchtop centrifuge for 25 min at 4°C. The pellet was
frozen for protein quantification, which was carried out using a
standard BCA protein assay reagent kit (Pierce, Rockford, IL,
USA). Then, 50 pL of the supernatant were injected onto the high-
performance liquid chromatography (HPLC) column through a
Rheodyne injection valve connected to a 20 pL loop. A BAS PM-80
solvent delivery system and BAS LC-4 ECD was used to detect
dopamine (DA) and its metabolites (DOPAC, HVA and 5-HLAA).
Isocratic mobile phase (75 mM sodium dihydrogen phosphate,
1.7 mM octanosulphonic acid sodium salt, 100 pL/L triethylamine
in 90% milliQ water, 10% acetonitrile, pH 3.0) was used to carry the
samples through a reverse phase ESA column (120 A
C18 150 x 3.2 mm column packed with 3-pm particles). Flow rate
was set at 0.6 mL/min and the detector was at 0.7 V.
Results
Intracellular compartmentalisation of y-synuclein in
substantia nigra neurones changes during development
SK23 antibody, which specifically recognizes mouse
y-synuclein was used to stain paraffin sections of embryonic
and post-natal mouse brains. In agreement with previously
published in situ hybridization data, expression of y-synuc¬
lein in neurones of subsatantia nigra or its primodium was
detected at all developmental stages studied, although
intracellular compartmentalisation of the protein was differ¬
ent at different stages. At El5, y-synuclein was detected in
the primodium of substantia nigra both in neuronal cell
bodies and in axons (Figs la and b). Later in embryonic and
post-natal development, y-synuclein disappears from perik-
aria (Figs Id and e), whereas axons of the nigro-striatal tract
remain intensively stained (Figs lc and g). However, in adult
SNpc, haphazard TH-positive neurones display positive
y-synuclein immunostaining in their cell bodies (Figs li
and j). In developing and adult brain, punctuate neuropil
staining was detected in striatum (data not shown), suggest¬
ing that y-synuclein is localized not only in axons but also in
pre-synaptic regions of dopaminergic neurones of SNpc.
Thus, neurones of the mouse nigro-striatal system display the
same developmental dynamics of intracellular compartmcn-
talization of y-synuclein as brain stem motoneurones (Ninlc
ina et al. 2003), another neuronal population expressing high
levels of this protein. Recently, we generated y-synuclein
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Fig. 1 Intracellular comparetmentalisation of y-synuclein in develop¬
ing and adult mouse nigro-striatal system. Immunostainlng of paraffin
sections of mouse E15 (a, b), E18 (c, d), P2 (e) or adult (g) brains with
antiy-synuclein antibody. In a sagittal section of E15 mouse brain (a),
three small arrowheads denote the strongly stained fasciculus retro-
flexus, an important landmark in identifying the primordium of the
substantia nigra (large arrowhead). An arrow designates the positively
stained nigro-striatal tract. At a higher magnification (b), labelled cell
bodies of the primordium of substantia nigra are visible. In a sagittal
section of E18 mouse brain (c), the third and fourth ventricles are
shown; other designations as in (a). At the higher magnification (d), no
labelled cell bodies are visible but the primordial region is clearly
outlined by a dotted neuropil stain. In a coronal section of P2 mouse
brain (e), cell bodies of neurones in the red nucleus (RN) and nerve
fibres in medial lemniscus (ML) are stained but no y-synuclein-positive
cell bodies are apparent in VTA or SNpc. An adjacent section stained
with anti-TH antibody to delineate VTA and SNpc is shown in (f). A
fragment of sagittal section of adult mouse brain shows y-synuclein-
positive axons in the nigro-striatal tract (g); an adjacent section stained
with anti-TH antibody and counterstained with H&E (h). Double-
immunoflourescent staining of adult SNpc neurones with antiy-syn-
udein (i) and anti-TH G) antibody. Scale bars are 500 gm (a and c).
20 jim (b) and 50 gm (d).
null mutant mice and demonstrated that the number of
motoneurones in several brain stem nuclei is not affected by
targeted inactivation of y-synuclein gene (Ninkina et al.
2003). However, various data suggest that dopaminergic
neurones might be more susceptible to changes in
r*u r1'
adutt
Fig. 2 The number of dopaminergic neurones in midbrain of wild-type
and y-synuclein null mutant mice. Bar chart shows mean ± SEM of
total number of TH-positive neurones in SN + VTA of E18, P5 and
adult mice. No difference was found in E18 (p > 0.5, Student's Mest;
n = 6 for each genotype) but P5 and adult y-synuclein null mutant
mice (n = 8 and 6, respectively) have significantly less (*p < 0.05,
Student's f-test) neurones than adult wild-type mice (n = 9).
metabolism of synucleins than other types of neurones
(Zhou et al. 2000, 2002; Kirik et al. 2002; Xu et al. 2002).
Therefore, we studied the number of dopaminergic neurones
in midbrain structures of y-synuclein null mutant mice.
Deficit of dopaminergic neurones in substantia nigra pars
compacta of y-synuclein null mutant mice
In embryonic mouse brain, topographical discrimination
between dopaminergic neurones of SN and VTA is prob¬
lematic. Therefore, we compared the total (SN + VTA)
numbers of TH-positive neurones in midbrain of wild-type
and y-synuclein null mutant El8 embryos. At this develop¬
mental stage the same number of dopaminergic neurones was
observed in SN + VTA of y-synuclein null and wild-type
mice (Fig. 2). However, in early post-natal (P5) and adult
(15-20 weeks) animals, small (15-20%) but statistically
significant deficit of TH-positive neurones in SN + VTA of
y-synuclein null mutant has been found (Fig. 2). To reveal if
both structures lost the same proportion of neurones during
post-natal development we studied more samples and
counted separately the number of TH-positive neurones in
SNpc and VTA of these two groups of adult mice. The results
shown in Fig. 3 clearly demonstrate that the loss of
dopaminergic neurones in y-synuclein null mutant mice
takes place in SNpc (85.5 ± 5.2% of the number of neurones
in wild-type mice) but not in VTA (102.5 ± 5.0% of the
number of neurones in wild-type mice). In 18-month-old
animals, the oldest studied so far, we found similar difference
in the number of TH-positive neurones in SNpc between
y-synuclein null mutant mice and wild-type littermates
(81.4 ± 3.5% of the number of neurones in wild-type mice).
Double y-synuclein/a-synuclein null mutant mice
Inactivation of y-synuclein gene ultimately results in an
increase of a-synuclein to y-synuclein ratio in cells that
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Fig. 3 The number of dopaminergic neurones in midbrain structures
of wild-type and synuclein null mutant mice. Bar charts show
mean ± SEM of total number of TH-positive neurones in SNpc (a) or
VTA (b) of wild-type (ot+,+/y+/+), y-synuclein null mutant (oi+,+/y~'~),
a-synuclein null mutant (of'7y+/+) and double null mutant (of'Ty7"")
mice. Neurones were counted separately in left and right structures of
at least seven animals for each genotype. Statistic analysis (Kruskal-
Wallis one-way anova) showed no difference in VTA (p > 0.3) but
significantly reduced number of neurones in SNpc (p < 0.01) of all
three types of mutant mice when compared to wild-type mice.
normally express these two proteins, including dopaminergic
neurones of SNpc. As such imbalance might be responsible
for the increased toxicity of a-synuclein in the most
vulnerable neuronal population, we produced mice lacking
both a-synuclein as well as y-synuclein and studied neuronal
complement in their SNpc and VTA.
For these studies, ot-synuclein-deficient mice on the pure
C57B16J genetic background (Ninkina et al. 2003) were first
crossed with y-synuclein-deficient mice on the same pure
genetic background, to produce double heterozygous ani¬
mals. Mice lacking both ix-synuclein and y-synuclein genes
were obtained in litters from double heterozygous parents
with expected Mendelian frequency. Similar to both single
null mutants, double null mutant mice were viable, fertile and
did not show any obvious abnormalities in development,
behaviour or in gross morphology of the nervous system
(data not shown). Neither of our three populations of mutant
mice developed motor dysfunction, as can be judged from
their performance in either constant speed (Fig. 4a) or
accelerated (Fig. 4b) rotarod tests.
The number of TH-positive neurones in SNpc and VTA
of adult double at-synuclein/y-synuclein null mutant mice
(b)"
J jgg|3*5*
Fig. 4 Performance of wild-type and synuclein null mutant mice in
rotarod tests. Bar charts show mean ± SEM of time intervals from the
test start to animal fall from the rotating rod. Results of 3 min test with
constant, 24 rpm, rotation speed (a) and 5 min accelerating rotation
test (b) are shown. Statistic analysis (Kruskal Wallis one-way anova)
showed no significant difference in performance of wild-type and
mutant mice in both tests (p > 0.4).
was similar (79.9 ± 5.3% and 91.4 ± 5.9% of the number
of neurones in wild-type mice, respectively) to the number
of TH-positive neurones in the same structures of
y-synuclein null mutant mice (Fig. 3). Moreover, a similar
deficit in the number of TH positive neurones was found in
SNpc (82.2 ± 4.4% of the number of neurones in wild-type
mice) but not VTA (91.6 ±5.3% of the number of
neurones in wild-type mice) of ot-synuclein null mutant
mice (Fig. 3).
To assess the effect of null mutation on the levels of
dopamine and its metabolites, striatum was dissected from
nine months old male mice and HPLC analysis was used to
measure DA, DOPAC, 5-HIAA and HVA levels in the
extract of each of individual striatum. For all tour neuro¬
chemicals, no statistically significant differences were found
between four studied genotypes (Fig. 5).
Dopaminergic neurones of single and double synuclein
deficient mice are resistant to MPTP toxicity
To address the question of whether the absence of
synucleins changes the sensitivity of dopaminergic neurones
to specific toxic insults, we treated a-synuclein, y-synuclein
and double a-synuclein/y-synuclein null mutant mice with
MPTP, a neurotoxic drug that affects predominantly dop¬
aminergic neurones of SNpc. A protocol of MPTP admin¬
istration (see Experimental procedures) resulting in
apoptotic death of dopaminergic neurones (Tatton and Kish
1997) has been chosen. This protocol allows for the
identification both of animals more sensitive as well as
less sensitive to the neurotoxic effect of the drug because it
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DOPAC
Fig. 5 Dopamine and its metabolite levels
in striatum of wild-type and synuclein null
mutant mice. Striatal concentrations (ng/mg
protein) of dopamine (DA), 3,4-dihydroxy-
phenylacetic acid (DOPAC), 5-hydroxyin-
dolacetic acid (5-HIAA) and homovanillic
acid (HVA) in mutant animals were nor¬
malized to corresponding mean values for
wild-type animals (100%) in each experi¬
ment. Mean ± SEM for nine animals per
genotype from two separate experiments
are shown. Statistical analysis showed no
significant difference between wild-type and
mutant mice for all four neurochemicals




causes only moderate reduction in the number of TH-
positive neurones in SNpc of treated wild-type mice, which
is not accompanied by substantial decrease of striatal
dopamine level and, consequently, do not compromise
animal performance in rotarod tests. As expected, in a group
of wild-type mice this treatment substantially reduced the
number of TH-positive neurones in SNpc (64.7 ± 11.1% of
neurones remain in MPTP-treated group; 100% is the mean
of neurone numbers in a vesicle-treated group of wild-type
animals, p < 0.05) without significant effect on rotarod
performance of these mice (Fig. 6).
However, no significant decrease in number of TH-
positive neurones after MPTP treatment was observed in
SNpc of mice lacking either ot-synuclein (88.1 ± 4.7% of
neurones remain in MPTP-treated group; 100% is the mean
of neurone numbers in a vesicle-treated group of
a-synuclein deficient animals, p >0.1), or y-synuclein
(95.3 ± 7.4% of neurones remain in MPTP-treated group;
100% is the mean of neurone numbers in a vesicle-treated
group of y-synuclein deficient animals, p >0.6), or both
synucleins (85.9 ± 6.6% of neurones remain in MPTP-
treated group; 100% is the mean of neurone numbers in a
vesicle-treated group of double null mutant animals, p > 0.2;
Fig. 6).
Increased levels of p-synuclein in midbrain of single and
double synuclein deficient mice
Immunoblotting was used to compare levels of synucleins in
midbrain of adult wild-type and synuclein null mutant mice.
Equal amounts of total protein from four combined mid¬
brains per each genotype were analysed using antibodies
specific to a-, [)- and y-synucleins and ot-tubulin as a loading
control. As expected, a-synuclein was absent in samples of
ot-synuclein null mutant and y-synucleins - in samples of
y-synucleins null mutant animals, both these synucleins were
Fig. 6 Effect of chronic MPTP treatment on wild-type and synuclein
null mutant mice, (a) Performance of wild-type (a7y+), y-synuclein null
mutant (a+/y~), a-synuclein null mutant (cT/y+) and double null mutant
(a7y~) mice in 5 min accelerating rotarod test before (-) and 2 weeks
after (+) MPTP treatment, (b) The number of dopaminergic neurones
in SNpc of wild-type and synuclein null mutant treated with MPTP (+)
or vehicle (-). Neurones were counted separately in left and right
SNpc of at least six animals for each experimental group. Statistic
analysis (Kruskal-Wallis one-way anova and Student's f-test sepa¬
rately for each genotype) showed significant reduction in the number
of neurones after MPTP treatment only for wild-type animals (\ see
Results for details).
absent in samples of double null mutant animals (Fig. 7). In
three independent experiments we consistently detected
higher levels of P-synuclein in midbrain samples of all three
null mutant mouse lines than in samples of wild-type mice
(Fig- 7).
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Fig. 7 Expression of synucleins in midbrain of adult mice. Each of
three identical western blots with 10 pg of total protein lysates per lane
were probed with antibody against a-synuclein, p-synuclein or y-syn-
uclein. The filter probed with anti (5-synuclein antibody was re-probed
with antia-tubulin antibody (lower panel). The lysates were prepared
by homogenisation and boiling in SDS-PAGE loading buffer of mid¬
brains of wild-type (a+/7y+'+), y-synuclein (a+'+/y"'~), a-synuclein (of"7
y+/+) or double null mutant (a~'7y~'~) mice (four combined midbrains for
each genotype).
Discussion
In a search for phenotypical manifestations of targeted
inactivation of y-synuclein gene in mice we carried out
quantitative studies ofmesencephalic dopaminergic neurones
of SNpc and VTA, neuronal populations, which in wild-type
adult mouse express high levels of y-synuclein mRNA
(Lavedan et al. 1998a; Abeliovich et al. 2000; and our
unpublished observations). A relatively small (~15%) but
consistent and statistically significant reduction in the
number of TH-positive neurones has been found in SNpc
of adult ysynuclein null mutant mice when compared with
their wild-type littermates. This neuronal loss is not
progressive, as the same difference in the number of
neurones has been found between groups of ageing mutant
and wild-type animals. Reduced number of midbrain
dopaminergic neurones is already evident in P5 animals
but earlier in development, at the late embryonic stage (El8),
Y-synuclein null mutant and wild-type mice have the same
number of these neurones, suggesting that observed neuronal
loss occurs peri- or early post-natally. It is well established
that in rodents the natural cell death (NCD) of dopaminergic
neurones in SNpc takes place during this perinatal and early
post-natal period (reviewed in Burke 2003). Therefore it is
feasible that the absence of y-synuclein makes dopaminergic
neurones more vulnerable to NCD during this critical stage
of their development.
Despite the observed neuronal deficit, null mutant mice
did not develop any detectable motor dysfunction. This is
not surprising because clinical signs of nigro-striatal
pathology become obvious only following a substantial
decrease of striatal dopamine level, which in turn is usually
associated with much more extensive loss of nigral
neurones. Indeed, direct measurement of striatal dopamine
and its metabolites has not shown significant difference in
their levels between wild-type and null mutant animals. In
contrast to previously reported data (Abeliovich et al.
2000), we have not found reduction of striatal dopamine
level in a-synuclein null mutant mice. The most probable
explanation of this discrepancy is different genetic back¬
ground of mice used in two studies. Abeliovich et al.
(2000) used 129SV/j x C57B16 F2 intercrosses and all our
experimental animals were transferred on pure C57B16
background as described earlier (Ninkina et al. 2003).
Notably, two other groups that independently produced
a-synuclein null mutant mice also did not find statistically
significant decrease of their striatal dopamine levels (Cabin
et al. 2002; Schluter et al. 2003).
In the absence of a clear understanding of normal
synuclein function, various scenarios can be employed to
explain why y-synuclein null mutant mice develop a
neuronal deficit in SNpc and why only a fraction of
dopaminergic neurones are lost Recently, the importance
of a correct balance of synucleins for the survival of certain
types of neurones has been proposed. Selective neurotoxicity
of a-synuclein to dopaminergic neurones has been demon¬
strated in cell cultures (Zhou et al. 2000, 2002; Xu et al.
2002) as well as in invertebrate (Feany and Bender 2000;
Auluck et al. 2002; Lakso et al. 2003), rodent (Kirik et al.
2002; Lo Bianco et al. 2002) and primate (Kirik et al. 2003)
in vivo models. The ability of P-synuclein and y-synuclein to
block formation of toxic intermediates of a-synuclein
aggregation (Uversky et al. 2002; Windisch et al. 2002;
Park and Lansbury 2003) and a-synuclein-induced cell death
(Hashimoto et al. 2001; Windisch et al. 2002; our unpub¬
lished data) suggested that in the absence of endogenous
P-synuclein or y-synuclein, dopaminergic neurones might
become more susceptible to various internal and/or external
insults due to the lack of natural counterbalance to the
intrinsic toxicity of endogenous a-synuclein. However, our
finding that dopaminergic neurones of VTA, which in wild-
type mice express both a- and y-synuclein, are not affected in
Y-synuclein null mutant mice, suggests that neuronal loss
seen in SNpc could not be explained only by selective
toxicity of endogenous a-synuclein for dopaminergic neu¬
rones. Also, intracellular a-synuclein-positive inclusions,
obvious indicators of the increased propensity of endogenous
a-synuclein to aggregate in the absence of Y-synuclein, have
never been observed in brain sections of adult and ageing
Y-synuclein null mutant mice. Most importantly, we have
found the same reduction in the number of TH-positive
neurones in SNpc of double a-synuclein/y-synuclein null
mutant mice as in Y-synuclein null mutants. This suggests
that the absence of a-synuclein does not rescue a susceptible
population of Y-synuclein-negative dopaminergic neurones
from developmental cell death. Moreover, we have found
similar neuronal deficit in SNpc of a-synuclein null mutant
mice. The latter result is consistent with findings of another
group, although authors did not comment on the significance
of the difference they have shown (Dauer et al. 2002).
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We believe that the most plausible interpretation of our
experimental data is that both a- and y-synuclein are
involved in and equally important for a certain intracellular
process required for effective survival of SNpc dopaminergic
neurones during a critical period of SNpc development. The
roles of a- and y-synuclein in this process might be
complementary, but not interchangeable. Therefore, the same
neuronal population is affected in a-synuclein and
y-synuclein null mutant mice and the absence of both these
synucleins does not have an additive effect on neuronal
survival. Experimental data obtained in various model
systems implicate synucleins in many intracellular pathways
associated with regulation of cell survival. The next obvious
challenge is to reveal which of these pathways are indeed
involved in synuclein-dependent survival of dopaminergic
neurones of SNpc in the developing brain.
However, it is obvious from our previous (Ninkina et al.
2003 and unpublished data) and present data, that in most
neurones that normally express high levels of both a- and
y-synuclein, including the majority of dopaminergic neu¬
rones of SNpc, the absence of these proteins are compen¬
sated and this allows them to survive through all critical
stages of development. Furthermore, synuclein-deficient
dopaminergic neurones of SNpc, which survived until
adulthood, become resistant to MPTP toxicity. Stimulation
of expression, post-translational modification and aggrega¬
tion of ot-synuclein in neurones of SNpc by MPTP are well
documented, but it is less clear how these correlate with
neuronal death (Kowall et al. 2000; Vila et al. 2000;
Przedborski et al. 2001b; Meredith et al. 2002; Kuhn et al.
2003). Studies of dopaminergic neurones overexpressing
different forms of human a-synuclein produced controver¬
sial results - either increased (Richfield et al. 2002) or
unchanged (Rathke-Hartlieb et al. 2001; Dong et al. 2002)
sensitivity to MPTP toxicity has been demonstrated. Results
are more consistent for mice with targeted inactivation of
a-synuclein gene. Resistance to MPTP toxicity has been
shown previously for two independently generated mouse
strains with targeted inactivation of at-synuclein gene (Dauer
et al. 2002; Schluter et al. 2003) and we have demonstrated
the same effect for the third strain. However, we have
shown that dopaminergic neurones of SNpc of y-synuclein
and double a-synuclein/y-synuclein null mutant mice are
also resistant to MPTP toxicity. Concurrently, we detected
increased levels of (3-synuclein in midbrain of adult mice
lacking a-, y- or both synucleins. Neuroprotective effect of
(3-synuclein overexpression has recently been demonstrated
in different experimental systems (Hashimoto et al. 2001;
da Costa et al. 2003) and it is feasible to suggest that
compensatory increase of (3-synuclein level in midbrain
neurones survived beyond the period of NCD makes them
less sensitive to certain neurotoxic insults. The levels of
(3-synuclein are similar in midbrains of a-synuclein and
y-synuclein null mutant mice and loss of both a- and
y-synuclein in double mutant mice is not accompanied by
further increase of (3-synuclein level. These data are
consistent with the discussed above idea that a- and
y-synuclein are involved in the same intracellular processes
and a suggestion that increased level of P-synuclein might
be a factor required for effective survival of neurones in
which these processes are compromised. Further experi¬
ments should reveal spatial and developmental patterns of
P-synuclein accumulation in brains of mutant mice as well
as if and how increased p-synuclein level is linked with
activation of pro-survival or inhibition of pro-death mech¬
anisms that might be responsible for resistance of synuclein-
deficient SNpc neurones to MPTP.
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